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Abstract
Integration of spectroscopic and mass spectrometric tools for the analysis of novel
psychoactive substances in forensic and toxicology applications
Travon Cooman
Analytical methods aiming the detection of novel psychoactive substances are continuously
revised due to their utility in the seized drug and toxicology realms. One method frequently
employed for the preliminary identification of illicit materials is portable Raman spectroscopy.
Even when a substance in possession of an offender is identified, conclusive evidence that it may
have been consumed requires additional confirmatory work and further toxicological evaluation
of a biological specimen. Many times, the substance consumed may not be detected in the analyzed
specimen due to its extensive metabolism. It is therefore challenging to rule out the identity of the
drug ingested if metabolic studies have not been performed on a particular substance. This research
aims to evaluate portable Raman as a quick, safe, non-destructive method for rapid drug analysis
using the instrument’s built-in algorithms and in-house machine and deep learning algorithms.
Furthermore, metabolic and toxicologic studies using zebrafish and human liver microsomes are
used to elucidate selected opioids.
In the first part of this research, a portable Raman instrument—TacticID was validated according
to the United Nations Office on Drugs and Crime guidelines using 14 drugs and 15 cutting agents
commonly encountered in seized drugs. Analysis was performed through glass and plastic
packaging. In-house binary mixtures (n=64) at the following ratios—1:4, 1:7, 1:10, and 1:20 were
evaluated and the results compared to direct analysis in real-time mass spectrometry (DART-MS).
Whereas Raman performed better at detecting diluents which consisted of the majority in the
mixtures, DART-MS resulted in higher identification for easily ionizable drugs which were present
in lower percentages. To minimize the weaknesses in each technique, both methods were
combined, resulting in 96% accuracy. However, analysis of 15 authentic adjudicated cases resulted
in 83% accuracy using the combined methods, demonstrating the usefulness of these methods as
preliminary tests over traditional subjective techniques as color tests.
In instances where a portable Raman instrument is used for drug screening, its accuracy as a single
technique is crucial. In this study, the correct identification of the instrument detecting both drug
and diluent in binary mixtures was 19%. Therefore, machine and deep learning methods such as
naïve bayes, k-nearest neighbors, support vector machine, random forest, neural network (NN),
and convolutional neural networks (CNN) were explored as alternatives to the instrument’s builtin hit quality index algorithm. The findings in this research demonstrated NN and CNN superior
to the other algorithms, increasing the correct identification of both compounds to 65 and 64%,
respectively. Furthermore, ternary and quaternary mixtures were simulated using data
augmentation methods and 100% accuracy was observed with CNN models. Similar accuracies
were observed when the substances were reported by their drug classes. This work demonstrated

how the contribution of machine learning can help improve the accuracy of analytical instruments
outputs, thereby increasing confidence in compounds reported.
In the second part of this research, zebrafish which share 70% of gene similarity to humans, were
used as a toxicity model to provide information about drug effects on a living system. Fentanyl
was selected as a model drug and zebrafish (0 – 96 hours post fertilization) were dosed at 0.01 –
100 µM. Major dose dependent phenotypic effects included pericardial malformations, spine and
yolk extension malformation, all of which inhibited the normal growth and development of the
larvae. This has laid the foundation for future studies to understand the mechanisms of action.
Furthermore, three metabolites—4-ANPP, norfentanyl, and β-hydroxyfentanyl, were detected in
the zebrafish assay. All the observed metabolites have been reported in human specimens.
The final aim of this work was to elucidate an uncharacterized opioid—valerylfentanyl using
zebrafish and human liver microsomes as a comparative model. Although valerylfentanyl carboxy
metabolite is sold as a metabolite, a complete metabolic study was not found in the literature.
Therefore, the well-studied microsome model was used to compare the results to zebrafish (30
days post fertilization). Although 19 metabolites were detected in the microsome model, and fewer
in the zebrafish assay, the major marker metabolite valeryl norfentanyl was consistent in both
studies, demonstrating zebrafish can be used to study opioid metabolism.
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Introduction
Novel psychoactive substances (NPS) have flooded the illegal market over the last decade and
pose a challenge for their detection by forensic chemists and toxicologists. Their extensive
metabolism, lack of metabolite elucidation, and limited availability of standards suggest that these
emerging drugs of abuse can go undetected or unconfirmed using existing screening technologies.
Even when some NPS and other drugs of abuse have been thoroughly studied and reported in the
literature, it may take several months for a crime lab to finalize casework due to the limited number
of certified reference materials for these chemical entities and their metabolites. The incorporation
of a fast, easy, and accurate onsite method for screening these substances and knowledge of their
metabolism can help decrease case turnaround times.
This research project aims to develop a comprehensive study in two critical areas: seized drug
analysis in forensic chemistry, and drug metabolism of NPS within forensic toxicology. Chapter
1 focuses on utilizing a portable Raman instrument to screen common drugs of abuse and diluents
in seized drugs mixtures. To improve the accuracy of the portable Raman instrument, selected
machine learning techniques are discussed in chapter 2. Chapter 3 presents zebrafish as a
toxicology and metabolism model for fentanyl, and chapter 4 extends this knowledge to
valerylfentanyl by comparing human liver microsomes data to zebrafish.
Current methods for onsite drug screening include color tests [1, 2], mass spectrometry [3], and
electrochemistry [4], amongst others [5]. Whereas many of these methods require opening
packages for sampling, putting operators at risk of exposure, Raman spectroscopy is capable of
through packaging analysis. Raman spectroscopy, a well-established, nondestructive technique
used to analyze drugs of abuse, is the study of inelastic scattering of UV, visible or near infrared
light. When light strikes a molecule, elastic—no change in photon frequency and inelastic
scattering—shift in photon frequency, occurs. Inelastic scattering of radiation was experimentally
discovered by Chandrashekhara Venkata Raman in 1928 [6, 7] and it is the principle on which
Raman was developed. When light in the ultraviolet or visible spectrum strikes a molecule, an
electronic transition occurs as shown in Figure 1. For a molecule to absorb light, the energy of the
light must be equivalent to the energy band gaps. Light in the mid-IR range (2.5 to 49 µm) causes
molecules to vibrate through a stretching or bending motion. Depending on the structure of the
molecule, it may undergo symmetric or asymmetric stretching as shown in Figure 2, or any of the
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four bending modes–scissoring, rocking, wagging, and twisting, as shown in Figure 3. Stretching
modes usually have higher energy than bending modes and are denoted by 𝜈 and 𝜎 respectively
[8]. Molecules excited to a virtual energy state may scatter light back to the ground state at the
same frequency as the incident light, this phenomenon is called Rayleigh scattering. Rayleigh
scattering is usually more intense and is filtered in Raman spectrometers. When molecules gain
vibrational energy, the resulting scattered light is higher than that of the incident light giving rise
to anti-Stokes Raman scattering [6]. Stokes- Raman scattering, a fairly weak process, results when
molecules are excited to a virtual state, attain an induced dipole and emit photons at a different
frequency than that of the incident light as shown in Figure 1.

Figure 1. Diagram showing the excitation of molecules in the presence of visible light and infrared light.

Figure 2. Different modes of stretching for a CH2 group.
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Figure 3. Different modes of bending for a CH2 group.
The two major Raman techniques are Dispersive and Fourier Transform (FT) Raman spectroscopy.
Dispersive systems filter scattered light through a notch filter or edge filter and removes the laser
line. The light is shone on a diffraction grating where the wavelengths of scattered light are
separated and focused on a detector–usually a Peltier cooled charge-coupled device (CCD) array
detector. Fourier Transform systems contain an interferometer which allows for a fast,
simultaneous measurement of all frequencies and result in an interferogram which is converted to
a spectrum using Fast Fourier Transformation calculations performed by the software. FT- Raman
systems use a 1064 nm laser as the excitation source to minimize fluorescence whereas dispersive
systems use a 785 nm laser. Lasers are selected based on their excitation efficiency, and
fluorescence capabilities. Raman scattering is inversely proportional to the fourth order of
excitation wavelength ( 𝜆-4) implying lasers with shorter wavelengths are more efficient and
sensitive than longer wavelengths [9]. The scan time is also shorter when short wavelength lasers
are used.
The major drawbacks of Raman spectroscopy include: the occurrence of photodecomposition–
where the sample is destroyed before data is obtained making dark samples unsuitable for analysis,
and Raman signals are masked by the background and fluorescence interfering with analysis. A
background spectrum is not normally required as this is a scattering technique unlike when Fourier
Transform Infrared spectroscopy is used. However, Raman spectroscopy is considered a Category
A technique by the Scientific Working Group for the Analysis of Seized Drugs indicating it has
the highest discriminatory power [10]. Raman is highly selective, provides specific functional
group information, does not interfere with water, allowing for analysis of aqueous samples, and
provides rapid analysis.
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The construction of low-cost, battery-powered, portable Raman spectrometers have increased the
versatility of Raman [11]. For example, portable devices have been used in the analysis of
explosives [12], drugs [7, 13], paints [14], and inks [15] due to very little to no sample preparation
being required for testing. Portable Raman instruments have also been used at ports of entry for
the identification of chemicals and biohazards using a non-contact approach in comparison to ion
mobility spectroscopy and other techniques which require contact with these substances [13, 16].
A noncontact approach helps reduce exposure risks to workers. Although drugs such as cocaine,
amphetamine, and methylenedioxymethamphetamine (MDMA) have been studied with portable
Raman systems, novel psychoactive substances and mixtures have been a challenge to identify. To
successfully identify a compound, it must first be present in the instrument’s library, and the search
algorithm must be accurate and account for mixtures and other interferences. Novel psychoactive
substances can be structurally similar to each other, and although the change in one functional
group can result in unique spectra, there is a need for it to be evaluated.
Therefore, the main goal of chapter 1 was to evaluate the performance of a portable Raman
instrument—TacticID as a screening technique, through analysis of pure powdered substances,
mixtures and adjudicated cases. Fifteen common drugs of abuse and 15 diluents were analyzed as
pure substances and mixtures comprising of various ratios after validating the instrument. The
accuracy through glass and plastic packaging was 91% and 89%, respectively. A subset of the
samples was analyzed using direct analysis in real time mass spectrometry (DART-MS) and when
combined with the Raman data, the accuracy increased to 96%. Analysis of authentic case samples
resulted in 83% correct identification when the two techniques were combined, hence providing a
rapid and accurate method for drug screening. Chapter 1 was published in the Journal of Forensic
Chemistry.
The limitations of portable Raman instruments continue to make it a challenge in forensic science.
Some limitations include: its low sensitivity to drugs in small concentrations, fluorescence from
samples interfering with signals, unsuitable for dark samples and complex matrices, fluctuation
from the laser source, and its limited use for qualitative analysis [17]. Chemometrics and machine
learning have sought to improve some of these challenges especially the analysis of
multicomponent mixtures. Guirguis used principal component analysis (PCA)—a data reduction
and exploratory technique as a classification method for the analysis of NPS using a hand-held
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Raman with a 1064 nm laser and reported 89% correct classification [18]. Omar et al also used
PCA to distinguish fentanyl, cathinone, and synthetic cannabinoids in seized Customs samples by
comparing three hand-held Raman instruments—Progeny (1064 nm laser), Cora 5600 (1064 nm
laser) and Bravo (785- 1000 nm laser) but did not provide classification rates although each drug
class formed separate clusters [19]. Weng et al used PCA followed by discriminant algorithms to
classify methamphetamine and 3,4-methylenedioxy methamphetamine with accuracy >95% using
surface-enhanced Raman spectroscopy [20]. Although the selected algorithm can affect
misclassification rates, preprocessing of the data is important as spectral peak overlap,
fluorescence, and variable Raman intensities can influence this process. O’Connell et al reported
correct classification rates of about 90% after using the first derivative of the Raman spectrum as
a preprocessing technique [21].
Simple methods such as PCA or linear discriminant analysis do not perform as well with mixtures
which are commonly encountered in seized materials. Therefore, chapter 2 builds on the research
in chapter 1 and focuses on methods that can improve detection of compounds by portable Raman
instruments. A database was created containing simulated binary, ternary, and quaternary
mixtures. This data was used to explore machine learning algorithms to classify compounds by
their drug class and drug name. The models improved the correct classification of binary mixtures
from 19% using the instrument’s hit quality index algorithm to 64% using convolutional neural
networks. Therefore, incorporating machine learning algorithms in portable instruments, can
improve the detection of unknown substances with high accuracies. Chapter 2 was published in
Chemical Physics Letters.
Although Raman spectroscopy can be used to detect NPS, their metabolism and toxicity are not
always extensively studied. Therefore chapters 3 and 4 discusses zebrafish as an alternative drug
metabolism and toxicology model. Zebrafish (Danio rerio), one of 45 Danio species are a small
teleost (3-4 cm) first used in genetic studies in the 1980s [22]. The name is derived from the stripes
on the side of their body. They are typically found in standing or slow-moving water such as ponds,
lakes, ditches or rice paddies [23–25]. Zebrafish exhibit a circadian pattern of daytime activity and
night-time rest similar to mammals; and possess all the classes of senses—taste, touch, smell,
balance, vision, and hearing [26]. Their natural diet consists mainly of zooplankton and insects
[27] and they are surface feeders. At 5 days post fertilization (dpf) they can feed on their own,
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using pharyngeal ‘jaws’ with tooth rows in the back of the throat. Zebrafish are broadcast spawners
that release eggs and sperm in a cloud over a substrate [28]. A female generally produces around
100 transparent eggs 1.0 to 1.5 mm in a single spawning [29]. Figure 4 shows the different stages
of the zebrafish life cycle. At 0- 72 hours post fertilization (hpf)—embryos, 72 hpf to 13 dpf—
early larvae, 14 dpf to 29 dpf—mid larvae, 30 dpf to 3 or 4 months—adults [30].

Figure 4. Zebrafish developmental stages (adapted from
http://www.mun.ca/biology/desmid/brian/BIOL3530/DEVO_03/ch03f09.jpg)
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Their small size, high reproductive rate [31], low cost and easy maintenance make zebrafish a
rapidly increasing model to study toxicity and in vivo drug metabolism. Assessment of toxicity is
critical for drug discovery and scheduling of NPS. Zebrafish embryo is accepted as a toxicity test
[32, 33] and is used to determine acute toxicity of chemicals on embryonic stages of fish—
maximum tolerated concentration. This concentration can be used for dosing regimens since
therapeutic concentrations for humans may not necessarily be the same in zebrafish. Additionally,
dosing embryos until 96 to 120 hpf has been performed to evaluate developmental defects in
zebrafish and used as a model to predict toxicity in humans. Zoupa and Machera evaluated the
effects of triadimefon—a fungicide used in agriculture by measuring several effects in zebrafish—
hatching rate, body length, spinal defects, heart shape and other deformities, and compared their
findings to previous studies in mammals [34]. Cornet et al., developed an assay to predict the
cardiotoxicity, neurotoxicity and hepatotoxicity for twenty compounds with known effects in
humans by exposing observing developmental defects and mortality rates of embryos exposed to
drugs of varying concentrations. Specificity was reported as 89%, sensitivity was 68%, and
accuracy, 78%, confirming zebrafish embryo assays are promising to extend toxicity to humans
[35]. Gonzalez-Nunez and Rodriguez performed developmental studies which demonstrated
zebrafish expressed opioid receptors fundamentally similar to those found in mammals and can be
extrapolated to higher vertebrates but did not perform toxicity studies [36].
The complexities of rodent and mammalian models for in vivo drug metabolism have resulted in
alternative models being explored. The zebrafish model has been used for both targeted—known
metabolites monitored and untargeted—comprehensive, metabolomics—study of metabolite
profiles [37]. Metabolomics have been combined with analytical techniques such as gas
chromatography- mass spectrometry (GC/MS), and nuclear magnetic resonance (NMR), but liquid
chromatography high-resolution mass spectrometry has been most useful in evaluating metabolic
profiles since it provides higher sensitivity and mass accuracy information of compounds as
metabolites are in low concentrations and most times unconfirmed without reference standards.
Zebrafish contain cytochrome P450 (CYP) enzymes and approximately 70% of human genes have
a zebrafish orthologue [38], suggesting metabolic profiles from zebrafish may be similar to
mammals. However, differences have been observed in metabolites in zebrafish and humans. For
example, Jones et al., investigated the metabolism of ibuprofen in zebrafish larvae and reported
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the absence of carboxy-ibuprofen and the glycoconjugate metabolites observed in human [39]. In
another study by Chng et al., the differences between zebrafish liver microsomes, human liver
microsomes and zebrafish larvae were observed [40]. The major metabolite in larvae was 6βhydroxytestosterone and unique metabolites of zebrafish were observed only in zebrafish.
Differences are expected because the enzymes in zebrafish may interact with certain substrates
differently since the genetic makeup is not a complete match to humans.
There is wide variability in the stage of zebrafish development when metabolism studies are
performed. The age of zebrafish used in previous studies include 4 dpf [41], 5 dpf [32, 40], and 3
to 8 months [42, 43]. Studies report that zebrafish liver—a major site for metabolism, starts
developing 24 hpf and is complete between 3 and 5 dpf [44, 45] and cytochrome P450 activity
dramatically increases at 3 dpf [46]. Figure 5 shows the difference in the size of the liver in larvae
and an adult. Verbueken et al., compared the drug metabolizing capability of embryos from 5 hpf
to 120 h and compared the results with zebrafish liver microsomes and adult zebrafish assays [47].
The authors reported that zebrafish embryos have poor CYP- related metabolizing capacity with
benzyloxy-methyl-resorufin—a mammalian CYP substrate but this statement needed to be
evaluated with other CYP substrates. Considerations for the age of zebrafish are important because
in some countries larvae are not considered animals until 120 hpf or when they develop
independently feeding capacity [48]. Studies which focus on early stage (<96 hpf) zebrafish
metabolism result in a shorter wait time for results compared to waiting >30 days for the fish to
become adults before performing metabolism studies. However, the capability of both larvae and
adult zebrafish for metabolism studies have been demonstrated.
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Figure 5. General anatomy of a larval—3 to 5 dpf (top) and adult (bottom) zebrafish (adapted
from Santoriello and Zon [49]).
The incubation time, dosing methods and number of zebrafish are also variable. Rodrigues Matos
et al., used 18 adult zebrafish dosed via bath application and collected water samples for analysis
of xylazine metabolites at 0, 1, 3, 6, 24, 48, 72, 96, 120, 144, 168 hours [43]. In a similar experiment
with stanozolol and sibutramine, de Souza Anselmo et al. used 12 adult zebrafish [50]. Richter et
al. used ten 4 dpf zebrafish and administered the drug via microinjection in the yolk sac and
analyzed the incubation media and zebrafish tissue after 24 hours [41]. In another study, 16 5-dpf
larvae were dosed with meta-chlorophenylpiperazine (mCPP) and collected 0.25, 1, 3, 6, 8, and 10
hours after exposure [32]. Although bath application seems to be the easiest method of dosing,
the solubility of the drug must be evaluated, and it must be ensured that most of the drug does not
adhere to particles in the water. Microinjection requires personnel training, but this is the only
method to ensure the fish receives the desired dose.
Like other models, zebrafish models have their limitations. There are substantial differences in
organ/ body size between zebrafish and mammals, the differences in the biological environment
may affect metabolism, the mode of drug delivery does not always reflect the method of intake by
mammals, and zebrafish are maintained at a lower temperature than mammals [37].
The most common in vitro models used to evaluate the pharmacodynamics and pharmacokinetics
of drugs in humans include hepatocytes and human liver microsomes (HLM). Hepatocytes, or liver
cells play a key role in detoxification and biotransformation of xenobiotics and contain both phase
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I and II enzymes. However, they are expensive, difficult to obtain, and the isolation of viable cells
is challenging [51]. HLMs are subcellular fractions derived from the endoplasmic reticulum of
hepatic cells after liver homogenization and differential centrifugation [52, 53]. Although they
contain mainly phase I enzymes, uridine diphosphate glucuronic acid (UDPGA) can be added to
the assay to observe phase II enzymes conjugation [54]. The list of enzymes in HLMs include
cytochrome P450s, flavin monooxygenases, carboxyl esterases and epoxide hydrolase, and UDP
glucuronyl transferases. The low cost, easy, multiple use from freeze-thaw cycles, high stability
of enzymes after being stored for many years make HLMs a good model. In addition to metabolic
data, microsomes can also provide half-life data which can be used to optimize incubation times
for metabolism.
Therefore, chapter 3, focuses on using early-stage zebrafish larvae to assess the toxic effects of
fentanyl and to evaluate the larvae’s ability to metabolize fentanyl. Fertilized eggs were exposed
to fentanyl concentrations ranging from 0.01 to 100 µM and observed until 96 hours. Phenotypic
observations for toxicity included egg coagulation, somite formation, heartbeat, tail and yolk
morphology, pericardial formation, and swim bladder inflation. The incubation media was
analyzed for the presence of metabolites using a targeted metabolomics approach. Fentanyl
concentration caused significant effects on survival and development, with notable defects to the
tail, yolk, and pericardium at 50 and 100 μM. Despropionyl fentanyl (4-anilino-Nphenethylpiperidine, 4-ANPP), β-hydroxy fentanyl, and norfentanyl were detected in zebrafish
larvae. Chapter 3 was published in the Journal of Applied Toxicology.
The metabolism of valerylfentanyl—a novel synthetic opioid, less potent than fentanyl, is
elucidated in chapter 4. Although valerylfentanyl is less potent than fentanyl, it was previously
detected in postmortem samples [55, 56], but its metabolism was not elucidated in the literature.
An in vitro—HLM model was compared to an in vivo—zebrafish model. Nineteen metabolites
were detected with N-dealkylation as the most abundant metabolite—valeryl norfentanyl being
observed followed by hydroxy valerylfentanyl. The major metabolites in HLM were also detected
in 30 dpf zebrafish. An authentic liver specimen which tested positive for valerylfentanyl, among
other opioids and stimulants, revealed the presence of a metabolite which shared transitions and
retention time as the hydroxylated metabolite of valerylfentanyl but could not be confirmed
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without reference standards. 4-ANPP—a common metabolite to other fentanyl analogues was also
detected. Chapter 4 was published in Drug Testing and Analysis.
The overall contribution of this work has: (1) highlighted the importance of validating portable
instruments for seized drug analysis and demonstrated in one of the first studies of its kind that the
combination of Raman and DART-MS can improve the detection of drugs of abuse in street
samples, (2) demonstrated machine and deep learning algorithms for the detection of unknown
compounds and their class performed better than a portable Raman instrument’s built-in algorithm,
(3) elucidated the toxicity and metabolism of fentanyl using a single early stage zebrafish assay
and, (4) fully characterize the metabolic pathway of valerylfentanyl using zebrafish and human
liver microsomes.
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Objectives

Chapter 1
The main goal of chapter 1 was to evaluate the performance of a portable Raman instrument in
comparison to direct analysis in real time mass spectrometry (DART-MS) using seized drugs
samples, and to evaluate their combined performance for orthogonal analysis. The central
hypothesis of this chapter is the combination of Raman and DART-MS improves the correct
identification of components in a seized drug sample.
Task 1.1: The first task was to review the literature for common drugs of abuse and diluents.
Selected binary ratios based on the literature search were created using powdered drug-diluent
samples.
Task 1.2: The second task was to validate a portable Raman instrument—TacticID, according to
the United Nations Office on Drugs and Crime guidelines for handheld Raman field identification
devices for seized material. Validation parameters included library verification, repeatability/
reproducibility, interference studies, and matrix effects.
Task 1.3: Selected binary mixtures from Task 1.1 were analyzed using DART-MS and the
performance compared to Raman.
Task 1.4: Adjudicated case samples from the Maryland State Police were analyzed using both
Raman and DART-MS. The performance of each technique was evaluated independently, and in
combination with each other.

Chapter 2
The main aim of chapter 2 was to explore machine learning algorithms to improve the correct
identification of components in seized materials analyzed using the TacticID portable Raman. The
central hypothesis of this chapter is that machine learning algorithms perform better than the builtin algorithm of the TacticID instrument.
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Task 2.1: Spectra from chapter 1 were compiled and used for data augmentation by creating
binary, ternary, and quaternary mixtures.
Task 2.2: Machine learning and deep learning algorithms were selected to evaluate spectra by
compound name and drug class. Algorithms included artificial neural network, convolutional
neural network, k-nearest neighbor, naïve bayes, random forest, and support vector machine.
Task 2.3: The machine learning algorithms in Task 2.2 were evaluated on authentic datasets
consisting of single compounds and binary mixtures and the correct classification was compared
to the hit quality index algorithm built into the TacticID portable Raman instrument.
Task 2.4: Proposed a workflow that can be implemented in portable Raman instruments.

Chapter 3
Chapter 3 evaluated zebrafish larvae as a model to investigate the toxic effects of fentanyl while
providing metabolism data. The central hypotheses of this chapter are that fentanyl causes toxic
effects to zebrafish in a dose dependent manner, and zebrafish larvae are capable of metabolizing
fentanyl.
Task 3.1: Administered fentanyl (0.01 to 100 µM) to 0 dpf zebrafish until 96 hpf and observed
phenotypes indicative of toxicity.
Task 3.2: Performed a targeted metabolism study through analysis of zebrafish incubation media
for fentanyl metabolites—norfentanyl, β-hydroxyfentanyl, and 4-ANPP.

Chapter 4
Chapter 4 elucidated the metabolic pathway of valerylfentanyl using zebrafish and human liver
microsomes. The central hypothesis of chapter 4 is that metabolites observed in zebrafish and
human liver microsomes are similar.
Task 4.1: Incubated valerylfentanyl with human liver microsomes and performed metabolite
analysis using high-resolution mass spectrometry (Q-Exactive Orbitrap).
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Task 4.2: Incubated valerylfentanyl with 30 dpf zebrafish and performed analysis using a QExactive Orbitrap mass spectrometer.
Task 4.3: Proposed structures of valerylfentanyl metabolites using mass spectra data.
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Chapter 1: Screening of Seized Drugs Utilizing Portable Raman Spectroscopy
and Direct Analysis in Real Time-Mass Spectrometry (DART-MS)
Reproduced with additions and permission from Travon Cooman, Colby E. Ott, Kourtney A. Dalzell, Amber Burns,
Edward Sisco, Luis E. Arroyo, Forensic Chemistry, Vol. 25 (2021): 100352 and Elsevier. DOI:
10.1016/j.forc.2021.100352

1.1. Introduction
Forensic chemists rely on an assortment of analytical techniques and instrumentation to reach
conclusions when dealing with unknown seized compounds. However, every year forensic
laboratories in the United States are burdened by over one million submissions of suspected drugs
[57], requiring significant time and resources despite often limited budgets. To alleviate these
problems and improve the speed of analysis, rapid screening of samples is a logical first step.
Current screening practices often involve the use of color tests. This approach is prone to
subjective, visual, judgments from the chemist [1, 2] and requires the use of different chemicals,
some of which are toxic [58]. Furthermore, sensitivity and selectivity problems are common,
especially for impure or low concentration samples and with novel substances [6, 58]. Also of
issue is the collection and submission of unknown samples to the forensic laboratory that, upon
analysis, turn out to be harmless or legal substances. To address these concerns, innovative, safer,
and more cost-effective methods for screening unknown seized substances are needed both within
the laboratory and in the field.

Raman spectroscopy, a well-established, nondestructive technique is attractive because it can
provide high discrimination between drug structures. The selectivity of Raman spectroscopy is
superior to chemical color tests, increasing the ability to reliably differentiate and identify a wider
range of compounds. The use of Raman spectroscopy for the identification of drugs of abuse has
been well documented using both conventional desktop models [19, 59, 60] and portable
instrumentation [13, 59, 61–63]. The implementation of low-cost, battery powered, portable
Raman spectrometers in forensic drug chemistry casework has harnessed their versatility as a fast
and safe option [11], simplifying the testing process, eliminating the need for sample preparation,
and opening the door to a wider range of materials and packaging types [7, 16, 63].
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Another means of improving drug screening has been the use of mass spectrometry techniques
such as high-resolution mass analyzers coupled with ambient ionization. Direct analysis in real
time mass spectrometry (DART-MS) has been shown to provide rapid, and sensitive analysis of a
wide range of materials, including drugs of abuse, through direct introduction of small sample
amounts with minimal to no sample preparation [3, 64–66]. In addition, recent literature reports
have demonstrated the ability of DART-MS to detect trace drug residues on the outside of
packaging, allowing prediction of the internal contents prior to opening the packaging [67, 68].
The combination of the DART ionization source with high-resolution mass spectrometry results
in accurate mass measurements, providing more confident screening of drug compounds.

Combining the results from the orthogonal techniques for the detection of 15 common drugs of
abuse and 15 diluents is presented herein. After establishing bias, precision, and reproducibility of
portable Raman spectroscopy, a suite of pure and binary mixture samples was analyzed to
determine the accuracy of this approach. A subset of these samples and mixtures was analyzed
using DART-MS to establish the accuracy of the technique by itself and when these results were
combined with portable Raman. To demonstrate real-world utility, this combination of screening
techniques was used to analyze a set of authentic samples provided by the Maryland State Police
Forensic Sciences Division (MSP-FSD).

1.2. Materials and Methods
1.2.1 Reagents and Materials
A total of 15 drugs of abuse and 15 diluents were purchased, as neat materials with a minimum
purity of 99 % from a number of chemical suppliers. Drug purity was verified using GC-MS. All
drugs were purchased from Cayman Chemical (Ann Arbor, MI), and the identities of the
compounds and the suppliers for the diluents are listed in Table 1.1.
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Table 1. 1. Analyte panel for drugs and diluents. Abbreviations or alternate, common, names are
shown in parenthesis next to the name. Compounds with an asterisk (*) were purchased as
hydrochloride salts. For the diluents, superscript letters indicate chemical supplier.
Drugs

Diluents

4-Methylethcathinone (4-MEC)

Acetaminophenb

4-Methylmethcathinone (Mephedrone)

Benzocaineb

Alprazolam

Boric Acide

Buprenorphine*

Caffeinee

Cocaine*

Diltiazem*c

Codeine

Hydroxyzine*d

Fentanyl

Levamisole*c

Heroin

Lidocaine*b

Methamphetamine*

Maltosef

Mitragynine

myo-Inositolh

Morphine

Phenacetina

Naltrexone*

Phenolphthaleing

PB-22

Procaine*c

Sufentanil

Sorbitold

Δ9-Tetrahydrocannabinol (THC)

Starchi

Suppliers: aTCI Chemicals (Portland, OR), bMillipore-Sigma (St. Louis, MO), cAcros Organics (Geel,
Belgium), dSpectrum Chemical MFG (New Brunswick, NJ), eBaker (Radnor, PA), fMPBio (Salon, OH),
g

Fisher Chemical (Fairlawn, NJ), hAlfa Aesar (Ward Hill, MA), iKroger (Morgantown, WV).

1.2.2 Instrumentation
Raman spectra were obtained using a TacticID portable 785 nm laser Raman instrument from
B&W Tek (Newark, DE). The unit was operated at either 20 %, 60 %, or 90 % laser power. Spectra
were acquired between the range of 176 cm-1 and 2900 cm-1 with 9 cm-1 resolution. Spectra were
automatically compared with the stored instrument library, as well as an in-house library created
using the same instrument. Assessment of spectral similarity was determined by the hit-qualityindex (HQI) with the low-end cut-off set to the instrument’s default of 85 %. A polystyrene
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reference material was utilized daily to verify the performance of the instrument before any further
measurements.

DART-MS spectra were acquired in positive ionization mode using an IonSense DART-SVP ion
source (Saugus, MA) with a JEOL AccuTOF 4G LC-plus mass spectrometer (Peabody, MA).
DART analysis was performed using the parameters outlined in Table 1.2. Direct sampling was
implemented by first placing the closed end of a capillary tube within the DART gas stream for
several seconds. Following brief cooling, the capillary was dipped and swirled into the powdered
sample before being introduced to the ion source. To perform drift compensation, polyethylene
glycol (PEG) was used. Resulting mass spectra were extracted and background subtracted using
an area of the chronogram where samples were not analyzed in msAxel. Spectra were assessed
manually, as well as through use of Mass Mountaineer (Fineview, NY) software with an in-house
library of over 600 compounds provided by the National Institute of Standards and Technology
(NIST). Search parameters for mixture analysis included a minimum peak height of 5 % relative
intensity, to minimize the potential for false positive identification, and an m/z agreement of 0.005
Da, based on the MS manufacturers tolerance. DART-MS is a well-established technique in
forensic seized drug analysis and therefore a validation of the technique was not required [69, 70].

Table 1. 2. DART-MS parameters for analysis.
DART Temperature

400 C

DART Gas

He

Orifice 1 Voltage

30 V, 60 V, 90 V switching at 0.2 s/scan

Ring Voltage

5V

Orifice 2 Voltage

20 V

Ion Guide

500 V

m/z Scan Range

m/z 50 – m/z 800
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1.2.3 Establishing Bias, Precision, & Reproducibility for the Portable Raman

Establishment of bias, precision, and reproducibility of the portable Raman instrument was
performed following ASTM E1683-02 [71], ASTM E1840-96 [72], and United Nations Office on
Drugs and Crime (UNODC) guidelines [17] by investigating interference from different types of
packaging, variability between analysts, mixture analysis, and verification of libraries within the
instrument. For these studies only a diluent panel was used for testing. Pure diluents were analyzed
inside glass vials and 2 mil plastic bags. The point-and-shoot adapter was used for analysis through
plastic bags and no adaptor for analysis through glass. Spectra were acquired in triplicate at both
60 % and 90 % laser power. Reproducibility and repeatability were established through triplicate
analysis performed by a total of three different operators. Analysis of variance (ANOVA) was
used to evaluate within and between operator variability. The instrument’s accuracy when
analyzing pure drugs and diluents was reported.

1.2.4 Assessment of Mixtures
A total of 64 mixtures of target drugs and common diluents were created to simulate street samples
and are shown in Table 1.3. Mixtures and ratios were selected based on published literature [73–
78]. As an example, a 1:4 ratio was prepared by mixing 10 mg of target drug with 40 mg of diluent.
All mixtures were analyzed via Raman through the plastic bags in triplicate at different areas to
account for variability in the sample. The mixture analysis setting was used for all mixtures, to
allow for identification of multiple compounds, with the number of hits—high spectrally correlated
compounds, set to 5 and the ratio threshold set to 15 %.

Previous studies have shown that DART-MS is an established technique for drugs of abuse
analysis [64, 67, 79, 80]. Therefore, a subset of 25 samples of the original 64 mixtures, highlighted
in Table 1.3, was selected to demonstrate the applicability of DART-MS for mixture analysis. The
accuracy of DART-MS, the TacticID instrument, and the orthogonal combination of both
techniques were determined. The combined accuracy was determined when the compounds were
correctly reported by either DART-MS or Raman. For example, if the drug was only reported from
the DART-MS results and the diluent reported with Raman, a correct identification of both drug
and diluent resulted for that particular mixture.
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Table 1. 3. Mixtures of drugs and diluents investigated in this study. Ratios with a checkmark
were analyzed using the portable Raman system (n = 64). Samples with an asterisk (*) were also
analyzed using DART-MS (n = 25).
Mass Ratio (Drug : Diluent)
Mixture
Heroin HCl / acetaminophen

1:4

1:7

✓*

✓

1:10

✓
✓

Fentanyl HCl / caffeine
Fentanyl HCl / methamphetamine HCl

✓

Cocaine HCl / levamisole

✓*

Fentanyl HCl / cocaine HCl

✓

Methamphetamine HCl / levamisole

✓*

Methamphetamine HCl / caffeine

✓*

Cocaine HCl / benzocaine

✓*

Alprazolam / caffeine

✓*

✓*

Alprazolam / levamisole

✓

✓

4-MMC HCl / maltose

✓*

✓

✓
✓*

4-MMC HCl / lidocaine
4-MEC HCl / maltose

1:20

✓*

4-MEC HCl / benzocaine

✓

✓
✓*

✓

PB-22 / lidocaine

✓

Sufentanil / caffeine

✓

Codeine / acetaminophen

✓

✓

✓

✓

Codeine / maltose

✓*

✓*

✓*

✓*

Morphine / maltose

✓*

✓*

✓*

✓

Naltrexone HCl / maltose

✓*

✓*

✓*

✓*

Buprenorphine HCl / starch

✓*

✓*

✓*

✓

Cocaine HCl / caffeine

✓

✓

✓

✓

Cocaine HCl / diltiazem

✓

✓

✓

✓

Cocaine HCl / hydroxyzine

✓

Cocaine HCl / lidocaine

✓

Cocaine HCl / maltose
Cocaine HCl / procaine
Cocaine HCl / boric acid

✓

✓
✓

✓

✓

✓

✓

✓
✓
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1.2.5. Authentic Samples
Fifteen adjudicated case samples were provided by the Maryland State Police Forensic Sciences
Division and analyzed via both the portable Raman system and DART-MS. Samples were assessed
in triplicate using both methods and compared against their respective libraries. The Raman laser
power was altered based on the color of the test material—20 % or 60 % for colored samples and
90 % power for white powders. Analysis of the authentic samples by DART was performed as
described previously in Table 1.2. Samples were prepared following MSP-FSD protocols by
dissolving 1 mg to 2 mg of powder in ≈1 mL of methanol. The averaged mass spectrum was
obtained for each sample from the triplicate analyses and used for identification in
MassMountaineer with a tolerance of ±0.005 Da and threshold of 5 %, which was lowered to 1 %
for differentiation of isomers. A multi-point drift compensation with tetracaine was used for
calibration to serve as a positive control.

1.3. Results and Discussion
1.3.1 Portable Raman
1.3.1.1 Laser Power and Operator Reproducibility
The hit quality index (HQI)—a common spectral comparison method [81, 82], is a measure of the
spectral correlation between the known library spectrum and the unknown test spectrum.
Rodriguez et al. described HQI by Equation 1.1 [83]. The Raman system reports the HQI as a
percentage where a value closer to 100 % represents higher similarity and a value closer to 0 %
represents poor similarity. Validation of the instrument was performed with diluents only as a cost
saving option. Figure 1.1 shows the distribution of the HQI for the diluents at 60 % (Figure 1.1A)
and 90 % (Figure 1.1B) power for three operators. All HQI values were greater than 90 % although
there was higher variation with Operator 3. ANOVA results showed myo-inositol with the highest
variation in the HQI value—2 % coefficient of variation (CV) observed between and within
operators. The percent CV for all other compounds was less than 2 %.
𝐻𝑄𝐼 =

(𝐿𝑖𝑏𝑟𝑎𝑟𝑦∗𝑇𝑒𝑠𝑡)2
(𝐿𝑖𝑏𝑟𝑎𝑟𝑦 ∗ 𝐿𝑖𝑏𝑟𝑎𝑟𝑦)(𝑇𝑒𝑠𝑡∗𝑇𝑒𝑠𝑡)

Equation (1.1)
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Figure 1. 1. Boxplots showing the distribution of the HQI (%) between three operators when the
portable Raman was operated at 60 % (A) and 90 % (B) power. All diluents were powders and
analyzed through plastic. Results for diltiazem are not shown because it was not present in the
instrument library. Each box and whisker plot represents nine total measurements.

1.3.1.2 Packaging Container
Figure 1.2 shows the distribution of HQIs when the diluents were measured through glass (Figure
1.2(A)) and plastic (Figure 1.2(B)) at 60 % and 90 % power as part of the instrument validation.
Although all HQI values were greater than 85 %, there was higher variation when the packaging
material was glass at both laser powers. Analysis of corn starch through glass only returned a result
using the mixture setting on the instrument and was not plotted in Figure 1.2. However, the
portable Raman instrument returned all the pure diluents tested as the top hit through both glass
and plastic. The instrument is designed to analyze compounds through transparent glass vials <5
mm diameter thickness, as used in this study. The thickness of the plastic bags used in this study
was 2 mil (0.0508 mm), which provided more consistent spectral intensities, and therefore
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typically higher HQIs compared to glass. Most of the drugs analyzed in this study were white
powders and the laser power selected for subsequent analysis was 90 % because of the lower
variation in the observed HQIs.

Figure 1. 2. Boxplot comparing the type of packaging—glass (A), and plastic (B), through which
the diluents were analyzed when the instrument was operated at 60 % and 90 % power, by three
operators. Diltiazem is not plotted as it was not present in the instrument’s library and returned a
“no match” result. Corn starch and maltose are not shown for glass (A) since the mixture setting
was used to get a hit and the mixture setting provides a spectral weight percentage instead of an
HQI. Note the differences between the y-axes, where (A) is from 84 % to 100 % and (B) is from
92 % to 100 %.
1.3.1.3. Performance Measures
The performance of an instrument in relation to a particular purpose is important to understand,
especially the false identification rates within a forensic context. Given that portable Raman
systems can be used for field applications or laboratory case work, the ability to correctly identify
compounds through glass or plastic packaging was investigated. A true positive (TP) was defined
as the instrument correctly associating the spectrum of the drug with the spectrum of the drug in
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its library; a true negative (TN) was defined as the instrument returning a “no match” result when
the drug was absent from the library or no drug was present in the sample; a false positive (FP)
was defined as the instrument erroneously returning a match for a drug that was not present; and a
false negative (FN) was defined as the instrument returning a “no match” result or failing to detect
a drug when it was present and its spectrum was in the library. Equations 1.2– 1.5 were used to
calculate the accuracy, sensitivity, specificity, and precision for pure target drugs and diluents.
When the compounds listed in Table 1.1 (except for THC) were analyzed through plastic, the
accuracy was 89 %, the true positive rate (TPR) was 100 %, the true negative rate (TNR) was 23
% and the precision was 88 %. When analysis was performed through glass, these values were 91
%, 100 %, 38 %, and 90 %, respectively. Although the portable Raman instrument demonstrated
high accuracy and TPR, the high false positive rate is one reason it is regarded as a preliminary
method. For this reason, we explored the potential of combining the portable Raman technique
with DART-MS.
(𝑇𝑃+𝑇𝑁)

𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 = (𝑇𝑃+𝐹𝑁+𝐹𝑃+𝑇𝑁)
𝑇𝑃

𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦(𝑇𝑃𝑅) = (𝑇𝑃+𝐹𝑁)
𝑇𝑁

𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦(𝑇𝑁𝑅) = (𝑇𝑁+𝐹𝑃)
𝑇𝑃

𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 = (𝑇𝑃+𝐹𝑃)

Equation (1.2)
Equation (1.3)
Equation (1.4)
Equation (1.5)

When binary diluent–diluent mixtures were analyzed, both compounds were correctly identified
in 17 % of the samples as shown in Figure 1.3(A). For drug-diluent mixtures as shown in Figure
1.3(B), both compounds were correctly identified in 19 % of the samples. In one instance, the
drug-diluent mixture of naltrexone-maltose (1:7 ratio), both compounds were incorrectly
identified. The mixtures at 1:4 and 1:7 ratios produced greater success in observing both
compounds, possibly due to the more equal proportions of each compound.
Cocaine is one of the most prevalent drugs of abuse. A study conducted in Austria reported 10 %
of seized samples analyzed contained cocaine as the active ingredient [84] with purities ranging
from 30 % to 60 % based on the geographic location [74, 85, 86]. Cocaine seizures in the European
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Union increased by more than 42 tonnes in 2018 from the previous year, the highest level recorded
[87]. A 2020 midyear report in the US ranked cocaine as the third most popular drug of abuse
comprising 13 % of drug seizures [88]. To gain a better understanding of the ability to identify
binary mixtures involving cocaine using portable Raman, the 90 % laser power data was analyzed
separately. Figure 1.3(C) shows both cocaine and the diluent were correctly identified in 14 % of
the tested mixtures. However, cocaine was reported as the detected drug in only 24 % of the
samples while the diluent was correctly identified 90 % of the time. Figure 1.4 presents the Raman
spectra obtained using the TacticID for cocaine, levamisole, and a ratio 1:4 cocaine-levamisole,
demonstrating areas of congruence for both compounds within the mixture. The peaks at 1000 cm1

, 1024 cm-1, 1276 cm-1, 1600 cm-1, and 1716 cm-1 are attributed to symmetric stretching of

aromatic ring breathing, asymmetric stretching of the aromatic ring, C-N stretching, C=C
stretching of the aromatic ring, and C=O symmetric stretching, respectively in cocaine HCl [89].
The levamisole spectrum is marked by the absence of a peak at 1716 cm-1 present in the mixture
and the cocaine spectra. Although cocaine and levamisole have a peak at 1260 cm-1 – 1276 cm-1,
representing CN stretching, it is weaker in levamisole. Similarly, cocaine has a stronger peak at
1600 cm-1 than levamisole.

Fentanyl remains a drug of interest especially in the United States due to the ongoing opioid crisis.
Three mixtures containing fentanyl were investigated in this study, but the portable Raman system
was only able to detect fentanyl in one sample. Possible reasons for the missed detections include
the limited amount of sample used in preparing the mixtures due to the high exposure risk
associated with fentanyl, and fluorescence. Surface-enhanced Raman spectroscopy (SERS) was
used by Haddad, Green and Lombardi to detect fentanyl in binary cocaine mixtures at 65 ppm
[90], overcoming the low concentrations of fentanyl found in street samples [74]. Green et al. also
compared the sensitivity of immunoassay based fentanyl testing strips, a TruNarc™ Raman
spectrometer and a Bruker Alpha™ Fourier-Transform Infrared (FTIR) spectrometer for detecting
fentanyl in street samples [91]. The TruNarc system resulted in an overall sensitivity of 25.7 %,
and 81.9 % sensitivity with FTIR for all test compounds including fentanyl. Although the
immunoassay test strips produced a higher sensitivity than both TruNarc and FTIR, they do not
discriminate between fentanyl and its analogues.
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Several portable Raman instruments are currently on the market for forensic applications. For a
comparison of the specifications between some of these instruments, refer to the Forensic
Technology Center of Excellence report [92]. Although the Scientific Working Group for the
Analysis of Seized Drugs (SWGDRUG) lists Raman spectroscopy as a category A technique
indicating it has the highest discriminatory power [10], some laboratories consider portable Raman
spectroscopy as category B due to the challenge in detecting all components in mixture samples.
For example, Spicher et al. reported an accuracy of 97.6 % when certified reference materials were
analyzed with a portable Raman, but 76.9 % accuracy for case samples [93] which usually contain
several compounds and have the controlled substance as the minor ingredient. The overall
accuracy of the portable Raman system in our study was 32 % in detecting the target drug, 89 %
in detecting the diluent, and 19 % in detecting both compounds in the binary mixtures analyzed
above, highlighting the need for complementary techniques that also provide results just as fast as
Raman and with minimal sample preparation.

Figure 1. 3. (A)— Percent of correctly reported compounds for each ratio and the total dataset
(purple) by the portable Raman system for diluent-diluent mixtures (ratios 1: 4 and 1:20, n = 6;
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ratios 1:7 and 1:10, n = 9). 83 % of correctly identified substances matched 1 compound and 17 %
matched for both compounds as shown by the purple bars; (B)—Percent of correctly reported
compounds by the portable Raman for drug-diluent mixtures (ratio 1: 4, n = 69; ratio 1:7, n = 51;
ratios 1:20 and 1:10, n = 36). 81 % of the identified substances returned a hit for 1 compound, and
19 % for both compounds in binary mixtures; (C)—Percent of correctly identified compounds in
cocaine- diluent mixtures (ratio 1:4, n = 21; ratios 1:10 and 1:7, n = 21; ratio 1:20, n = 12). All
mixtures were analyzed with 90 % laser power. The combined ratio is the overall percentage for
the number of identified compounds calculated from the total number of samples.

Figure 1. 4. Raman spectra of solid powders within plastic bags for cocaine, levamisole, and a
mixture ratio of 1:4, cocaine-levamisole. Areas of congruence with levamisole are highlighted in
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green and with cocaine are highlighted in blue to demonstrate spectral regions for each analyte
compared to the mixture. The area highlighted in gray represents contributions from both
levamisole and cocaine.
1.3.2. DART-MS
DART-MS was utilized as an orthogonal detection method for the samples tested by portable
Raman. SWGDRUG lists mass spectrometry as a category A technique [10], but like portable
Raman, DART-MS is used as a screening method. A polyethylene glycol standard was run on the
instrument to account for drift compensation. For analysis by traditional DART sampling, m/z
283.17513 was chosen for drift compensation by the software. Figure 1.5 shows a representative
DART-MS spectrum for a 1:4 mixture ratio of cocaine-levamisole mixture analyzed using
traditional microcapillary sampling.
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Figure 1. 5. Representative DART mass spectrum of a 1:4 mixture ratio of cocaine to levamisole.
Peaks of interest are labeled based on MassMountaineer identification along with the difference in
milli-mass units (mmu) between the library and the spectrum. Due to high concentration, the
levamisole peak fell outside of the ±5 mmu window, which was widened to encompass this peak.
For simplicity, only the spectrum collected at the 30 V voltage is shown.
Identification was based on manual inspection of the mass spectrum for each sample run in
triplicate and using MassMountaineer data analysis software (Rev: 5.0.7.0) with an in-house
library as demonstrated. Due to the structural properties of maltose and starch, these molecules do
ionize easily and were therefore not observed in the DART-MS spectra. Previous work has
demonstrated the ability to analyze carbohydrates via DART-MS; however, the authors utilized an
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in situ permethylation step to allow positive mode analysis [94]. In our proposed protocol, a
generic drug screening method was used with direct analysis and minimal sample preparation.
When considering positive identification of both the drug and diluent, the samples where the
diluent was not identified contained either maltose or starch, while the remaining samples had
positive identifications for the diluent, representing the loss of carbohydrate information due to the
ionization mode rather than instrument ability. As such, performance of the DART analysis was
judged by positive identification of the drug of abuse. The true positive rate was determined to be
93 % with false negative rate of 7 %.

In many cases, peaks not corresponding to the protonated molecule were present in the mass
spectrum. Upon analysis, the majority of these peaks were easily explained through the presence
of dimers and loss of water. Codeine, acetaminophen, naltrexone, caffeine, levamisole, and
alprazolam demonstrated the formation of dimers while –OH losses were observed for
buprenorphine, morphine, and codeine. In one instance, methamphetamine was not identified in
the sample due to the 5 % peak threshold set by the search algorithm. Manual examination of the
mass spectrum easily revealed the methamphetamine peak of m/z 150 (Figure 1.6).
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Figure 1. 6. Demonstration of the lack of identification of the methamphetamine peak in the
MassMountaineer software due to the peak threshold value of 5 %. MassMountaineer
identifications are shown along with the milli-mass unit difference between the library and the
spectrum. Methamphetamine m/z 150 can be seen when zooming into the group of peaks present
near m/z 150. Abundance of less than 2 %. The relative abundance window was widened to
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observe the methamphetamine peak. For simplicity, only the spectrum collected at the 30 V
voltage is shown.

1.3.3. Orthogonal Detection
Analytical schemes which leverage orthogonal techniques to provide complimentary identification
data have demonstrated improved reliability and accuracy, and therefore the data from the portable
Raman and DART-MS were combined to compare the performance rates of the orthogonal
approach. It is important to note that although Raman spectroscopy and mass spectrometry are
considered SWGDRUG category A techniques, these instruments are being assessed as rapid
screening techniques. Although the portable Raman initially struggled to identify the drug analyte
in dilute mixture ratios, the diluent was correctly identified 100 % of the time in the subset of
mixtures used for the orthogonal detection study. In contrast, DART-MS excelled at detecting both
drug and diluent compounds; however, many diluents were not identified due to analysis in
positive mode. Therefore, the combination of both techniques yielded high accuracy for both drug
and diluent compounds in all the analyzed samples, demonstrating the combined strength and
enhanced reliability through orthogonal combination. Table 1.4 presents the comparison of overall
performance rates for the samples assessed orthogonally, first by portable Raman and followed by
DART-MS analysis. Specificity does not apply because the instruments always returned a match
based on the library search. Performance measures were determined using Equations 1.2-1.5.
Accuracy for both analytes (drug + diluent) was determined by the sum of the samples producing
identifications for both the drug and diluent divided by the total number of samples. Lastly, the
accuracy of the combination of the two instruments was assessed as the sum of the samples
producing the respective identifications by either portable Raman and/or DART-MS divided by
the total number of samples (Table 1.4).
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Table 1. 4. Comparison of accuracy between Raman, DART-MS, and the orthogonal combination
when mixtures were analyzed. The accuracy of the Raman shown below is only for the 25 mixtures
that were also analyzed by DART-MS. Specificity is not applicable as there were no True negatives
in this study.
Raman
Drug

Diluent

Accuracy

48 %

100 %

Sensitivity

56 %

Specificity
Precision

DART-MS
Both

Combined
Both

Both

Analytes*

Analytes

33 %

26 %

96 %

92 %

36 %

28 %

96 %

NA

NA

NA

NA

NA

100 %

92 %

82 %

78 %

100 %

Drug

Diluent*

56 %

85 %

100 %

56 %

NA

NA

78 %

100 %

Analytes

* Diluents measured by DART-MS were acetaminophen, benzocaine, caffeine, levamisole,
lidocaine, maltose, and starch.

1.3.4. Authentic Sample Results
To investigate how the orthogonal approach worked for real samples, fifteen authentic adjudicated
case samples were obtained from the Maryland State Police Forensic Sciences Division. The
majority of the samples were white powders or white crystalline samples and several samples were
off-white to gray-brown. All samples were analyzed by portable Raman through plastic bags or
through capsules. Table 1.5 provides the results of the portable Raman and DART-MS analyses
along with the ground-truth results which were obtained using GC-MS analysis. Accuracy was
defined as the ability of the instrument to detect those compounds assigned as ground truth for
each respective group (drug, diluent, or all analytes). For example, if the ground truth contained
two diluents, both needed to be detected for a positive result for diluent accuracy. In this manner,
detection of all ground truth compounds was required. The overall accuracy of the portable Raman
was 44 % for all analytes, whereas the accuracy of the DART-MS analysis was 74 % for all
analytes. The failure of the portable Raman instrument to detect some controlled substances due
to their low proportion, was compensated for with DART-MS as the combination of the two
techniques resulted in 83 % accuracy in the detection of all ground truth compounds for the
authentic samples. It is important to note that while both instruments performed well, in one
instance, both instruments were needed to yield a full profile of the unknown substance as
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demonstrated by case #1. Some diluents can foul the GC-MS source, therefore most drug
chemistry laboratories screen samples for controlled substances but do not always report diluents.
In one case, #3, a diluent was detected by both Raman and DART-MS but not observed by GCMS. Given that the diluent was mannitol it is expected as GC-MS is not sensitive to sugar alcohols.

Table 1. 5. Summary of authentic samples analyzed through Raman and DART-MS and ground
truth as observed from GC-MS. An explanation is provided for compounds detected via DARTMS but not observed via GC-MS analysis.
Case

1

GC-MS Results (Ground

Portable Raman

DART-MS Result

Truth)

Results

Heroin

--

Heroin

Mannitol

Mannitol

--

Quinine

--

Quinine

6-Monoacetylmorphine

--

6-Monoacetylmorphine

Additional Hits:
Hydrogen peroxide
Sodium azide
JWH-122
2

3

Cocaine

Cocaine HCl

Cocaine

Levamisole

Levamisole HCl

Levamisole

Fentanyl

--

Fentanyl

Caffeine

Caffeine

Caffeine

Diphenhydramine

--

--

Quinine

--

Quinine

Additional Hits:

Additional Hits:

Erythromycin

Levamisole

Mannitol

Mannitol

Sodium azide
4

MDMA

MDMA HCl

MDMA

Additional Hits:
Centrophenoxine
Buprenorphine HCl
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Case

GC-MS Results (Ground

Portable Raman

Truth)

Results

DART-MS Result

2-N,N-diethylamino-1-(4methoxyphenyl)-1-propanone
5

Fentanyl

--

Fentanyl

Acetaminophen

Acetaminophen

Acetaminophen
Additional Hits:
Xylitol

6

7

Cocaine

Cocaine base

Cocaine

Levamisole

Levamisole

Levamisole

Phenacetin

Phenacetin

Phenacetin

Caffeine

Caffeine

Caffeine

Starch
8

9

Caffeine

--

Caffeine

Mannitol

Mannitol

Mannitol

Quinine

--

Quinine

No Drugs of Abuse

Maleic anhydride

Caffeine

Hexobarbitone
10

11

Fentanyl

--

Fentanyl

Acetylsalicylic Acid

Acetylsalicylic Acid

Acetylsalicylic Acid

Benzocaine

--

--

Caffeine

--

Caffeine

N-Phenylpropamide

--

--

Quinine

--

Quinine

Cocaine

Cocaine base

Cocaine

Levamisole

--

Levamisole

Phenacetin

Phenacetin

Phenacetin

Inositol

--

--

Additional Hits:
Thebaine
12

Phentermine

Phentermine HCl

Phentermine

13

Methamphetamine

--

Methampehtamine

Ketamine

Ketamine HCl

Ketamine

Phenacetin

Phenacetin
Additional Hits:
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Case

GC-MS Results (Ground

Portable Raman

Truth)

Results

DART-MS Result

Dimethyl sulfone
14

Heroin

--

Heroin

6-Monoacetylmorphine

--

6-Monoacetylmorphine

Mannitol

Mannitol

Mannitol

Quinine

--

Quinine

6-Acetylcodeine

--

--

Additional Hits:
Sorbitol
Hydrogen peroxide
Hydroxyzine pamoate
Codeine
15

Cocaine

Cocaine HCl

Cocaine

Benzoylecgonine

--

--

Table 1. 6. The accuracy results for the authentic case samples. The calculation of the accuracy
was performed in similar fashion as described above in section 1.3.5. Sample #9 was not included
since it was a true negative sample.
Performance

Raman

DART-MS

Combined

Drug Accuracy

41 %

82 %

82 %

Diluent Accuracy

45 %

68 %

83 %

44 %

74 %

83 %

Measure

Accuracy for All
Analytes

1.4. Conclusions
On-site drug testing can help reduce drug backlogs, but the safety of personnel conducting the tests
is important due to the increasing potency of illicitly manufactured substances. Portable Raman
analysis allows for testing without opening certain types of packing, thereby reducing potential
drug exposures. It produces high confidence in results when analyzing pure substances, but
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accuracy suffers when mixtures are present, as demonstrated in this study. The use of orthogonal
techniques such as DART-MS can help resolve some of the challenges encountered in Raman
analysis.

In this study, a portable Raman spectrometer was validated according to the UNODC guidelines
on a panel of 15 commonly encountered drugs of abuse and 15 diluent compounds. The HQI for
pure diluents through plastic was higher than that for glass, >90 % and >86 %, respectively. The
between-operator precision was low at 2 %. Analysis through plastic resulted in an accuracy of
89 % and precision of 88 %, while analysis through glass resulted in an accuracy of 91 % and
precision of 90 %. The system excelled at identification of analytes in their pure form and in higher
percent ratio but demonstrated some difficulty in detection the analyte at low concentrations. In
comparison, DART-MS demonstrated high accuracy and sensitivity for the drug analytes of
interest and many of the diluent compounds. However, DART-MS struggled with diluent
compounds that perform better in negative mode (only positive mode was used). Although these
techniques are strong on their own, the combination of both instruments resulted in a drug accuracy
of 96 %, diluent accuracy of 100 %, and overall accuracy for two-part mixtures of 96 %. Analysis
of authentic case samples using both techniques resulted in 44 % accuracy by Raman, 74 % by
DART-MS, and 83 % accuracy when both techniques were combined. This combination of
orthogonal data demonstrates the improved reliability and accuracy possible when both techniques
are used in screening. The ability to detect both drug and diluent analytes provides useful
information for drug intelligence operations that can be performed rapidly for improved
investigative leads and real-time decision making.
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Chapter 2: Implementing Machine Learning for the Identification and
Classification of Compound and Mixtures in Portable Raman Instruments
Reproduced with additions and permission from Travon Cooman, Tatiana Trejos, Aldo H. Romero, Luis E. Arroyo,
Chemical Physics Letters, Vol. 787 (2022): 139283, and Elsevier. DOI: 10.1016/j.cplett.2021.139283

2.1.0 Introduction
Portable instruments are becoming more prevalent due to their ability to provide quick results onthe-spot [2, 5, 16, 95–97]. While data can be acquired in a short time, the specificity and accuracy
of these instruments and the safety of the operators remain important. Portable analytical
techniques for on-site applications include electrochemical systems [4], paper-based analytical
devices [98, 99], mass spectrometry methods [3, 100–102], and spectroscopy methods [2, 103–
105]. In scenarios where analysis requires packages to be opened at point-of-contact areas, the risk
of exposure to unknown substances by personnel remains high. Raman spectroscopy provides
unique advantages over other techniques due to its ability to be noninvasive [106–108] and even
to analyze substances through packaging [109–111], thereby minimizing the risk of exposure to
operators. For example, the Agilent Resolve Handheld Raman—a spatially offset Raman
spectrometer (SORS) which allows subsurface analysis, is capable of analyzing explosives, drug
precursors, toxic industrial chemicals, chemical warfare agents, and narcotics through packaging
such as colored plastic and glass, paper, sacks, cardboard and fabric [110]. Conventional Raman
systems are better suited for analysis through clear plastic bags and vials, and translucent
packaging. Portable Raman systems have proved useful for the molecular identification of
minerals [112, 113], analysis of biomaterials [114], food quality monitoring [115–118], and
analysis of drugs [5, 13, 119, 120]. Raman spectroscopy is broadly applied in chemistry,
biochemistry, biology, and medicine [121–123] due to its ability to provide a structural fingerprint
by which molecules can be identified. Nonetheless, the instrument’s accuracy is dependent on the
incorporated algorithms that return an identification for an unknown compound.
Organic molecules, when stimulated by an excitation source such as a laser, results in a photon
frequency shift due to the vibration produced by the interaction between the applied
electromagnetic field and the electronic charge, which is unique to the molecule. Depending on
the functional groups in the molecule, it may undergo symmetric, asymmetric stretching, or
36

bending. These factors influence the Raman shifts and peak shapes and intensities observed in the
resulting Raman spectrum. Unknown compounds can be compared to the vibrational signatures in
a library. A common metric used for spectral comparisons is the hit quality index (HQI) where 1.0
represents a perfect correlation and 0.0 represents poor correlation [83]. A threshold for a ‘match’
or ‘no match’ result can be predetermined by the user based on the application. For example, in
forensic science where mixtures are commonly encountered in seized drugs, a threshold of 85%
for the HQI may be selected, but in the pharmaceutical industry where purer substances are
encountered, the threshold might be 95% [82]. Spectra can be preprocessed to reduce the baseline
by computing the first derivative to allow for higher discrimination [83]. One drawback to using
the HQI is that incorrect identifications of similar compounds with small spectra differences may
result [124]. Other metrics for spectral comparison include Pearson’s correlation—where a value
of 1 represents a perfect correlation and -1 represents a poor correlation, and cosine similarity—
where 0 represents poor correlation and 1 represents perfect correlation [125]. However, these
methods work well when there is a linear relationship between spectral features but can perform
poorly with complex spectra of multiple mixtures.
One method used to recognize spectral features, otherwise difficult to visualize by the naked eye,
is machine learning. Developed algorithms are trained to extract relevant features or patterns in
complex spectra and predict the classes of new compounds, thereby improving detection,
identification, and classification. Several supervised and unsupervised algorithms have been used
in combination with spectroscopic data, including principal component analysis, k-nearest
neighbors, random forests, support vector machines and deep learning methods [126–129].
Principal component analysis (PCA)—a dimensionality reduction technique, can also be used for
classification, although it is not a preferred technique, or it can be used as a pipeline for
discriminant analysis and other classification techniques [19, 120, 130, 131]. k-nearest neighbors
(kNN) which performs classification by assigning unlabeled data to a class most similar to the
labeled data [132] has been used to classify drugs of abuse [126], tablets [128, 129], and solvents
[127]. Support vector machines (SVM) use a decision boundary to separate classes by maximizing
their distance using a hyperplane [133]. High accuracy was achieved with SVM when analyzing
mixtures of acetaminophen with sugars and inorganic materials [134], adulterated olive oil [135],
and the differentiation between human and animal blood [136].
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A less commonly used classifier for spectral classification is the naïve bayes (NB) which computes
the probability that an unknown sample belongs to a class [137]. A drawback of the NB algorithm
is that it assumes each spectral feature is independent which is not the case for spectral data [134].
A commonly used classifier due to its robustness and ability to handle regression and multiclass
classification is random forests [126, 127, 138, 139]. Random forests (RF) consist of tree-like
classifiers where an input spectrum receives a vote for a class by each tree and assigned to the
most popular class determined by the trees [140].
Deep learning methods—an important branch of machine learning, are becoming more prevalent
over traditional classification methods due to their ability to extract relevant information about
labeled data in more complex datasets which contain non-linearly separable classes. Two
algorithms used for Raman spectroscopy include artificial neural networks (NN) and convolutional
neural networks (CNN) which are mathematically modeled after the nervous system [141]. CNNs
are preferably used for image classification and object recognition over NNs—which can lead to
overfitting, making CNNs ideal for spectral comparison [142] as spectra can be considered
fingerprints of molecules or crystalline materials. A smart Raman spectrometer was developed to
analyze pure compounds, binary and ternary mixtures with 99.9%, 96.7%, and 85.7% accuracy,
respectively using a CNN [143].
Whereas many of these techniques have been used post acquisition of the spectra [120, 130,
131][128, 144–148], few have incorporated these methods in portable Raman instruments
[143][82, 149]. Additionally, the combination of existing spectral comparison methods with
classification techniques have not been explored. When machine learning algorithms are utilized,
the main goal is to report a compound, but misclassification is common when new compounds are
absent from the instrument’s library, or the trained model has not seen the new compound.
In this study, we evaluate the accuracy of six machine learning algorithms— kNN, NB, RF, SVM,
NN, and CNN, on pure drug spectra, binary, ternary and quaternary mixtures and compare their
accuracy to a recently validated portable Raman instrument which uses a HQI algorithm [150].
The findings presented here can be easily adapted to many other materials and applications.
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2.2.0 Methods
2.2.1 Spectra Acquisition
Spectra were acquired using a TacticID portable Raman spectrometer with a 300 mW, 785 nm
laser, and 9 cm-1 resolution (B&W Tek, Newark, DE). As previously described [150], spectra were
measured for 14 drugs—4-methylethcathinone (4-MEC), 4-methylmethcathinone (4-MMC),
alprazolam, buprenorphine, cocaine, codeine, fentanyl, heroin, methamphetamine, mitragynine,
morphine, naltrexone, PB-22, sufentanil and 15 diluents— acetaminophen, benzocaine, boric acid,
caffeine, diltiazem, hydroxyzine, levamisole, lidocaine, maltose, myo-inositol, phenacetin,
phenolphthalein, procaine, sorbitol, starch, using a laser power of 60% and 90%. The powder
samples were measured through glass vials and 2 mil plastic bags. A total of 444 pure spectra were
collected.
The spectra were baseline corrected and truncated to include Raman shifts from 176 to 2000 cm 1

. A Savitsky-Golay filter [151] was applied to smooth the spectra with a 5 point window length

and third order polynomial.
2.2.2 Spectral Comparison
The cosine similarity and Pearson’s correlation were used to compare an authentic test set of pure
compounds (referred to as authentic pure set). These compounds included acetaminophen,
benzocaine, boric acid, caffeine, diphenhydramine, levamisole, lidocaine, maltose, mannitol, myoinositol, phenacetin, and procaine. Spectra were acquired in triplicate through 2 mil plastic bags
and the instrument was operated at 90% power. A second database was created comprising of the
first derivative of the spectra from section 2.2.1 and comparisons to the test spectra were reported.
2.2.3 Pure Spectra Algorithms
To increase the number of spectra used for training and testing the algorithms, 444,000 spectra
were created by multiplying each spectrum by 1000 random numbers between 0 and 1. This
introduced variation in the spectra and simulated instances where there might be suppression of
signals, hence training the algorithms under the worst-case scenario. Data augmentation is
common when spectra are limited for training machine learning algorithms (MLA) [146, 152,
153]. Each spectrum was normalized to its maximum intensity.
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Six machine learning algorithms including k-nearest neighbors (kNN), naïve bayes (NB), support
vector machine (SVM), random forest (RF), neural network (NN), and convolutional neural
network (CNN) were explored. Scikit-learn v 0.24.1 [154] in python was used for kNN, NB, SVM
and RF classifiers. NN and CNN were based on Keras v 2.4.0 with Tensorflow v 2.4.1 backend
[155]. Two models were created for each algorithm—one based on the compounds (n = 29) where
the output is the compounds listed in Table 2.1 and the second based on the compounds’ class (n
= 17), also listed in Table 2.1. Training was performed on 80% of the data in each class and testing
on 20% using the stratify argument in the train_test_split function in Scikit-learn. The optimized
parameters selected for the algorithms included neighbors = 2 for kNN, RF— estimators = 1000,
max depth = 20, and SVM— kernel = linear, regularization parameter -C =0.09.
Table 2. 1. The compounds and their designated class used for training the pure spectra algorithms.
Compounds

Class

4-MEC

Cathinone

4-MMC

Cathinone

Acetaminophen

Analgesic

Alprazolam

Benzodiazepine

Benzocaine

Anesthetic

Boric acid

Acid

Buprenorphine

Opioid

Caffeine

Stimulant

Cocaine

Cocaine

Codeine

Opioid

Diltiazem

Calcium channel blocker

Fentanyl

Opioid

Hydroxyzine

Antihistamine

Levamisole

Anthelmintic

Lidocaine

Anesthetic

Maltose

Sugar

Methamphetamine

Amphetamine

Mitragynine

Opioid
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Compounds

Class

Morphine

Opioid

Myo-inositol

Sugar

Naltrexone

Opiate antagonist

PB-22

Cannabinoid

Phenacetin

Analgesic

Phenolphthalein

Dye

Procaine

Anesthetic

Sorbitol

Sugar

Starch

Carbohydrate

Sufentanil

Opioid

The CNN architecture was the same for the compound model and compound class model. The
entire spectrum of shape 457x1 was used as the input with 200 3x1 filters in the first convolutional
layer, followed by a 2x1 MaxPooling layer, a second convolutional layer with 100 3x1 filters, a
2x1 MaxPooling layer, a Flatten layer and an output layer with 29 units for the compound model
and 17 units for the compound class model. The ReLU activation function was used in the
convolutional layers whereas the softmax function was used in the output layer. The model was
compiled using the categorical cross entropy loss function and the adam optimizer function. Early
stopping was implemented and the batch size for the fitted models was 5.
Two fully connected NN models were created—one for compound, and another for compound
class prediction. The compound model contained 457 neurons in the first hidden layer, 20%
dropout to prevent overfitting [156], 128 and 114 neurons in the second and third hidden layers,
respectively, with 10% dropout in both layers, the output layer contained 29 units. The compound
class model contained 457 neurons in the first hidden layer with 20% dropout, 100 neurons in the
second, third and fourth layers with 20% dropout in the second layer, and 10% in the third and
fourth layers. The output layer contained 17 units. Both models used the sigmoid activation
function in the output layer, the ReLU activation function in the hidden layers, a batch size of 32
for fitting the model, and implemented early stopping.
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The authentic pure set was used to evaluate the models. Two drugs—diphenhydramine
(antihistamine), and mannitol (sugar) were not included in the training data and misclassification
of these substances were expected with the models trained based on the compounds. However, we
evaluated their classification based on the drug class.
2.2.4 Binary Mixture Algorithms
Simulated binary mixtures of the drugs and diluents from Section 2.2.2 were created using
Equation 2.1.
𝑀𝑖𝑥𝑡𝑢𝑟𝑒 = (𝑑𝑟𝑢𝑔 ∗ 𝑟) + (𝑑𝑖𝑙𝑢𝑒𝑛𝑡 ∗ (1 − 𝑟))

𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟐. 𝟏

Where r = [0.05, 0.10, 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45, 0.50, 0.55, 0.60, 0.65, 0.70, 0.75,
0.80, 0.85, 0.90, 0.95], drug and diluent are the spectrum of each drug or diluent, respectively, and
mixture is the resulting spectrum. Machine learning algorithms including SVM, kNN, CNN, NN,
NB and RF were first evaluated on this simulated dataset (binary mix #1). A second dataset (binary
mix #2) was created by applying a Fast Fourier transformation (FFT) to the spectra and multiplying
each intensity by a random number between 0.8 and 1.2 as an additional data augmentation
technique, adding unequal variation to the spectra. The two datasets were combined, and
algorithms were selected to evaluate the data based upon the reported accuracy on binary mix #1
and the time taken to train the models. Therefore, NB was not selected due to poor accuracy and
RF due to longer training times. The combined binary mixtures dataset contained 1,152,312
spectra with 224 unique binary compound mixtures and 88 binary compound class mixtures. A list
of the mixtures can be found in Table 2.2.
Table 2. 2. Compound mixtures and class mixtures used for binary mixtures algorithms.
Compound Mixtures

Compound Class Mixtures

4-MEC – Acetaminophen

Cathinone – Analgesic

4-MEC – Benzocaine

Cathinone – Anesthetic

4-MEC – Boric acid

Cathinone – Acid

4-MEC – Caffeine

Cathinone – Stimulant

4-MEC – Diltiazem

Cathinone – Calcium Channel Blocker

4-MEC – Hydroxyzine

Cathinone – Antihistamine

4-MEC – Levamisole

Cathinone – Anthelmintic
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Compound Mixtures

Compound Class Mixtures

4-MEC – Lidocaine

Cathinone – Anesthetic

4-MEC – Maltose

Cathinone – Sugar

4-MEC – Morphine

Cathinone – Opioid

4-MEC – Myo-inositol

Cathinone – Sugar

4-MEC – Phenacetin

Cathinone – Analgesic

4-MEC – Phenolphthalein

Cathinone – Dye

4-MEC – Procaine

Cathinone – Anesthetic

4-MEC – Sorbitol

Cathinone – Sugar

4-MEC – Starch

Cathinone – Carbohydrate

4-MMC – Acetaminophen

Cathinone – Analgesic

4-MMC – Benzocaine

Cathinone – Anesthetic

4-MMC – Boric acid

Cathinone – Acid

4-MMC – Caffeine

Cathinone – Stimulant

4-MMC – Diltiazem

Cathinone – Calcium Channel Blocker

4-MMC – Hydroxyzine

Cathinone – Antihistamine

4-MMC – Levamisole

Cathinone – Anthelmintic

4-MMC – Lidocaine

Cathinone – Anesthetic

4-MMC – Maltose

Cathinone – Sugar

4-MMC – Morphine

Cathinone – Opioid

4-MMC – Myo-inositol

Cathinone – Sugar

4-MMC – Phenacetin

Cathinone – Analgesic

4-MMC – Phenolphthalein

Cathinone – Dye

4-MMC – Procaine

Cathinone – Anesthetic

4-MMC – Sorbitol

Cathinone – Sugar

4-MMC – Starch

Cathinone – Carbohydrate

Alprazolam – Acetaminophen

Benzodiazepine – Analgesic

Alprazolam – Benzocaine

Benzodiazepine – Anesthetic

Alprazolam – Boric acid

Benzodiazepine – Acid

Alprazolam – Caffeine

Benzodiazepine – Stimulant

Alprazolam – Diltiazem

Benzodiazepine – Calcium Channel
Blocker

Alprazolam – Hydroxyzine

Benzodiazepine – Antihistamine

Alprazolam – Levamisole

Benzodiazepine – Anthelmintic
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Compound Mixtures

Compound Class Mixtures

Alprazolam – Lidocaine

Benzodiazepine – Anesthetic

Alprazolam – Maltose

Benzodiazepine – Sugar

Alprazolam – Morphine

Benzodiazepine – Opioid

Alprazolam – Myo-inositol

Benzodiazepine – Sugar

Alprazolam – Phenacetin

Benzodiazepine – Analgesic

Alprazolam – Phenolphthalein

Benzodiazepine – Dye

Alprazolam – Procaine

Benzodiazepine – Anesthetic

Alprazolam – Sorbitol

Benzodiazepine – Sugar

Alprazolam – Starch

Benzodiazepine – Carbohydrate

Buprenorphine – Acetaminophen

Opioid – Analgesic

Buprenorphine – Benzocaine

Opioid – Anesthetic

Buprenorphine – Boric acid

Opioid – Acid

Buprenorphine – Caffeine

Opioid – Stimulant

Buprenorphine – Diltiazem

Opioid – Calcium Channel Blocker

Buprenorphine – Hydroxyzine

Opioid – Antihistamine

Buprenorphine – Levamisole

Opioid – Anthelmintic

Buprenorphine – Lidocaine

Opioid – Anesthetic

Buprenorphine – Maltose

Opioid – Sugar

Buprenorphine – Morphine

Opioid – Opioid

Buprenorphine – Myo-inositol

Opioid – Sugar

Buprenorphine – Phenacetin

Opioid – Analgesic

Buprenorphine – Phenolphthalein

Opioid – Dye

Buprenorphine – Procaine

Opioid – Anesthetic

Buprenorphine – Sorbitol

Opioid – Sugar

Buprenorphine – Starch

Opioid – Carbohydrate

Cocaine – Acetaminophen

Cocaine – Analgesic

Cocaine – Benzocaine

Cocaine – Anesthetic

Cocaine – Boric acid

Cocaine – Acid

Cocaine – Caffeine

Cocaine – Stimulant

Cocaine – Diltiazem

Cocaine – Calcium Channel Blocker

Cocaine – Hydroxyzine

Cocaine – Antihistamine

Cocaine – Levamisole

Cocaine – Anthelmintic

Cocaine – Lidocaine

Cocaine – Anesthetic
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Compound Mixtures

Compound Class Mixtures

Cocaine – Maltose

Cocaine – Sugar

Cocaine – Morphine

Cocaine – Opioid

Cocaine – Myo-inositol

Cocaine – Sugar

Cocaine – Phenacetin

Cocaine – Analgesic

Cocaine – Phenolphthalein

Cocaine – Dye

Cocaine – Procaine

Cocaine – Anesthetic

Cocaine – Sorbitol

Cocaine – Sugar

Cocaine – Starch

Cocaine – Carbohydrate

Codeine – Acetaminophen

Opioid – Analgesic

Codeine – Benzocaine

Opioid – Anesthetic

Codeine – Boric acid

Opioid – Acid

Codeine – Caffeine

Opioid – Stimulant

Codeine – Diltiazem

Opioid – Calcium Channel Blocker

Codeine – Hydroxyzine

Opioid – Antihistamine

Codeine – Levamisole

Opioid – Anthelmintic

Codeine – Lidocaine

Opioid – Anesthetic

Codeine – Maltose

Opioid – Sugar

Codeine – Morphine

Opioid – Opioid

Codeine – Myo-inositol

Opioid – Sugar

Codeine – Phenacetin

Opioid – Analgesic

Codeine – Phenolphthalein

Opioid – Dye

Codeine – Procaine

Opioid – Anesthetic

Codeine – Sorbitol

Opioid – Sugar

Codeine – Starch

Opioid – Carbohydrate

Fentanyl – Acetaminophen

Opioid – Analgesic

Fentanyl – Benzocaine

Opioid – Anesthetic

Fentanyl – Boric acid

Opioid – Acid

Fentanyl – Caffeine

Opioid - Stimulant

Fentanyl – Diltiazem

Opioid – Calcium Channel Blocker

Fentanyl – Hydroxyzine

Opioid – Antihistamine

Fentanyl – Levamisole

Opioid – Anthelmintic

Fentanyl – Lidocaine

Opioid – Anesthetic

Fentanyl – Maltose

Opioid – Sugar
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Compound Mixtures

Compound Class Mixtures

Fentanyl – Morphine

Opioid – Opioid

Fentanyl – Myo-inositol

Opioid – Sugar

Fentanyl – Phenacetin

Opioid – Analgesic

Fentanyl – Phenolphthalein

Opioid – Dye

Fentanyl – Procaine

Opioid – Anesthetic

Fentanyl – Sorbitol

Opioid – Sugar

Fentanyl – Starch

Opioid – Carbohydrate

Heroin – Acetaminophen

Opioid – Analgesic

Heroin – Benzocaine

Opioid – Anesthetic

Heroin – Boric acid

Opioid – Acid

Heroin – Caffeine

Opioid – Stimulant

Heroin – Diltiazem

Opioid – Calcium Channel Blocker

Heroin – Hydroxyzine

Opioid – Antihistamine

Heroin – Levamisole

Opioid – Anthelmintic

Heroin – Lidocaine

Opioid – Anesthetic

Heroin – Maltose

Opioid – Sugar

Heroin – Morphine

Opioid – Opioid

Heroin – Myo-inositol

Opioid – Sugar

Heroin – Phenacetin

Opioid – Analgesic

Heroin – Phenolphthalein

Opioid – Dye

Heroin – Procaine

Opioid – Anesthetic

Heroin – Sorbitol

Opioid – Sugar

Heroin – Starch

Opioid – Carbohydrate

Methamphetamine –

Amphetamine – Analgesic

Acetaminophen
Methamphetamine – Benzocaine

Amphetamine – Anesthetic

Methamphetamine – Boric acid

Amphetamine – Acid

Methamphetamine – Caffeine

Amphetamine – Stimulant

Methamphetamine – Diltiazem

Amphetamine – Calcium Channel
Blocker

Methamphetamine – Hydroxyzine

Amphetamine – Antihistamine

Methamphetamine – Levamisole

Amphetamine – Anthelmintic

Methamphetamine – Lidocaine

Amphetamine – Anesthetic
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Compound Mixtures

Compound Class Mixtures

Methamphetamine – Maltose

Amphetamine – Sugar

Methamphetamine – Morphine

Amphetamine – Opioid

Methamphetamine – Myo-inositol

Amphetamine – Sugar

Methamphetamine – Phenacetin

Amphetamine – Analgesic

Methamphetamine –

Amphetamine – Dye

Phenolphthalein
Methamphetamine – Procaine

Amphetamine – Anesthetic

Methamphetamine – Sorbitol

Amphetamine – Sugar

Methamphetamine – Star

Amphetamine – Carbohydrate

Mitragynine – Acetaminophen

Opioid agonist – Analgesic

Mitragynine – Benzocaine

Opioid agonist – Anesthetic

Mitragynine – Boric acid

Opioid agonist – Acid

Mitragynine – Caffeine

Opioid agonist – Stimulant

Mitragynine – Diltiazem

Opioid agonist – Calcium Channel
Blocker

Mitragynine – Hydroxyzine

Opioid agonist – Antihistamine

Mitragynine – Levamisole

Opioid agonist – Anthelmintic

Mitragynine – Lidocaine

Opioid agonist – Anesthetic

Mitragynine – Maltose

Opioid agonist – Sugar

Mitragynine – Morphine

Opioid agonist – Opioid

Mitragynine – Myo-inositol

Opioid agonist – Sugar

Mitragynine – Phenacetin

Opioid agonist – Analgesic

Mitragynine – Phenolphthalein

Opioid agonist – Dye

Mitragynine – Procaine

Opioid agonist – Anesthetic

Mitragynine – Sorbitol

Opioid agonist – Sugar

Mitragynine – Starch

Opioid agonist – Carbohydrate

Morphine – Acetaminophen

Opioid – Analgesic

Morphine – Benzocaine

Opioid – Anesthetic

Morphine – Boric acid

Opioid – Acid

Morphine – Caffeine

Opioid – Stimulant

Morphine – Diltiazem

Opioid – Calcium Channel Blocker

Morphine – Hydroxyzine

Opioid – Antihistamine

Morphine – Levamisole

Opioid – Anthelmintic
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Compound Mixtures

Compound Class Mixtures

Morphine – Lidocaine

Opioid – Anesthetic

Morphine – Maltose

Opioid – Sugar

Morphine – Morphine

Opioid – Opioid

Morphine – Myo-inositol

Opioid – Sugar

Morphine – Phenacetin

Opioid – Analgesic

Morphine – Phenolphthalein

Opioid – Dye

Morphine – Procaine

Opioid – Anesthetic

Morphine – Sorbitol

Opioid – Sugar

Morphine – Starch

Opioid – Carbohydrate

Naltrexone – Acetaminophen

Opiate antagonist – Analgesic

Naltrexone – Benzocaine

Opiate antagonist – Anesthetic

Naltrexone – Boric acid

Opiate antagonist – Acid

Naltrexone – Caffeine

Opiate antagonist – Stimulant

Naltrexone – Diltiazem

Opiate antagonist – Calcium Channel
Blocker

Naltrexone – Hydroxyzine

Opiate antagonist – Antihistamine

Naltrexone – Levamisole

Opiate antagonist – Anthelmintic

Naltrexone – Lidocaine

Opiate antagonist – Anesthetic

Naltrexone – Maltose

Opiate antagonist – Sugar

Naltrexone – Morphine

Opiate antagonist – Opioid

Naltrexone – Myo-inositol

Opiate antagonist – Sugar

Naltrexone – Phenacetin

Opiate antagonist – Analgesic

Naltrexone – Phenolphthalein

Opiate antagonist – Dye

Naltrexone – Procaine

Opiate antagonist – Anesthetic

Naltrexone – Sorbitol

Opiate antagonist – Sugar

Naltrexone – Starch

Opiate antagonist – Carbohydrate

PB-22 – Acetaminophen

Cannabinoid – Analgesic

PB-22 – Benzocaine

Cannabinoid – Anesthetic

PB-22 – Boric acid

Cannabinoid – Acid

PB-22 – Caffeine

Cannabinoid – Stimulant

PB-22 – Diltiazem

Cannabinoid – Calcium Channel Blocker

PB-22 – Hydroxyzine

Cannabinoid – Antihistamine

PB-22 – Levamisole

Cannabinoid – Anthelmintic
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Compound Mixtures

Compound Class Mixtures

PB-22 – Lidocaine

Cannabinoid – Anesthetic

PB-22 – Maltose

Cannabinoid – Sugar

PB-22 – Morphine

Cannabinoid – Opioid

PB-22 – Myo-inositol

Cannabinoid – Sugar

PB-22 – Phenacetin

Cannabinoid – Analgesic

PB-22 – Phenolphthalein

Cannabinoid – Dye

PB-22 – Procaine

Cannabinoid – Anesthetic

PB-22 – Sorbitol

Cannabinoid – Sugar

PB-22 – Starch

Cannabinoid – Carbohydrate

Sufentanil – Acetaminophen

Opioid – Analgesic

Sufentanil – Benzocaine

Opioid – Anesthetic

Sufentanil – Boric acid

Opioid – Acid

Sufentanil – Caffeine

Opioid – Stimulant

Sufentanil – Diltiazem

Opioid – Calcium Channel Blocker

Sufentanil – Hydroxyzine

Opioid – Antihistamine

Sufentanil – Levamisole

Opioid – Anthelmintic

Sufentanil – Lidocaine

Opioid – Anesthetic

Sufentanil – Maltose

Opioid – Sugar

Sufentanil – Morphine

Opioid – Opioid

Sufentanil – Myo-inositol

Opioid – Sugar

Sufentanil – Phenacetin

Opioid – Analgesic

Sufentanil – Phenolphthalein

Opioid – Dye

Sufentanil – Procaine

Opioid – Anesthetic

Sufentanil – Sorbitol

Opioid – Sugar

Sufentanil – Starch

Opioid – Carbohydrate

Models were created to evaluate the prediction of compound mixtures and compound class
mixtures. The number of estimators used for the RF algorithms was 1000, and the depth of each
tree set to 20. A linear kernel with a regularization parameter of 0.09 were selected for the SVM
models.
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The entire spectrum of size 457x1, was used as the input for the CNN models. The first
convolutional layer contained 200 3x1 filters, followed by a 2x1 MaxPooling layer, a
convolutional layer with 100 3x1 filters, a second 2x1 MaxPooling layer, a Flatten layer and a
fully connected layer with 224 output units for the compound mixtures model and 88 units for the
compound class mixtures model. The minimum validation loss was monitored, and the best model
used to evaluate the test data. The model was fitted using a batch size of 5.
Fully connected NN models were created with 457 neurons in the first hidden layer with 20%
dropout, 114 neurons in the second and third layers with 20% dropout in the second layer and 10%
dropout in the third, 36 neurons in the fourth layer with 10% dropout, and the output layer with
224 units for the compound mixtures model and 88 for the compound class mixtures model. The
batch size for both fitted models were 64.
To demonstrate the accuracy of the models, spectra from authentic in-house binary drug: diluent
mixtures (n = 186) previously acquired using the TacticID instrument [150] were used to evaluate
the algorithms and to compare with the instrument’s reported results. The drug: diluent ratios were
1:4, 1:7, 1:10, and 1:20. As an example, for a 1:7 ratio, 10 mg of the drug and 70 mg of the diluent
were mixed prior to analysis. Selected classifiers which included SVM, kNN, NN, and CNN were
used to test the authentic in-house mixtures. The accuracy of the predictions was based on the three
highest probabilities that a compound belonged to a class.
2.2.5 Ternary Mixture Algorithms
Selected ternary mixtures were created from the spectra in Section 2.2.1. using Equation 2.2.
𝑇𝑒𝑟𝑛𝑎𝑟𝑦 𝑀𝑖𝑥𝑡𝑢𝑟𝑒 = (𝑑𝑟𝑢𝑔 ∗ 0.05) + (𝑑𝑖𝑙𝑢𝑒𝑛𝑡1 ∗

(1−0.05)

(1−0.05)

2

2

) + (𝑑𝑖𝑙𝑢𝑒𝑛𝑡2 ∗

) Equation

2.2

The resulting spectra were processed using the Fast Fourier Transformation (FFT) and multiplied
by a random number between 0.8 and 1.2 as a data augmentation technique which introduced
unequal variations in peak intensities. A total of 829,440 spectra were created and there were 60
ternary compound mixtures and 50 ternary compound class mixtures. A list of the mixtures can be
found in Table 2.3 and 2.4. The evaluated algorithms included CNN, kNN, NN, and SVM. A
linear kernel was used for the SVM models, with a regularization parameter of 0.09 for both the
compound mixtures model and compound class mixtures model. The CNN models contained 200
3x1 filters in the first convolutional layer, a 2x1 MaxPooling layer, a convolutional layer with 100
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3 x 1 filters, a MaxPooling layer, a Flatten layer, and a fully connected layer with a softmax
activation function. The ReLU activation function was used in all convolutional layers. The model
was compiled using the categorical cross entropy loss function and adam optimizer function. Early
stopping allowed for the best model to be saved based on the minimum validation loss, with the
patience parameter set to 10, and the batch size to 5.
Table 2. 3. Ternary compound mixtures.
4MEC – Acetaminophen –

Cocaine– Benzocaine –

Methamphetamine–

Benzocaine

Maltose

Acetaminophen – Levamisole

Alprazolam – Acetaminophen –

Codeine– Benzocaine –

PB22– Acetaminophen –

Benzocaine

Maltose

Levamisole

4MEC– Acetaminophen –
Caffeine

Cocaine – Caffeine – Maltose

Methamphetamine –
Benzocaine – Caffeine

Alprazolam – Acetaminophen –

Codeine – Caffeine –

Caffeine

Maltose

4MEC– Acetaminophen –

Cocaine – Diltiazem–

Methamphetamine –

Maltose

Levamisole

Benzocaine – Levamisole

Alprazolam – Acetaminophen –

Codeine – Diltiazem –

PB22– Benzocaine –

Maltose

Levamisole

Levamisole

Cocaine – Diltiazem –

Methamphetamine – Caffeine

Lidocaine

– Levamisole

4MEC– Benzocaine – Caffeine

Alp– Benzocaine – Caffeine

Codeine – Diltiazem –
Lidocaine

PB22– Benzocaine – Caffeine

PB22– Caffeine – Levamisole

Cocaine – Diltiazem –

Fentanyl– Acetaminophen –

Phenacetin

Caffeine

Alprazolam – Benzocaine –

Codeine – Diltiazem –

Heroin – Acetaminophen –

Maltose

Phenacetin

Caffeine

Cocaine – Levamisole–

Fentanyl– Acetaminophen –

Lidocaine

Lidocaine

4MEC– Benzocaine – Maltose

4MEC– Caffeine – Maltose

51

Alprazolam – Caffeine –

Codeine – Levamisole –

Heroin – Acetaminophen –

Maltose

Lidocaine

Lidocaine

Cocaine – Acetaminophen –

Cocaine – Levamisole –

Fentanyl – Acetaminophen –

Benzocaine

Phenacetin

Procaine

Codeine– Acetaminophen –

Codeine – Levamisole –

Heroin – Acetaminophen –

Benzocaine

Phenacetin

Procaine

Cocaine – Acetaminophen –

Cocaine – Lidocaine –

Fentanyl – Caffeine –

Caffeine

Phenacetin

Lidocaine

Codeine – Acetaminophen –

Codeine – Lidocaine –

Caffeine

Phenacetin

Cocaine – Acetaminophen –
Maltose

Methamphetamine –
Acetaminophen –
Benzocaine

Heroin – Caffeine – Lidocaine

Fentanyl – Caffeine –
Procaine

Codeine – Acetaminophen –

PB22– Acetaminophen –

Maltose

Benzocaine

Cocaine – Benzocaine –

Methamphetamine –

Fentanyl – Lidocaine –

Caffeine

Acetaminophen – Caffeine

Procaine

Codeine – Benzocaine –

PB22– Acetaminophen –

Caffeine

Caffeine

Heroin – Caffeine – Procaine

Heroin– Lidocaine– Procaine

Table 2. 4. Ternary compound class mixtures.
Cathinone-Analgesic-Anesthetic

Cocaine-Anesthetic-Sugar

Amphetamine-Analgesic-Anthelmintic

Benzodiazepine-Analgesic-Anesthetic

Opioid-Anesthetic-Sugar

Cannabinoid-Analgesic-Anthelmintic

Cathinone-Analgesic-Stimulant

Cocaine-Stimulant-Sugar

Amphetamine-Anesthetic-Stimulant

Benzodiazepine-Analgesic-Stimulant

Opioid-Stimulant-Sugar

Cannabinoid-Anesthetic-Stimulant

Cathinone-Analgesic-Sugar

Cocaine-Calcium Channel Blocker-Anthelmintic

Amphetamine-Anesthetic-Anthelmintic

Benzodiazepine-Analgesic-Sugar

Opioid-Calcium Channel Blocker-Anthelmintic

Cannabinoid-Anesthetic-Anthelmintic

Cathinone-Anesthetic-Stimulant

Cocaine-Calcium Channel Blocker-Anesthetic

Amphetamine-Stimulant-Anthelmintic

Benzodiazepine-Anesthetic-Stimulant

Opioid-Calcium Channel Blocker-Anesthetic

Cannabinoid-Stimulant-Anthelmintic
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Cathinone-Anesthetic-Sugar

Cocaine-Calcium Channel Blocker-Analgesic

Opioid-Stimulant-Anesthetic

Benzodiazepine-Anesthetic-Sugar

Opioid-Calcium Channel Blocker-Analgesic

Opioid-Anesthetic-Anesthetic

Cathinone-Stimulant-Sugar

Cocaine-Anthelmintic-Anesthetic

Benzodiazepine-Stimulant-Sugar

Opioid-Anthelmintic-Anesthetic

Cocaine-Analgesic-Anesthetic

Cocaine-Anthelmintic-Analgesic

Opioid-Analgesic-Anesthetic

Opioid-Anthelmintic-Analgesic

Cocaine-Analgesic-Stimulant

Cocaine-Anesthetic-Analgesic

Opioid-Analgesic-Stimulant

Opioid-Anesthetic-Analgesic

Cocaine-Analgesic-Sugar

Amphetamine-Analgesic-Anesthetic

Opioid-Analgesic-Sugar

Cannabinoid-Analgesic-Anesthetic

Cocaine-Anesthetic-Stimulant

Amphetamine-Analgesic-Stimulant

Opioid-Anesthetic-Stimulant

Cannabinoid-Analgesic-Stimulant

The NN models for compound mixtures and compound class mixtures were fully connected with
457 neurons in the first hidden layer, 20% dropout, 114 neurons in the second layer, 20% dropout,
114 neurons in the third layer, 10% dropout, and 36 neurons in the fourth layer with 10% dropout.
The output layer contained 60 units for the compound mixtures model and 50 units for the
compound class mixtures model using the sigmoid activation function. The ReLU activation
function was used for all other layers. Early stopping was implemented and the model with the
minimum validation loss was saved. The model was fitted with the patience parameter of 5, and
batch size of 16 for the compound mixtures model and 24 for the compound class mixtures model.
2.2.6 Quaternary Mixture Algorithms
Three subsets of quaternary mixtures were created from the spectra in Section 2.2.1 using
Equation 2.3. The value 0.05 was selected to simulate the effect of high signal suppression of the
drug in comparison to the diluents, as is usually the case in street drug mixtures, although this
methodology can be easily generalized to other compounds. The spectra were also processed using
the FFT prior to evaluation using machine learning algorithms created for classification by
compound mixture and compound class mixture. SVM, kNN, CNN and NN were used to evaluate
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the data. A linear kernel with 0.09 regularization was used for all SVM models. The number of
layers, neurons and batch size were optimized for each model.
𝑄𝑢𝑎𝑡𝑒𝑟𝑛𝑎𝑟𝑦 𝑀𝑖𝑥𝑡𝑢𝑟𝑒 = (𝑑𝑟𝑢𝑔 ∗ 0.05) + (𝑑𝑖𝑙𝑢𝑒𝑛𝑡1 ∗

(1−0.05)

(1−0.05)

(1−0.05)

3

3

3

) + (𝑑𝑖𝑙𝑢𝑒𝑛𝑡2 ∗

) + (𝑑𝑖𝑙𝑢𝑒𝑛𝑡3 ∗

)

Equation 2.3

2.2.6.1 Subset 1
Subset 1 contained 4 quaternary mixtures of cocaine with acetaminophen, diltiazem, and
hydroxyzine. See Table 2.5 for additional information about the mixtures. A total of 663,552
spectra were created in this set. The entire Raman spectrum (457x1) was used as the input for the
CNN models. The first convolutional layer for the compound mixtures model contained 200 3x1
filters with ReLU activation, a MaxPooling layer, followed by another convolutional layer with
100 3x1 filters, a second MaxPooling layer, a Flatten layer, followed by a fully connected layer
with the softmax activation function, and compiled with categorical cross entropy loss and the
adam optimizer function. Early stopping was implemented where the best model was saved for
the minimum validation loss, with patience set to 10 and batch size to 5. The same parameters
were selected for the CNN compound class mixtures model.
Table 2. 5. Subset 1 mixtures.
Compound Mixtures

Compound Class Mixtures

Cocaine- Acetaminophen-Diltiazem-

Cocaine- Analgesic- Calcium channel blocker-

Hydroxyzine

Antihistamine

Cocaine- Acetaminophen-Diltiazem-

Cocaine- Analgesic-calcium channel blocker-

Procaine

Anesthetic

Cocaine- Acetaminophen-Hydroxyzine-

Cocaine- Analgesic- Antihistamine-

Procaine

Anesthetic

Cocaine- Diltiazem-Hydroxyzine-

Cocaine-Calcium Channel Blocker-

Procaine

Antihistamine-Anesthetic
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A fully connected NN was created for both the compound mixtures model and compound class
mixtures model, with the same architecture. There were 457 neurons in the first hidden layer,
followed by 20% dropout, 128 neurons with 20% dropout and 64 neurons with 10% dropout with
the output layer containing a sigmoid activation function. All other layers used the ReLU activation
function. The minimum validation loss was monitored with patience set to 5, and batch size to 64
as early stopping was implemented.
2.2.6.2 Subset 2
Subset 2 comprised of 1,327,104 spectra. Quaternary mixture combinations were created with the
drug as buprenorphine and naltrexone and the diluents as acetaminophen, caffeine, procaine, and
maltose. This resulted in 8 compound mixtures and a complete description can be found in Table
2.6. The same architecture and parameters described in Section 2.2.6.1 were selected to create
CNN models for compound mixtures and compound class mixtures.
Table 2. 6. Subset 2 mixtures.
Compound Mixtures

Buprenorphine -Acetaminophen –
Caffeine - Maltose
Buprenorphine- Acetaminophen
_Caffeine- Procaine
Buprenorphine- AcetaminophenMaltose- Procaine
Buprenorphine- CaffeineMaltose- Procaine
Naltrexone- AcetaminophenCaffeine- Maltose
Naltrexone- AcetaminophenCaffeine- Procaine

Compound Class Mixtures

Opiate antagonist- Analgesic- Stimulant- Anesthetic

Opiate antagonist- Analgesic- Stimulant- Sugar

Opiate antagonist- Analgesic- Sugar- Anesthetic

Opiate antagonist- Stimulant- Sugar- Anesthetic

Opioid- Analgesic- Stimulant- Anesthetic

Opioid- Analgesic- Stimulant- Sugar
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Compound Mixtures

Naltrexone- AcetaminophenMaltose- Procaine
Naltrexone- Caffeine- MaltoseProcaine

Compound Class Mixtures

Opioid- Analgesic- Sugar- Anesthetic

Opioid- Stimulant- Sugar- Anesthetic

The NN models had the same architecture with 228 neurons in the first hidden layer followed by
10% dropout, 152 neurons in the second layer with 10% dropout, an output layer with the sigmoid
activation function and the ReLU activation function in the other layers. The batch size was 32,
patience set to 5 and the minimum validation loss monitored for early stopping during training of
the models.
2.2.6.3 Subset 3
The quaternary mixtures in subset 4 contained codeine and morphine as drugs, and acetaminophen,
caffeine, lidocaine, maltose as diluents. A total of 8 compound mixture classes (Table 2.7) were
created with 1,327,104 spectra. The architectures of the CNN models described in Section 2.2.6.1
were used to evaluate the data in subset 3.
Table 2. 7. Subset 3 mixtures.
Compound Mixtures

Compound Class Mixtures

Codeine- Acetaminophen- Caffeine- Lidocaine

Opioid- Analgesic- Stimulant- Anesthetic

Codeine- Acetaminophen- Caffeine- Maltose

Opioid- Analgesic- Stimulant- Sugar

Codeine- Acetaminophen- Lidocaine- Maltose

Opioid- Analgesic- Anesthetic- Sugar

Codeine- Caffeine- Lidocaine- Maltose

Opioid- Stimulant- Anesthetic- Sugar

Morphine- Acetaminophen- Caffeine- Lidocaine
Morphine- Acetaminophen- Caffeine- Maltose
Morphine- Acetaminophen- Lidocaine- Maltose
Morphine- Caffeine- Lidocaine- Maltose
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The NN model created to evaluate the data by compound mixtures contained 304 neurons in the
first hidden layer with 10% dropout, 76 in the second layer with 10% dropout, 152 in the third
layer with 10% dropout, and 76 in the fourth layer with 10% dropout. The sigmoid activation
function was used in the output layer, and the ReLU activation function in all other layers. Early
stopping was implemented by monitoring the minimum validation loss, patience set to 5, and a
batch size of 64. The compound class mixtures model was similar, but the first, second and third
hidden layers contained 228, 57, and 114 neurons, respectively. The optimized batch size was 32.
A summary of the methods is shown in Figure 2.1.
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Figure 2. 1. Summary of the workflow used in this study. *— The Naïve Bayes algorithm was not
used to evaluate the authentic pure test and authentic binary mixture datasets. All simulated
datasets excluding the pure spectra dataset included Fast Fourier transformed data. The Quaternary
mixture dataset contained a total of 3,317,760 spectra and was divided into 3 subsets: subset 1
contained 663,552 spectra with 4 compound mixtures and 4 compound class mixtures; subset 2
contained 1,327,104 spectra with 8 compound mixtures and 8 compound class mixtures; and subset
3 contained 1,327,104 spectra with 8 compound mixtures and 4 compound class mixtures.
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2.3.0 Results
2.3.1 Spectra Creation and Comparison
A visual representation of the pure simulated spectra and binary, ternary, and quaternary mixtures
recreation is shown in Figure 2.2. Mixtures were created to represent complex combinations of
drugs and diluents that represent common street drugs as well as worst case scenarios.
Multiplication of the pure spectra by numbers between 0 and 1 resulted in a relative suppression
or scaling of the signal intensities (Figure 2.2A). Figure 2.2B shows the individual spectrum of
maltose and morphine and the differences in the number, shape, and intensity of the peaks
characteristic of each compound. When the mixtures were simulated, the peak at 1640 cm-1 for
morphine decreased relative to the diluent— maltose, when the ratio of maltose to morphine was
higher (Figure 2.2C). For example, when the morphine spectrum was multiplied by 0.90 and the
maltose spectrum multiplied by 0.10, then combined, the resulting spectrum demonstrated more
features similar to morphine. Figure 2.2D shows the effect of applying the Fast Fourier
transformation to the spectra. Some peak intensities are higher whereas others are lower than those
in the original spectrum. Additionally, noise is added in random portions of the spectrum. Figure
2.2E and 2.2F demonstrate the spectrum of a ternary and quaternary mixture, respectively. The
deliberate suppression of the drug spectrum in relation to the diluents in both the ternary and
quaternary mixture makes it difficult to identify the Raman bands unique to the drugs—codeine
for the ternary mixture, and buprenorphine for the quaternary mixture.
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Figure 2. 2. (A)– Illustration of the resulting spectra when a methamphetamine (Meth) spectrum
is multiplied by 0.13, 0.35, 0.46, 0.54, 0.77, 0.87, 0.90. (B)–Comparison of maltose (Malt) and
morphine (Mor) spectrum. (C)– Illustrations of the resulting simulated spectra for morphine
(multiplied by 0.1, 0.3, 0.6, 0.9) and maltose (multiplied by 0.9, 0.7, 0.4, 0.1). (D)– The spectrum
of acetaminophen before (Acet_Orig) and after Fast Fourier transformation (Acet_FFT). (E)–
Creation of a ternary mixture of codeine, diltiazem, and levamisole with the codeine signal
suppressed to 5% of the original spectrum. (F)–Creation of a quaternary mixture containing
buprenorphine, acetaminophen, caffeine, and procaine with 5% suppression of the buprenorphine
signal.
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The cosine similarity and Pearson’s correlation coefficient for the authentic pure set is shown in
Figure 2.3. Although lower scores were observed when making comparisons of the first derivative
spectra, all scores were greater than 0.90 with the cosine similarity, and greater than 0.86 with the
Pearson’s correlation. Comparisons on the pure test set using the cosine similarity resulted in
methamphetamine having the highest similarity to diphenhydramine (0.820), and sorbitol having
the highest similarity to mannitol (0.878). When comparisons were made using the first derivative
algorithm combining the cosine similarity, the results were the same between mannitol and
sorbitol, but the score was 0.640. Diphenhydramine was also most similar to fentanyl (0.717) using
the first derivative comparison. The Pearson’s correlation resulted in mannitol and sorbitol being
most similar (0.817 and 0.640 for the original spectra and first derivative spectra algorithms
respectively). Fentanyl and methamphetamine were also reported as the closest compounds to
diphenhydramine. Although the first derivative provides lower correlation scores than the original
spectral correlations, they are not markedly different.

Figure 2. 3. Distribution of cosine scores (A), and correlation coefficients (B) of the test data. The
scores for the comparisons between the original spectra and first derivative spectra are shown.
Diphenhydramine and mannitol are not included since they were not present in the database.
2.3.2 Pure Spectra
Exploratory analysis of the 444 pure spectra using PCA of the original spectra and the first
derivative spectra is shown in Figure 2.4. Plots of the first two principal components of the original
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spectra labeled by compound and class show overlap of the clusters making PCA a challenge for
classification of this dataset. The explained variance in the first two components were 34% and
9%. Although some clusters are more separated when the first derivative of the spectra is computed
(Figure 2.4C, 2.4D), others still overlap. Linear discriminant analysis (LDA) results in higher
separation of the classes, but overlap is still observed for few drugs and classes (Figure 2.5). As a
result, neither PCA nor LDA were used for further evaluation of the data in this study. Various
machine learning algorithms were then evaluated in the pure spectra dataset, as explained below.
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Figure 2. 4. Principal component analysis on the 444 spectra acquired using the TacticID
instrument. (A)–Original spectra labeled by compound. (B) – Original spectra labeled by
compound class. Note there are 18 compound classes used here for illustration. (C) –First
derivative spectra labeled by compound. (D) –First derivative spectra labeled by compound class.
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Figure 2. 5. Linear discriminant analysis of the 444 pure spectra. A– Canonical plot for the original
spectra labeled by compounds. Variance in the canonical variable 1 is 23% and 15% in canonical
variable 2. B– Canonical plot of the original spectra for the compound classes. The variance in the
two canonical variables were 24% and 15%. C–Canonical plot of the first derivative spectra
labeled by compound. The variance in the two canonical variables were 26% and 14%. D–
Canonical plot for the first derivative spectra labeled by class. The variance in the two canonical
variables were 24% and 21%. Note that for illustration, there are 18 classes in B and C.
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The performance of the method was evaluated as correct identification or accuracy. Correct
identification was evaluated for the authentic datasets (pure and binary mixtures) where True
positives and False negatives were considered. The models created from the simulated data were
evaluated using accuracy. True positive (Tp), False positive (Fp), and their respective True negative
(Tn) and False negative (Fn) were used in the calculation of accuracy. Accuracy is given by
Equation 2.4. Precision or the positive predictive value is given by Equation 2.5. Recall, true
positive rate, or sensitivity is given by Equation 2.6. The F1-score—the harmonic mean of
precision and recall is given by Equation 2.7.

𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =

𝑇𝑝 + 𝑇𝑛
𝑇𝑝 + 𝑇𝑛 + 𝐹𝑝 + 𝐹𝑛

𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛(𝑃) =

𝑅𝑒𝑐𝑎𝑙𝑙(𝑅) =

𝑇𝑝
𝑇𝑝 + 𝐹𝑝

𝑇𝑝
𝑇𝑝 + 𝐹𝑛

𝐹1 − 𝑠𝑐𝑜𝑟𝑒 = 2 ∗

𝑃∗𝑅
𝑃+𝑅

𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟐. 𝟒

𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟐. 𝟓

𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟐. 𝟔

𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟐. 𝟕

The average accuracies of the kNN, RF and CNN algorithms for compound and compound class
were 100% (Table 2.8). The SVM resulted in 99% accuracy for both models whereas the NN
resulted in 98% for the compound model and 99% for the class model. The NB models resulted in
the lowest accuracies for both models—68% for compound and 67% for compound class.
All models except the NB algorithm were used to evaluate the authentic pure set. Only the CNN
resulted in 100% correct identification for both compound and class (Table 2.8). This also
included correctly classifying diphenhydramine and mannitol by compound class even though they
were not included in the training data. However, they were misclassified by compound because
the training data did not contain their labels. The RF model resulted in correct identifications of
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97% for compounds and 94% for compound classes. The next best model—kNN, resulted in 93%
correct identification for compounds and 86% for compound classes. The model with the lowest
correct identification for reporting compounds and class was the SVM with 80% and 56%,
respectively. Although at least 80% correct compound identification in the top 3 hits was observed
for all models, only the CNN resulted in the top hit corresponding to the ground truth compounds.
Complete classification reports can be found in Tables 2.9 – 2.19. Macro average is the accuracy
of each label is calculated, and the unweighted mean is reported. Imbalance is not considered.
Weighted average is the average accuracy of all labels, weighted by the number of true instances
for each label.
Table 2. 8. Comparison of the algorithms’ accuracy and evaluation of the models on an authentic
pure test dataset. The pure test set accuracy is based on compound’s presence in the top three hits.
kNN
Compound

NB
Class

Compound

RF
Class

Compoun

SVM
Class

Compound

NN
Class

d
Model

100

100

93

86

68

67

Compoun

CNN
Class

Compound

Class

d

100

100

99

99

98

99

100

100

97

94

80

56

90

86

100

100

Accuracy
(%)
Pure Test

---

---

Set
Correct
identificat
ion (%)

Table 2. 9. KNN Pure 444000 compound accuracy.
F1-

Precision

Recall

4-MEC

0.998

1.000

0.999

1200

4-MMC

1.000

0.999

1.000

1200

Acetaminophen

1.000

1.000

1.000

4800

Alprazolam

0.998

1.000

0.999

1200

Benzocaine

1.000

1.000

1.000

4800

Boric acid

1.000

1.000

1.000

4800

Buprenorphine

1.000

1.000

1.000

1200

Caffeine

1.000

1.000

1.000

4800

score

Support
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F1-

Precision

Recall

Cocaine

0.998

1.000

0.999

1200

Codeine

1.000

1.000

1.000

1200

Diltiazem

1.000

1.000

1.000

4800

Fentanyl

0.999

0.999

0.999

1200

Heroin

0.998

1.000

0.999

1200

Hydroxyzine

1.000

1.000

1.000

4800

Levamisole

1.000

1.000

1.000

4800

Lidocaine

1.000

1.000

1.000

4800

Maltose

1.000

1.000

1.000

4800

Methamphetamine

0.999

0.998

0.999

1200

Mitragynine

0.998

0.994

0.996

1200

Morphine

0.999

1.000

1.000

1200

Myo-inositol

1.000

1.000

1.000

4800

Naltrexone

1.000

0.999

1.000

1200

PB-22

1.000

0.998

0.999

1200

Phenacetin

1.000

1.000

1.000

4800

Phenolphthalein

1.000

1.000

1.000

4800

Procaine

1.000

1.000

1.000

4800

Sorbitol

1.000

1.000

1.000

4800

Starch

1.000

1.000

1.000

4800

Sufentanil

1.000

1.000

1.000

1200

accuracy

1.000

1.000

1.000

1.000

macro avg

1.000

1.000

1.000

88800

weighted avg

1.000

1.000

1.000

88800

score

Support

Table 2. 10. KNN Pure 444000 compound class accuracy.
Precision

Recall

F1-

Support

score
Acid

1.000

1.000

1.000

4800

Amphetamine

0.998

1.000

0.999

1200
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Precision

Recall

F1-

Support

score
Analgesic

1.000

1.000

1.000

9600

Anesthetic

1.000

1.000

1.000

14400

Anthelmintic

1.000

1.000

1.000

4800

Antihistamine

1.000

1.000

1.000

4800

Benzodiazepine

0.999

1.000

1.000

1200

Calcium channel blocker

1.000

1.000

1.000

4800

Cannabinoid

0.993

0.999

0.996

1200

Carbohydrate

1.000

1.000

1.000

4800

Cathinone

1.000

1.000

1.000

2400

Cocaine

1.000

0.998

0.999

1200

Dye

1.000

1.000

1.000

4800

Opiate

1.000

1.000

1.000

1200

Opioid

1.000

0.999

0.999

8400

Stimulant

1.000

1.000

1.000

4800

Sugar

1.000

1.000

1.000

14400

accuracy

1.000

1.000

1.000

1.000

macro avg

0.999

1.000

1.000

88800

weighted avg

1.000

1.000

1.000

88800

Table 2. 11. NB Pure 444000 compound accuracy.
Precision

Recall

F1-score

Support

4-MEC

0.766

0.698

0.730

1200

4-MMC

0.758

0.698

0.727

1200

Acetaminophen

1.000

0.740

0.850

4800

Alprazolam

0.665

0.620

0.642

1200

Benzocaine

0.340

0.954

0.502

4800

Boric acid

0.357

0.705

0.473

4800

Buprenorphine

0.888

0.649

0.750

1200

Caffeine

0.954

0.545

0.694

4800

Cocaine

0.940

0.644

0.765

1200
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Precision

Recall

F1-score

Support

Codeine

0.916

0.731

0.813

1200

Diltiazem

1.000

0.674

0.806

4800

Fentanyl

0.390

0.436

0.412

1200

Heroin

0.728

0.629

0.675

1200

Hydroxyzine

0.901

0.671

0.769

4800

Levamisole

0.654

0.718

0.684

4800

Lidocaine

1.000

0.654

0.791

4800

Maltose

0.837

0.632

0.720

4800

Methamphetamine

0.855

0.478

0.613

1200

Mitragynine

0.102

0.345

0.158

1200

Morphine

1.000

0.664

0.798

1200

Myo-inositol

0.702

0.621

0.659

4800

Naltrexone

0.758

0.635

0.691

1200

PB-22

0.506

0.763

0.608

1200

Phenacetin

0.936

0.792

0.858

4800

Phenolphthalein

1.000

0.839

0.913

4800

Procaine

0.876

0.731

0.797

4800

Sorbitol

0.813

0.517

0.632

4800

Starch

1.000

0.685

0.813

4800

Sufentanil

0.508

0.571

0.538

1200

accuracy

0.682

0.682

0.682

0.682

macro avg

0.764

0.657

0.686

88800

weighted avg

0.801

0.682

0.713

88800

Table 2. 12. NB Pure 444000 compound class accuracy.
Precision

Recall

F1-score

Support

Acid

0.224

0.898

0.358

4800

Amphetamine

0.724

0.508

0.597

1200

Analgesic

0.819

0.827

0.823

9600

Anesthetic

0.979

0.566

0.717

14400

Anthelmintic

0.671

0.726

0.697

4800
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Precision

Recall

F1-score

Support

Antihistamine

0.838

0.658

0.737

4800

Benzodiazepine

0.640

0.567

0.601

1200

Calcium channel blocker

1.000

0.685

0.813

4800

Cannabinoid

0.561

0.685

0.617

1200

Carbohydrate

0.899

0.666

0.765

4800

Cathinone

0.459

0.827

0.590

2400

Cocaine

0.761

0.617

0.681

1200

Dye

1.000

0.872

0.932

4800

Opiate

0.572

0.633

0.601

1200

Opioid

0.490

0.500

0.495

8400

Stimulant

0.953

0.595

0.733

4800

Sugar

0.890

0.615

0.728

14400

accuracy

0.667

0.667

0.667

0.667

macro avg

0.734

0.673

0.676

88800

weighted avg

0.796

0.667

0.700

88800

Table 2. 13. SVM Pure 444000 compound accuracy.
Precision

Recall

F1-score

Support

4-MEC

1.000

0.981

0.990

1200

4-MMC

1.000

0.974

0.987

1200

Acetaminophen

1.000

0.992

0.996

4800

Alprazolam

1.000

0.981

0.990

1200

Benzocaine

0.900

1.000

0.947

4800

Boric acid

0.988

0.998

0.993

4800

Buprenorphine

1.000

0.990

0.995

1200

Caffeine

1.000

0.994

0.997

4800

Cocaine

1.000

0.986

0.993

1200

Codeine

1.000

0.991

0.995

1200

Diltiazem

1.000

0.995

0.997

4800

Fentanyl

1.000

0.990

0.995

1200

Heroin

1.000

0.988

0.994

1200
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Precision

Recall

F1-score

Support

Hydroxyzine

0.988

0.996

0.992

4800

Levamisole

0.999

0.994

0.996

4800

Lidocaine

1.000

0.992

0.996

4800

Maltose

1.000

0.994

0.997

4800

Methamphetamine

1.000

0.983

0.992

1200

Mitragynine

0.998

0.982

0.990

1200

Morphine

1.000

0.984

0.992

1200

Myo-inositol

1.000

0.995

0.997

4800

Naltrexone

1.000

0.990

0.995

1200

PB-22

1.000

0.981

0.990

1200

Phenacetin

1.000

0.991

0.996

4800

Phenolphthalein

1.000

0.993

0.996

4800

Procaine

0.997

0.993

0.995

4800

Sorbitol

0.998

0.992

0.995

4800

Starch

1.000

0.994

0.997

4800

Sufentanil

1.000

0.987

0.993

1200

accuracy

0.992

0.992

0.992

0.992

macro avg

0.995

0.990

0.992

88800

weighted avg

0.993

0.992

0.993

88800

Table 2. 14. SVM Pure 444000 compound class accuracy.
Precision

Recall

F1-score

Support

Acid

1.000

0.989

0.994

4800

Amphetamine

1.000

0.984

0.992

1200

Analgesic

1.000

0.993

0.997

9600

Anesthetic

0.963

1.000

0.981

14400

Anthelmintic

1.000

0.992

0.996

4800

Antihistamine

1.000

0.990

0.995

4800

Benzodiazepine

1.000

0.980

0.990

1200

Calcium channel blocker

1.000

0.994

0.997

4800

Cannabinoid

1.000

0.973

0.986

1200

71

Precision

Recall

F1-score

Support

Carbohydrate

1.000

0.991

0.996

4800

Cathinone

1.000

0.985

0.993

2400

Cocaine

1.000

0.984

0.992

1200

Dye

1.000

0.993

0.996

4800

Opiate

1.000

0.984

0.992

1200

Opioid

0.996

0.992

0.994

8400

Stimulant

1.000

0.993

0.996

4800

Sugar

0.998

0.996

0.997

14400

accuracy

0.993

0.993

0.993

0.993

macro avg

0.997

0.989

0.993

88800

weighted avg

0.993

0.993

0.993

88800

Table 2. 15. RF Pure 444000 compound accuracy.
Precision

Recall

F1-score

Support

4-MEC

1.000

1.000

1.000

1200

4-MMC

1.000

1.000

1.000

1200

Acetaminophen

1.000

1.000

1.000

4800

Alprazolam

1.000

1.000

1.000

1200

Benzocaine

1.000

1.000

1.000

4800

Boric acid

1.000

1.000

1.000

4800

Buprenorphine

1.000

1.000

1.000

1200

Caffeine

1.000

1.000

1.000

4800

Cocaine

1.000

1.000

1.000

1200

Codeine

1.000

1.000

1.000

1200

Diltiazem

1.000

1.000

1.000

4800

Fentanyl

1.000

1.000

1.000

1200

Heroin

0.999

1.000

1.000

1200

Hydroxyzine

1.000

1.000

1.000

4800

Levamisole

1.000

1.000

1.000

4800

Lidocaine

1.000

1.000

1.000

4800

Maltose

1.000

1.000

1.000

4800
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Precision

Recall

F1-score

Support

Methamphetamine

1.000

1.000

1.000

1200

Mitragynine

1.000

0.997

0.998

1200

Morphine

1.000

1.000

1.000

1200

Myo-inositol

1.000

1.000

1.000

4800

Naltrexone

1.000

1.000

1.000

1200

PB-22

0.998

1.000

0.999

1200

Phenacetin

1.000

1.000

1.000

4800

Phenolphthalein

1.000

1.000

1.000

4800

Procaine

1.000

1.000

1.000

4800

Sorbitol

1.000

1.000

1.000

4800

Starch

1.000

1.000

1.000

4800

Sufentanil

1.000

1.000

1.000

1200

accuracy

1.000

1.000

1.000

1.000

macro avg

1.000

1.000

1.000

88800

weighted avg

1.000

1.000

1.000

88800

Table 2. 16. RF Pure 444000 compound class accuracy.
Precision

Recall

F1-score

Support

Acid

1.000

1.000

1.000

4800

Amphetamine

1.000

0.998

0.999

1200

Analgesic

1.000

1.000

1.000

9600

Anesthetic

1.000

1.000

1.000

14400

Anthelmintic

1.000

1.000

1.000

4800

Antihistamine

1.000

1.000

1.000

4800

Benzodiazepine

1.000

0.999

1.000

1200

Calcium channel blocker

1.000

1.000

1.000

4800

Cannabinoid

1.000

0.997

0.998

1200

Carbohydrate

1.000

1.000

1.000

4800

Cathinone

1.000

1.000

1.000

2400

Cocaine

1.000

0.998

0.999

1200

Dye

1.000

1.000

1.000

4800
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Precision

Recall

F1-score

Support

Opiate

1.000

0.995

0.997

1200

Opioid

0.998

1.000

0.999

8400

Stimulant

1.000

1.000

1.000

4800

Sugar

1.000

1.000

1.000

14400

accuracy

1.000

1.000

1.000

1.000

macro avg

1.000

0.999

1.000

88800

weighted avg

1.000

1.000

1.000

88800

Table 2. 17. NN Pure 444000 compound accuracy.
Precision

Recall

F1-score

Support

4-MEC

1.000

0.971

0.985

1200

4-MMC

1.000

0.968

0.983

1200

Acetaminophen

0.998

0.991

0.995

4800

Alprazolam

0.999

0.971

0.985

1200

Benzocaine

0.998

0.985

0.992

4800

Boric acid

0.996

0.993

0.994

4800

Buprenorphine

0.992

0.980

0.986

1200

Caffeine

0.982

0.983

0.983

4800

Cocaine

0.894

0.984

0.937

1200

Codeine

0.943

0.977

0.959

1200

Diltiazem

0.993

0.989

0.991

4800

Fentanyl

0.899

0.978

0.937

1200

Heroin

1.000

0.973

0.986

1200

Hydroxyzine

0.895

1.000

0.944

4800

Levamisole

0.999

0.986

0.993

4800

Lidocaine

0.997

0.989

0.993

4800

Maltose

0.988

0.994

0.991

4800

Methamphetamine

1.000

0.861

0.925

1200

Mitragynine

1.000

0.856

0.922

1200

Morphine

0.999

0.910

0.952

1200

Myo-inositol

1.000

0.989

0.994

4800
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Precision

Recall

F1-score

Support

Naltrexone

1.000

0.982

0.991

1200

PB-22

1.000

0.969

0.984

1200

Phenacetin

0.996

0.990

0.993

4800

Phenolphthalein

1.000

0.991

0.996

4800

Procaine

0.944

0.999

0.970

4800

Sorbitol

0.999

0.995

0.997

4800

Starch

1.000

0.984

0.992

4800

Sufentanil

1.000

0.973

0.986

1200

accuracy

0.984

0.984

0.984

0.984

macro avg

0.983

0.973

0.977

88800

weighted avg

0.985

0.984

0.984

88800

Table 2. 18. NN Pure 444000 compound class accuracy.
Precision

Recall

F1-score

Support

Acid

1.000

0.988

0.994

4800

Amphetamine

1.000

0.976

0.988

1200

Analgesic

0.981

0.998

0.990

9600

Anesthetic

0.996

0.997

0.996

14400

Anthelmintic

1.000

0.989

0.995

4800

Antihistamine

1.000

0.979

0.989

4800

Benzodiazepine

0.998

0.975

0.987

1200

Calcium channel blocker

0.990

0.993

0.992

4800

Cannabinoid

1.000

0.961

0.980

1200

Carbohydrate

1.000

0.994

0.997

4800

Cathinone

1.000

0.945

0.972

2400

Cocaine

1.000

0.982

0.991

1200

Dye

1.000

0.991

0.996

4800

Opiate

1.000

0.982

0.991

1200

Opioid

0.938

1.000

0.968

8400

Stimulant

1.000

0.988

0.994

4800

Sugar

1.000

0.992

0.996

14400
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Precision

Recall

F1-score

Support

accuracy

0.990

0.990

0.990

0.990

macro avg

0.994

0.984

0.989

88800

weighted avg

0.991

0.990

0.991

88800

Table 2. 19. CNN Pure 444000 compound accuracy.
Precision

Recall

F1-score

Support

4-MEC

1.000

0.993

0.997

1200

4-MMC

0.993

0.998

0.996

1200

Acetaminophen

0.986

1.000

0.993

4800

Alprazolam

1.000

0.998

0.999

1200

Benzocaine

1.000

0.999

1.000

4800

Boric acid

1.000

0.999

1.000

4800

Buprenorphine

1.000

1.000

1.000

1200

Caffeine

1.000

0.999

1.000

4800

Cocaine

1.000

1.000

1.000

1200

Codeine

1.000

1.000

1.000

1200

Diltiazem

1.000

0.998

0.999

4800

Fentanyl

1.000

0.999

1.000

1200

Heroin

1.000

0.999

1.000

1200

Hydroxyzine

1.000

1.000

1.000

4800

Levamisole

1.000

0.999

1.000

4800

Lidocaine

1.000

0.999

0.999

4800

Maltose

1.000

0.999

0.999

4800

Methamphetamine

1.000

0.998

0.999

1200

Mitragynine

0.997

0.997

0.997

1200

Morphine

1.000

0.999

1.000

1200

Myo-inositol

1.000

0.999

1.000

4800

Naltrexone

1.000

1.000

1.000

1200

PB-22

1.000

0.997

0.998

1200

Phenacetin

1.000

0.999

0.999

4800

Phenolphthalein

1.000

1.000

1.000

4800
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Precision

Recall

F1-score

Support

Procaine

1.000

0.999

1.000

4800

Sorbitol

1.000

1.000

1.000

4800

Starch

1.000

1.000

1.000

4800

Sufentanil

1.000

0.998

0.999

1200

accuracy

0.999

0.999

0.999

0.999

macro avg

0.999

0.999

0.999

88800

weighted avg

0.999

0.999

0.999

88800

The accuracy and loss plots during training and testing of the CNN model are shown in Figure
2.6. Although the model was created with 100 epochs, the implementation of early stopping to
prevent overfitting meant that after 25 to 30 epochs, the training automatically stopped. The
training accuracy remained between 99.7 and 99.9% after 5 epochs for the compound model
(Figure 2.6A). The testing accuracy fluctuated between 99.6 and 99.9% while the training loss
continued to decrease from 0.030 to 0.005. A similar pattern was observed for the compound class
model, but the testing accuracy fluctuated between 99.5 and 99.9% after 30 epochs.0.030 to 0.005.
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A similar pattern was observed for the compound class model, but the testing accuracy fluctuated
between 99.5 and 99.9% after 30 epochs.

Figure 2. 6. Accuracy and validation loss plots for the CNN developed for the simulated pure
spectra. A- Accuracy plot on compounds, B- Loss during compound algorithm training, CAccuracy during compound class model training, D- Loss during compound class training.

2.3.3 Binary Mixtures
All models demonstrated at least 95% accuracy for compound mixtures or class mixtures except
NB which had 47% accuracy with class mixtures (Table 2.20). The RF, NB and CNN all had
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100% accuracy with the compound mixtures whereas only the RF, and CNN resulted in 100%
accuracy for the class mixtures model.
Table 2. 20. Reported accuracy for the algorithms used to evaluate the simulated binary mixtures
dataset. The NB and RF algorithms were only evaluated on binary mix #1 (spectra multiplied by
numbers between 0.05 and 0.95).
kNN

Accuracy (%)

NB

RF

SVM

NN

CNN

Compound

Class

Compound

Class

Compound

Class

Compound

Class

Compound

Class

Compound

Class

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

98

99

100

47

100

100

99

99

95

97

100

100

Training for the CNN algorithm stopped after 17 and 16 epochs for the compound mixtures, and
class mixtures model, respectively. Figure 2.7 demonstrates an increase in training and testing
accuracies while the loss decreased, indicating no overfitting.
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Figure 2. 7. Accuracy and validation loss plots for the CNN developed for the simulated mixtures.
A- accuracy plot on compound mixtures model, B- Loss during compound mixtures model
training, C- Accuracy during compound class mixtures model training, and D- Loss during
compound class mixtures model training.
2.3.4 Application to Authentic In-house Binary Mixtures
The correct identification rates for the authentic in-house mixtures when using selected models
was compared to results previously reported for the TacticID Raman [150]. The reported
identification rates in Table 2.21 considers the presence of the ground truth in the top 3 hits. The
top 3 hits were determined based on the classification probability as shown in Table 2.22. For
example, a mixture containing morphine and maltose resulted in the correct mixture as hit #1
because of the highest probability they belonged to that class. However, the ground truth was
reported as hit #2 in one instance (Table 2.22) with a probability of 0.003.
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The authentic in-house mixtures were evaluated using the developed pure spectra algorithms to
demonstrate the importance of model selection based on the application. The SVM and RF models
resulted in the highest correct identifications for both drug and diluent in the top 3 hits—26% and
16%, respectively (Table 2.21). The SVM was the only algorithm that outperformed the HQI, with
51% correct identification for drug only compared to 30% with the HQI. Although, the Raman
instrument does not report the class of unknown compounds, the pure spectra algorithms by
compound class all provided correct identifications greater than 74% for diluents only and
performed poorly for drug classification (≤54%).

Table 2. 21. Correct identification rates of the in-house binary mixtures dataset using the pure
spectra algorithms for classification. The results are based on the presence of the mixtures in the
top 3 hits.
HQI

kNN

RF

SVM

NN

CNN

Correct

Compound

Class

Compound

Class

Compound

Class

Compound

Class

Compound

Class

Identification

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

(ID, %)
Drug

30

24

19

24

42

51

54

15

12

30

22

Diluent

89

80

81

89

96

74

77

75

77

75

78

Drug and

19

5

1

16

38

26

32

2

1

5

1

99

99

99

97

100

99

98

88

89

100

100

Diluent
At least one
compound/
class

Table 2. 22. Example of generated table for CNN drug algorithm evaluation on in-house mixtures.
(Mor- morphine, malt- maltose, 4MEC- methylethcathinone, 4MMC- 4-methylmethcathinone).
Ground Truth

Hit #1

Hit #2

Hit #2

Hit #1

Hit #2

Hit #3

Probability

Probability

Probability

Mor– Malt

Mor–Malt

4MMC–Malt

4MEC–Malt

0.996

0.004

0.000

Mor–Malt

Mor–Malt

4MMC–Malt

4MEC–Malt

0.986

0.014

0.000

Mor–Malt

4MMC–Malt

Mor–Malt

4MEC–Malt

0.997

0.003

0.000

The correct identification improved when the binary mixtures models were used to assess the
authentic in-house mixtures. All binary mixtures models demonstrated correct identifications at
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least double that which was observed with the Raman instrument (Table 2.23). Greater than 70%
correct drug classification was observed for most algorithms compared to 30% with the HQI, and
greater than 90% correct diluent classification for most algorithms as compared to 89%
identification of the diluent with the HQI. Moreover, all the algorithms were able to correctly
detect at least one compound or class in the mixture. The class mixtures correct identification rates
cannot be compared with the Raman instrument because the instrument only reports the drug based
on spectral similarity. However, the CNN and NN performed better than the other algorithms for
drug class identification with 78% and 77%, respectively. The correct diluent class identification
was ≥90% for all algorithms.
Table 2. 23. Correct identification rates for the in-house binary mixtures using the simulated
binary mixtures algorithms in comparison to the Raman instrument built-in hit quality index
(HQI). The NB models were not evaluated as the other algorithms resulted in higher identification
rates for both compound and compound class. The RF algorithm was not evaluated on the in-house
mixtures. The correct identification was based on the true compound/ class being in the top 3 hits.
HQI

kNN

SVM

NN

CNN

Compound

Class

Compound

Class

Compound

Class

Compound

Class

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Drug (%)

30

59

60

61

73

73

77

69

78

Diluent (%)

89

90

90

94

95

92

95

95

93

Both (%)

19

49

50

55

68

65

72

64

72

At least one

99

100

100

100

100

100

100

100

100

compound/Clas
s (%)

2.3.5 Ternary and Quaternary Mixtures
Molecular analysis of multiple component mixtures can be challenging using portable Raman
spectroscopy as the signal of compounds in a lower percentage can be masked by compounds that
are present in higher percentages. Therefore, investigating the performance of the algorithms on
more complex mixtures is critical in understanding their applicability as screening tools.
In general, the tested algorithms successfully identified ternary mixtures. An example of the
accuracy and validation loss plots during training and testing the ternary mixtures CNN algorithm
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is shown is Figure 2.8. Training stopped after 16 – 20 epochs when the validation loss no longer
decreased, and when the accuracy remained between 98.5% and 99.6%.

Figure 2. 8. Accuracy and validation loss plots for the CNN developed for the ternary mixtures.
A- accuracy plot on compound mixtures model, B- Loss during compound mixtures model
training, C- Accuracy during compound class mixtures model training, and D- Loss during
compound class mixtures model training.
Evaluation of ternary mixtures using selected algorithms resulted in the kNN performing the worst
with 83% accuracy for compound mixtures and 84% for compound class mixtures (Table 2.24).
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An accuracy greater than 95% was observed with all other models with the CNN’s performance
at 100%.
Table 2. 24. Accuracy of ternary mixtures models.
kNN

Accuracy (%)

SVM

NN

CNN

Compound

Class

Compound

Class

Compound

Class

Compound

Class

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

83

84

99

99

95

99

100

100

Interestingly, accuracy of identification of quaternary mixtures ranged from 93 to 100%,
depending on the model and subset. The accuracy for all models on subset 1 was 100%, at least
99% on subset 2, and at least 93% on subset 3 (Table 2.25). The lowest accuracy for the compound
mixtures model was observed with the NN.
Table 2. 25. Accuracy of quaternary mixtures models.
kNN

Subset 1

SVM

NN

CNN

Compound

Class

Compound

Class

Compound

Class

Compound

Class

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

Mixtures

100

100

100

100

100

100

100

100

100

100

100

100

99

100

100

100

97

100

99

100

93

100

99

100

Accuracy (%)
Subset 2
Accuracy (%)
Subset 3
Accuracy (%)

2.4.0 Discussion
The CNN algorithm performed better than the other algorithms in detecting the authentic pure test
compounds and their class with 100% correct identification (Table 2.1). The RF algorithm also
produced a comparable but lower correct identification of 97%. The use of a linear kernel with the
SVM models suggested our data was linearly separable due to the high accuracies observed in this
study. The inclusion of a model trained by compound class proved to be useful in understanding
the potential identity of an unknown compound when the HQI search results in no matches. This
is particularly useful when Raman is used as a quick screening tool for drug identification. The
two examples used in this study—diphenhydramine and mannitol, were correctly classified by
their compound class using the CNN model, even though they were misclassified when tested
using the compound model. Discrimination of three novel psychoactive substances (NPS)
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families—12 fentanyl related compounds, 8 synthetic cathinones, and 10 synthetic cannabinoids,
was achieved using PCA [19]. The authors’ intended use of this application was for law
enforcement and customs officers where a diversity of controlled substances or counterfeits is
encountered. The challenge with the use of PCA is when compounds of other drug families are
encountered, accuracy can suffer. We demonstrate in Figure 2.4 the difficulty in separating
multiple clusters using PCA and we believe it is not the ideal method for classification although it
can be used for feature selection with other algorithms. LDA provided better class separation than
PCA and reasonable accuracy—96%, 88%, 91%, and 78 for single compounds, single classes,
binary compound mixtures, and binary compound class mixtures, respectively, but emphasis was
given to machine learning classifiers due to their higher accuracies with more complex datasets.
Organic molecules which are structurally different by a functional group are of interest especially
in forensic science, where new drug analogues are constantly emerging as a way of evading local
laws and regulations. Although our study is not focused on differentiating between functional
groups, a study using CNN demonstrated 100% accuracy in discriminating between toluene,
aniline, o-xylene which differ by the number and position of a methyl group [146].
In many laboratories especially in forensic science, the ability to identify a controlled substance
from seized materials using portable Raman instruments can provide more effective decisionmaking onsite and more efficient processing of cases at points of entry, such as customs. However,
it is a challenge because most drug cases involve impure substances where the controlled drug is
of a lower percentage making detection by conventional Raman difficult. For this reason the use
of portable Raman is considered a screening tool requiring further confirmation using an additional
technique [10]. During a presumptive stage, accuracies above 70% are acceptable to inform the
user about a potential drug or compound of interest. The rapid and non-destructive nature of
portable Raman makes it an ideal technique to make quick sampling and investigative decisions at
the point of contact, with minimal sample manipulation and under safe conditions to the operators.
Similarly, in counterfeit pharmaceutical products, the high percentage of excipients may mask the
active pharmaceutical ingredients. Therefore, we decided to calculate correct identification of the
in-house binary mixtures test set based on its presence in the top three hits, accounting for
uncertainties in classification. The instrument’s accuracy for detecting the drug—a controlled
substance in the mixtures, using the HQI algorithm was 30%, and lower than all the evaluated
machine learning algorithms (Table 2.21). The NN and CNN models resulted in the highest correct
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identification rate—73% and 69% for drug only, and 65% and 64% for both compounds,
respectively.
The success of the CNN algorithm for pure compounds and mixtures has been supported by several
studies [126–128, 143, 145, 146, 148, 153]. In one study, a smart Raman instrument was developed
and the reported accuracy for ternary mixtures was 85.7% but 100% was observed with our CNN
algorithm although the tested compounds were different [143]. The architecture of the CNN model
reported by the authors contained 9 layers possibly due to the complexity of the acquired spectra,
and incorporated dropout to prevent overfitting. Our CNN model consisted of no more than 5
layers, and without dropout as there was no indication of overfitting. Additionally, the authors only
reported compound mixtures, but we also report compound class mixtures. However, despite the
algorithm used, sampling is also important. Some studies used solvent mixtures which allows for
a more homogeneous sampling which results in spectra that better represent the contents. Fan et
al evaluated binary mixtures of polyacrylamide and sodium acetate but at a 1:1 ratio with a 100%
true positive rate [127]. Our test mixtures included ratios of 1:4, 1:7, 1:10 and 1:20 where the
controlled drug was present in a smaller percentage, simulating what can be expected in street
drugs. The correct identification rates for the drug in the authentic mixtures decreased as the drug:
diluent ratios increased with all algorithms, demonstrating the difficulty in detecting low
concentration compounds in mixtures. Although, several measurements are required when
performing analysis using portable Raman instruments to account for inhomogeneous samples, the
acquired data may still be unrepresentative of the compounds in the mixture. One method that
addresses this issue is the orbital raster scanning technique which allows the Raman instrument’s
laser to sweep over large areas of the sample to yield an average spectrum [157, 158]. However,
evaluating the accuracy of this technique with machine learning would have to be studied and
compared to conventional Raman instruments. The simulated complex mixtures data demonstrated
that if measurements capture all components in a sample, the algorithm will detect them with high
accuracy. An alternative to conventional Raman—surface enhanced Raman spectroscopy (SERS)
requires collection of a small sample dissolved in a solvent prior to analysis. This technique can
provide more representative information about the components of a mixture even when the target
substance is in low quantities, but can be risky when performed outside a controlled environment
if the operator is exposed to unknown compounds [90, 159, 160].
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A comparison of the effect of training with the mixtures models (Table 2.23) or pure models
(Table 2.21) to predict the compounds in the test mixtures demonstrated the importance of having
the appropriate model in the library. For example, if ternary mixtures are being tested, the models
should be trained on ternary mixtures. If the pure model which returns a single compound is used
on mixtures, a result for the compound most representative of the spectrum will result, as
demonstrated by the accuracy of the diluent in Table 2.21. Additionally, the algorithms detected
differences in spectra of ternary and quaternary mixtures, that would otherwise be challenging to
observe by inspection, with high accuracies (~ 83-100%, Table 2.24 and 2.25). Depending on the
application, if the number of component mixtures is known, algorithms can be designed to meet
this expectation. For example, if the number of mixtures in street drugs does not typically exceed
5 compounds, then training algorithms to detect more than 4 components would not be necessary.
We propose the use of models created to report single compounds, single compound classes,
binary, ternary, and quaternary mixtures using the CNN algorithm due to the high correct
identification rates and accuracy reported in this study. Instead of implementing these
classification techniques post processing, they can be incorporated into portable instruments and
depending on the application, provide both spectral correlation information using the HQI, cosine
similarity or Pearson’s correlation, and classification as demonstrated by the proposed workflow
in Figure 2.9. One advantage of this classification and reporting workflow, is the gain of feedback
to the end-user. When the identity of a compound is unknown and misclassified by the
conventional HQI, having a built-in CNN algorithm can provide additional information about drug
classes and potential mixtures. For example, when pure PB-22 was analyzed using the portable
Raman instrument, it was reported as BB22 using the HQI due to the similarity between their
spectra. Nonetheless, using the machine learning algorithm for compound class classified it as a
synthetic cannabinoid even though it was absent from the library.
It should be noted that depending on the application, the proposed approach still has some
limitations. For example, in the pharmaceutical industry where purer compounds are encountered
and Raman is the primary technique used, instead of using the top three hits (Table 2.22), the top
hit might be more important. On the other hand, in forensic science, where portable Raman is used
as a screening method, it might be acceptable to consider the top three hits as potential compounds
since confirmation using a secondary technique would be required before reporting components
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of seized materials. One of the drawbacks of using machine learning algorithms on large datasets
is that it requires high computing capabilities as observed with Random Forests in this study.
However, given portable instruments such as the TacticID have Wi-Fi capabilities, access to a
server can be used to train the algorithms on new data and be used to perform searches. In future
studies, other data augmentation parameters such as Raman shift offset can be used in training the
models to increase their robustness. Additionally, creation of authentic ternary and quaternary
mixtures can be created to demonstrate the capability of the algorithms as more complex drug:
diluent mixtures have previously reported in casework [73].
Machine learning which detects minor differences in spectra of complex mixtures outperformed
the HQI algorithm incorporated in a portable Raman system. Implementation of machine learning
algorithms capable of detecting single compounds, mixtures, and their classes can provide useful
screening information about unknown compounds or molecules. Although, our proposed approach
provides a probability for each hit, when needed, a spectral correlation technique can be used.
Furthermore, having these methods built into the instrument eliminates the need to first export the
data for post processing, and does not require separate libraries to be installed on the instrument
as models can be trained offline then transferred to the device. Reporting the accuracy of the
models as shown in Figure 2.9, size of the training, and testing data results in more transparent
reporting of results. The concept proposed in this study will therefore benefit applications where
portable Raman instruments are used for compound screening including forensic science,
medicine, and pharmaceutical industries.
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Figure 2. 9. An example of a workflow that can be implemented in portable Raman instruments.
If the intended application requires a numerical value for spectral correlation, a similarity metric
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can provide a HQI for pure compounds and spectral weight for mixtures. Machine learning
algorithms can also be incorporated for identification of the compounds and their classes. In the
final report, a summary of the potential hits and their respective class probabilities is reported.

2.5.0 Conclusions
Six machine learning algorithms—kNN, NB, RF, SVM, NN, and CNN were investigated and
compared to a portable Raman instrument’s accuracy in detecting pure powders, binary, ternary,
and quaternary mixtures in this study. The CNN performed better than all algorithms with 100%
correct identification for pure substances by compound and class. Both the NN and CNN resulted
in superior correct identification on the authentic binary mixtures data— 65% and 64%,
respectively in detecting both compounds in comparison to 19% observed in the portable Raman
instrument. Improved accuracy in the binary simulated mixtures was observed, ranging from 83
to 100%, depending on the model and algorithm used, with superior performance observed for
CNN. The CNN also provided the highest accuracy on the ternary and quaternary mixtures—
100%, demonstrating its ability to provide compound and class information on samples that
simulate common seized drugs formulations.
We propose the use of the HQI for spectral correlation and CNN models in portable Raman
instruments to provide preliminary information about the identity of a compound and its class.
Incorporating machine learning algorithms into portable Raman systems can enhance the response
and feedback provided to law enforcement and scientists at the laboratory and onsite, facilitating
more efficient and safer decision-making during sampling and investigative stages. The methods
proposed here are broadly applicable to other materials and disciplines that use Raman
spectroscopy as a rapid method for point-of-contact analysis.
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Chapter 3: Evaluation of Fentanyl Toxicity and Metabolism using a Zebrafish
Model
Reproduced with additions and permission from Wiley and Travon Cooman, Sadie A. Bergeron, Rebecca
Coltogirone, Eric Horstick, Luis Arroyo, Journal of Applied Toxicology, Vol. 42 (2022): 706-714. DOI #:
10.1002/jat.4253

3.1.0 Introduction
The United States of America continues to experience an opioid epidemic fueled by not only
prescription opioids, but also their illegally synthesized analogues. Notably, synthetic opioids are
emerging at an alarming rate and has highlighted the lack of knowledge about their toxicity.
Currently, many of these compounds are scheduled under the Administrative Controlled
Substances Code 9850 [161] with minimal prior study. High throughput models are therefore
useful in evaluating the toxic effects of multiple drugs. Although in vitro cell culture models are
available, they do not always translate to in vivo toxicity due to differences in absorption,
distribution, metabolism, and excretion of xenobiotics [162]. In vivo models such as rodents, are
more expensive, and do not allow for high throughput experiments, and are time consuming. The
zebrafish model is a popular, cost-effective, and high throughput model used to study drug toxicity
and metabolism due to their similarities to human [39, 43, 50, 163–165]. The organization for
economic cooperation and development (OECD) developed guidelines for testing acute or lethal
toxicity of chemicals on zebrafish larvae and listed the endpoints as coagulation, lack of somite
formation, lack of tail detachment from the yolk sac, and lack of heartbeat [33].

Zebrafish have homologous opioidergic genes to human [166] and have therefore been used as a
model for behavioral studies with morphine [167], buprenorphine [168] and tramadol [169], where
hyperactivity was observed with all drugs. Fentanyl—a potent opioid, when consumed may cause
difficulty breathing and loss of consciousness in humans [170, 171]. Similar effects were reported
by Zaig et al., when they investigated fentanyl respiratory depression in zebrafish larvae by
monitoring the fish mandible movement [172]. Anatomical phenotypes have been used to observe
toxicity for multiple classes of drugs which affect human [35, 173], but few studies evaluate opioid
toxicity or metabolism. One study reported death and malformation of embryos when exposed to
100 nM morphine [174] while another reported pericardial edema and tail malformation when
larvae were exposed to furanoyl-1-benzyl-4-anilinopiperidine (Fu-BAP) [175]—a fentanyl
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analogue. Tramadol metabolism was studied via microinjection [169], and two fentanyl
analogues— cyclopropanoyl-1-benzyl-4’-fluoro-4-anilinopiperidine and Fu-BAP [175] were
characterized in zebrafish. However, no study evaluated both toxicity and metabolism
simultaneously as the fish developed from 24 to 96 hours post fertilization (hpf).

Here we investigate the toxicity and metabolism of fentanyl in zebrafish larvae. A single assay
was utilized to observe diverse morphological phenotypes, as well as the ability of embryos and
larvae to metabolize fentanyl when dosed through rearing-media. This approach provides
foundational knowledge to further elucidate fentanyl’s mechanism of action in fish and to translate
the observations to human.

3.2.0 Materials and Method
3.2.1 Chemicals
United States Pharmacopeia fentanyl citrate (CAS #: 990-73-8, >99% purity, verified by Gas
Chromatography Mass Spectrometry), 0.1 M sodium hydroxide, Tris base, 1 M 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer and magnesium sulfate (MgSO4•7H2O)

were purchased from Sigma Aldrich (St. Louis, MO). Methanol, ammonium formate,

formic acid, hexanes, sodium chloride (NaCl) and potassium chloride (KCl) were purchased from
Fisher Chemical (Waltham, MA). Calcium chloride (CaCl2) was purchased from LabChem (PA).
Tricaine (MS-222) was purchased from Syndel (Nanaimo, Canada). Deionized water was acquired
from a Direct-Q® 3UV Millipore Sigma system (Burlington, MA). Fentanyl, norfentanyl, βhydroxyfentanyl, and despropionyl fentanyl (4-ANPP) were obtained from Cayman Chemical
(Ann Arbor, MI).
3.2.2 Method
3.2.2.1 Embryo Toxicity Study
Adult wild-type zebrafish breeders (TL strain) were acquired from several generations of breeding
in our laboratory facility at West Virginia University. Adult fish were raised on a flow-through
system [176]. Daily and weekly water checks for optimal conditions included pH—7.0-8.0,
conductivity—600 – 800 µS/cm, temperature—27 – 30°C, chlorine—0 ppm, ammonia—0 ppm,
nitrate—<10 ppm, nitrite—0 ppm, hardness—80 – 300 ppm, alkalinity—50 – 150 ppm. Fertilized
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eggs were collected during the first hour of light period (14/10 hour light on/off) and incubated in
embryo media (5 µM NaCl, 0.17 µM KCl, 0.33 µM CaCl2, 0.33 µM MgSO4•7H2O, 1 M HEPES)
with a final pH of 7.4. Fertilized eggs <10 hours post fertilization (hpf) were placed in a 96 wellplate with one egg per well. Excess media was removed and 24 eggs per treatment level were
exposed to 200 µL fentanyl solution dissolved in embryo media. The treatment levels
recommended by the OECD [33] as a starting point included: 0, 0.01, 0.1, 1, 10, 100 µM, with the
addition of 50 µM. The experiment was performed in triplicate (n = 72 eggs per level) with each
replicate on a different day. The treatment groups were randomly placed on each plate and each
well-plate contained a negative control. The plates were incubated at 28- 29 °C (VWR 1535
general purpose incubator, Radnor, PA) under a 14/10 hour light on/off period. Observations were
made using a Leica MF205A FA stereomicroscope (Wetzlar, Germany) at 24, 48, 72 and 96 hours
post dosing (hpd) and the media was collected, stored at -20oC for metabolite analysis and
replenished each day. Phenotype observations included: yolk extension malformation, yolk
extension length, tail malformation, tail degree of curvature, pericardial edema, pericardial edema
size, and swim bladder inflation whereas endpoint observations included: egg coagulation, lack of
somite formation, lack of heartbeat, and tail non-detachment. Data for lack of somite formation
and tail-yolk non-detachment are not presented because few embryos were observed with these
characteristics. All experiments were performed in accordance with the West Virginia University
Institutional Animal Care and Use Committee and the ARRIVE guidelines [177].
The percentage of coagulated eggs after 24 hpd was calculated in Equation (3.1).
𝐶𝑜𝑎𝑔𝑢𝑙𝑎𝑡𝑖𝑜𝑛(%) =

𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑎𝑔𝑢𝑙𝑎𝑡𝑒𝑑 𝑒𝑔𝑔𝑠 𝑝𝑒𝑟 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 𝑙𝑒𝑣𝑒𝑙
𝑇𝑜𝑡𝑎𝑙 𝑒𝑔𝑔𝑠 𝑝𝑒𝑟 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡

∗ 100

Equation (3.1)

The embryos which survived were recorded for each treatment level daily. To normalize survival,
the number of deaths at 0 µM were subtracted from each level and reported as a percentage of the
number of surviving embryos at 0 µM.
Hatching was recorded at 48, 72 and 96 hpd. The percentage of embryos hatched at each time was
calculated as shown in Equations (3.2, 3.3, 3.4), where H48, H72, and H96 are the percentage of
hatching by 48, 72 and 96 hpd, respectively.
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𝐻48 (%) =

𝑁𝑢𝑚𝑏𝑒𝑟 ℎ𝑎𝑡𝑐ℎ𝑒𝑑 𝑎𝑡 48 ℎ𝑝𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑠𝑢𝑟𝑣𝑖𝑣𝑒𝑑 𝑎𝑡 48 ℎ𝑝𝑑

∗ 100

Equation (3.2)

𝐻72 (%) =

𝑁𝑢𝑚𝑏𝑒𝑟 ℎ𝑎𝑡𝑐ℎ𝑒𝑑 𝑎𝑡 48 ℎ𝑝𝑑 + 72 ℎ𝑝𝑑

𝐻96 (%) =

𝑁𝑢𝑚𝑏𝑒𝑟 ℎ𝑎𝑡𝑐ℎ𝑒𝑑 𝑎𝑡 48 ℎ𝑝𝑑 + 72 ℎ𝑝𝑑 + 96 ℎ𝑝𝑑

𝑁𝑢𝑚𝑏𝑒𝑟 𝑠𝑢𝑟𝑣𝑖𝑣𝑒𝑑 𝑎𝑡 72 ℎ𝑝𝑑

∗ 100

𝑁𝑢𝑚𝑏𝑒𝑟 𝑠𝑢𝑟𝑣𝑖𝑣𝑒𝑑 𝑎𝑡 96 ℎ𝑝𝑑

Equation (3.3)
∗ 100

Equation (3.4)

In one replicate, some larvae were missing tails at levels not limited to the negative control. These
larvae were omitted from the calculations for yolk extension length, pericardial edema size, degree
of tail curvature, and swim bladder inflation. A correction for the observed malformations in the
yolk extension, pericardium, and tail was done by subtracting the number observed at 0 µM from
each treatment level.
The percentage of larvae with malformed yolk extension, tail, and pericardium at 48, 72, and 96
hpd were calculated as shown in Equation (3.5).
𝑀𝑎𝑙𝑓𝑜𝑟𝑚𝑎𝑡𝑖𝑜𝑛(%) =

𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑚𝑎𝑙𝑓𝑜𝑟𝑚𝑒𝑑 𝑙𝑎𝑟𝑣𝑎𝑒
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑎𝑟𝑣𝑎𝑒 𝑠𝑢𝑟𝑣𝑖𝑣𝑒𝑑

Equation (3.5)

At 96 hpd, the larvae were anesthetized with MS-222 (1 mg/mL) in Tris buffer (pH 7), then imaged
using a Leica MF205 FA stereoscope. The images were calibrated and processed in Adobe
Photoshop CC 2018. The yolk extension length was measured using the Measurement Tool as
shown in Figure 3.1A. To measure tail curvature, a straight line measuring 0 degrees was drawn
from the otolith closest to the tail, then a second line was drawn through the spine as shown in
Figure 3.1B. The angle between the lines was recorded as the degree of curvature. The size of
pericardial edema was measured using the Record Measurement and Quick Selection tools in
Adobe Photoshop CC 2018. These malformation measurements were compared to the
measurements from the negative control.
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Figure 3. 1. (A)- annotation of yolk extension length; (B)- measurement of pericardial edema and
degree of spinal curvature.
The percentage of larvae with fully inflated swim bladder at 96 hpd was calculated using Equation
(3.6).
𝑆𝑤𝑖𝑚 𝑏𝑙𝑎𝑑𝑑𝑒𝑟 𝑖𝑛𝑓𝑙𝑎𝑡𝑖𝑜𝑛(%) =

𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑖𝑛𝑓𝑙𝑎𝑡𝑒𝑑 𝑠𝑤𝑖𝑚 𝑏𝑙𝑎𝑑𝑑𝑒𝑟
𝑁𝑢𝑚𝑏𝑒𝑟 𝑠𝑢𝑟𝑣𝑖𝑣𝑒𝑑 𝐻96

Equation (3.6)

One-way analysis of variance (ANOVA) was used to analyze the data when all assumptions were
met, and post-hoc testing with Tukey’s honestly significant differences (HSD) test. Kruskal-Wallis
test was used alternatively when the assumption of normality was violated and Dunn’s test for
post-hoc testing using the Benjamini and Hochberg (BH) procedure to control the false discovery
rate (FDR) [178]. Statistical analyses were performed using R v 4.0.3, R Studio v 1.4.1103 and the
packages— rstatix v 0.6.0[179] and DescTools v 0.99.39 [180].
3.2.2.2 Metabolism Study
The stored media from the toxicity study was thawed and pooled per concentration and observation
time. A liquid-liquid extraction procedure was performed using 1 mL hexanes and 150 µL 0.1 M
sodium hydroxide. The samples were vortexed and centrifuged for five minutes. The organic layer
was dried under nitrogen gas at 50oC and reconstituted with 100 µL methanol. Analysis was
performed using an Agilent 6470A triple quadrupole coupled to a 1290 Infinity II Liquid
Chromatography System (Agilent Technologies, Santa Clara, CA). Mobile phase A consisted of
water in 0.1% formic acid, and 5 mM ammonium formate, whereas mobile phase B consisted of
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methanol in 0.1% formic acid. A Hypersil GOLD™ C18 (30 mm x 2.1 mm x 3 µm) column with
a guard column holder and 5 µm drop-in guard cartridge (ThermoFisher Scientific, Waltham, MA)
were used. Fentanyl, norfentanyl, β-hydroxy fentanyl and 4-ANPP were monitored in dynamic
multiple reaction monitoring mode and the instrument operated in positive electrospray ionization
mode for the transitions in Table 3.1. The fragmentor voltage for fentanyl, 4-ANPP, Norfentanyl
and β-hydroxy fentanyl were 122, 107, 98, and 107 V, respectively. The cell accelerator voltage
was 4 V for all compounds. The source parameters were as follows: gas temperature—325°C, gas
flow—9 L/min, nebulizer pressure—30 psi, sheath gas heater temperature—350°C, sheath gas
flow—10 L/min, capillary voltage—3500 V, nozzle voltage—500 V. The elution gradient system
was as follows: 5% B ramped until 3.5 min, 40% B ramped until 4.5 min, 70% B held until 8.0
min, then ramped to 80% B until 8.5 min, and ramped down to 5% B until 9 min. The flow rate
was 0.3 mL/min and the volume of injected sample was 1 µL. Data analysis was performed using
MassHunter B.08.00 (Agilent Technologies).
Table 3. 1. Monitored transitions for fentanyl and metabolites.

Compound

Fentanyl

4-ANPP

Norfentanyl

β-hydroxy fentanyl

Precursor

Product

ion (m/z)

ions (m/z)

337.2

281.2

233.2

353.2

Collision
Energy
(V)

188.0Q

24

105.0

48

77.0

100

188.0Q

16

105.0

36

77.0

80

84.0Q

20

56.0

32

55.0

48

91.0Q

52

204.0

24

186.0

28

Q- quantifier ion (used to monitor peak areas of each metabolite)
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3.3.0 Results
3.3.1 Embryo Toxicity Study
Fentanyl causes malformations in zebrafish larvae, with the severity increasing at higher
concentrations (Figure 3.2). No pericardium, tail, and yolk extension malformations were
observed at 0 µM, whereas these phenotypes were more visible at 50 and 100 µM.

Figure 3. 2. Comparison of zebrafish larvae at 96 hpd. (A) 0 µM, (B) 0.01 µM, (C) 0.1 µM, (D) 1
µM, (E) 10 µM, (F) 50 µM, and (G) 100 µM. Pericardium (→), spine (#), and yolk extension
malformation (*) are visible in (F) and (G).

Survival
Although fentanyl affected mortality, the tested concentrations did not result in 100% mortality up
to 96 hpd. Higher mortality was observed at concentrations ≥ 0.1 µM (Figure 3.3). Whereas a
statistically significant difference was detected between concentrations, none was detected
between observation times (Figure 3.4).
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Figure 3. 3. Percentage of embryo survival in relation to fentanyl concentration ( *-α ˂ 0.05).
Significant differences were observed between 0 µM and concentrations ≥0.1.
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Figure 3. 4. Percentage of embryo survival in relation to time. No statistically significant
difference observed between times.
Pericardial malformation
Our study used pericardial edema and edema size quantification to understand the toxic effect of
fentanyl. Fentanyl exposure during early development induces pericardial malformation (Figure
3.5). Time did not have a significant effect on the percentage of pericardium malformations
(Figure 3.6), but an average of 28% and 29% malformations were observed at 72 and 96 hpd,
respectively.
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Figure 3. 5. The effect of concentration (A) on pericardial edema. The effect of concentration on
edema size (B) (***- α = 0.001, ****- α = 0.0001).

Figure 3. 6. The effect of fentanyl exposure duration on pericardium malformation. No statistically
significant differences were detected.
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Yolk extension malformation
Although incubation time did not affect yolk extension (Figure 3.8), fentanyl concentrations
affected the typical absorption of the yolk (Figure 3.7). In comparison to the control group, only
50 µM (α = 0.001) and 100 µM (α = 0.0001) groups were significantly deformed. Further
quantification of this malformation by measuring the yolk extension length at 96 hpd confirmed
these observations (Figure 3.7B), subsequently contributing to the impaired development of
zebrafish larvae. However, yolk extension length between 0 µM and 0.1 µM were significantly
different but no differences were detected at 1 and 10 µM.

Figure 3. 7. Percentage of yolk extension malformation in relation to concentration (A) and further
quantification of yolk extension length (mm) (B)( **- α = 0.01, ***- α = 0.001, ****- α = 0.0001).
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Figure 3. 8. The effect of fentanyl exposure duration on yolk extension malformation.

Tail malformation
As adult zebrafish age, they may develop spinal deformities resulting in curvature of the vertebral
column [181], making it an ideal degenerative spinal disease model. Moreover, developing larvae
also display spinal deformities upon exposure to toxic chemicals by either upward or downward
tail curvature [182–187]—a common phenotype observed in developmental toxicity assays. An
average of 13% tail malformations were observed at 96 hpd, higher than 48 (4%) and 72 (4%) hpd
(Figure 3.9). However, no statistically significant difference was detected between these times
(Figure 3.10). Conversely, higher fentanyl concentrations had a significant effect on percent tail
malformation and tail curvature (Figure 3.9). The mean tail curvature for the negative control was
0.4° whereas at 50 and 100 µM, tail curvature was 3.6° and 11.8°, respectively. A previous study
demonstrated neuroinflammation as a cause of spinal curvature [188]. Although spinal curvature
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is a possible outcome from inflammation in our study, future studies will help elucidate the
mechanism.

Figure 3. 9. The effect of concentration (A) on tail malformation percentage. The extent of tail
curvature at 96 hpd (B). **- α = 0.01, ***- α = 0.001, ****- α = 0.0001.
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Figure 3. 10. Tail malformation from fentanyl exposure duration.
Swim bladder inflation
Zebrafish use their swim bladder to regulate buoyancy and balance in the water column by
expending minimal energy [189]. Inflation of the swim bladder occurs at 96 – 120 hpf via air
gulping at the water surface [190, 191]. In our study, only 75% of larvae at 96 hpd in the negative
control showed fully inflated swim bladders yet was fully inhibited at 50 and 100 µM. Pairwise
comparison to the negative treatment resulted in statistically significant differences being detected
at 10, 50 and 100 µM (Figure 3.11). A previous study demonstrated that blood circulation was
crucial in swim bladder development and the authors hypothesized that swim bladder inflation was
secondary to heart malformations [192]. Further research is required to understand the mechanistic
effects of fentanyl on swim bladder inflation.
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Figure 3. 11. The effect of concentration on swim bladder inflation. *-α = 0.05, ***- α = 0.001,
****- α = 0.0001.

Hatching
Hatching begins after 48 hpf [44]. Fentanyl exposure did not significantly influence hatching
(Figure 3.12), but a statistically significant difference was detected between 48 hpf and 72 hpf
with a higher percentage of hatching (92%) being observed at 72 hours between all groups (Figure
3.13).
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Figure 3. 12. Hatching percentage in relation to concentration.
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Figure 3. 13. Percent hatching due to fentanyl exposure. *-α = 0.05, ***- α = 0.001.
3.3.2 Metabolism Study
The liver is the major site of metabolism in human. In vitro metabolomics studies use human liver
microsomes and hepatocytes to elucidate metabolism of novel compound exposure. Metabolomics
studies in zebrafish provide not only metabolism data, but also toxicity data as we demonstrate.
Adult fish, larvae of varying ages, fish media, and whole organism analysis have been used for
metabolite screening. Using a targeted metabolomics approach, we reported three of the major
metabolites of fentanyl as early as 24 hpf. 4-ANPP (Figure 3.14A), and β-hydroxy fentanyl
(Figure 3.14C) were detected when larvae were exposed to fentanyl at 1, 10, 50 and 100 µM.
Norfentanyl (Figure 3.14E) was observed in one sample at 0.1 µM and in all other samples ≥1
µM at all observed times. No metabolites were observed in the negative control or at 0.01 µM
(Figure 3.14). Here, the reported metabolites in zebrafish have also been detected in human with
norfentanyl as the primary metabolite in human. The concentrations at 50 and 100 µM were the
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most effective at causing deformities in larvae, but the highest peak areas of the metabolites were
observed at these levels.

Figure 3. 14. The concentrations 0- 100 µM represent that of fentanyl administered to zebrafish
larvae. 4-ANPP was not detected at 0.01 and 0.1 µM (A). The concentrations at 50 and 100 µM
produced the highest metabolite peak areas for 4-ANPP(A) but no significant difference was
observed over time (B). Significantly higher β-hydroxy fentanyl peak areas were observed at
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concentrations ≥10 µM (C) but no statistical differences were detected between the treatment times
(D) when the peak areas at the investigated concentrations were combined. The concentrations
≥10 µM produced significantly higher peak areas for norfentanyl (E) but no significant differences
were observed in relation to time (F). *-α = 0.05, **- α = 0.01, ***- α = 0.001, ****- α = 0.0001.

3.4.0 Discussion
This study presented three metabolites of fentanyl—4-ANPP, β-hydroxyfentanyl, and norfentanyl
produced by zebrafish at all stages of development between 0 and 96 hpf investigated, and the
significant morphological defects to the larvae and embryos (0-72 h) at fentanyl concentrations
above 10 µM. A previous study investigated the toxicity of opioids, including fentanyl in zebrafish
larvae but reported metabolic data for only tramadol and butyrfentanyl [193]. Here, a single assay
was used to evaluate toxicity and metabolism of fentanyl, further strengthening the case for
zebrafish as an in vivo model for opioid studies.

Upward tail curvature and pericardium malformations (Figure 3.2) in our study were similar to
those previously observed when larvae were exposed to Fu-BAP—a fentanyl analogue [175], yet,
observations were not quantified and focused on identifying a maximum tolerated concentration.
While these endpoints provide valuable information, they do not account for morphological defects
which may lead to further investigations into the chemicals’ mechanism of action and translation
to human. For this reason, we quantified additional observations and provided statistical analyses
to further explain the effect of fentanyl on the observed phenotypes.

Cardiotoxicity was one of the major factors affecting survival of zebrafish larvae, with significant
effects observed at 50 and 100 µM (Figure 3.5). The world health organization reported
cardiovascular disease as the leading cause of death globally [194], making this an active research
field. In recent years, the zebrafish model has gained popularity for cardiology studies due to the
translucent nature of the heart as it develops [195, 196]. Heart rate [197] and morphological defects
[35, 198–200] have been used to demonstrate the toxicity of chemicals on heart development in
zebrafish. Bradycardia and respiratory depression have been reported as the main cause of opioid
overdose in humans [201]. In zebrafish larvae, fentanyl caused analgesia and respiratory
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depression [172]. Although heart rate and respiratory depression were not quantified in our study,
larvae movement was reduced when exposed to higher concentrations of fentanyl.
Larvae are reliant on their yolk sac until they start feeding—4-5 days post fertilization [202]. A
normal larva as shown in Figure 3.2A, absorbs the yolk as it develops. Exposure to toxic
compounds can result in a shortening of the yolk extension or abnormal rate of nutrient metabolism
and uptake [203] (Figure 3.2G). Zebrafish have been proposed as a model to elucidate the toxic
effects of chemicals during human development and the metabolic birth defects observed in infants
[204]. The transparent nature of zebrafish embryos allow for easy visualization of nutrient uptake
and distribution through fluorescence assays [205, 206]. However, confirmation of metabolites
using secondary methods as mass spectrometry, as we have presented can provide further support
for metabolic rates. In our study, significant abnormal yolk extension occurred at 50 and 100 µM
(Figure 3.7), the same concentrations where pericardial edema was observed, and where higher
metabolites detected (Figure 3.14). It is possible that the larvae are preferentially metabolizing
fentanyl which may be inhibiting yolk metabolism at such high concentrations. Although zebrafish
have complementary xenobiotic metabolizing enzymes to human, the cytochrome P450 (CYP)
families 1- 4 have greater sequence diversity [207, 208]. CYP3A65, the zebrafish orthologue to
CYP3A4 in human—which metabolizes fentanyl to norfentanyl [53], is 54% similar [208],
possibly accounting for the differences in the major metabolite between species. Therefore, to gain
full understanding of the impact of fentanyl on nutrient uptake in zebrafish, and to extend this
knowledge to human, further research is required to isolate the enzyme metabolizing fentanyl in
zebrafish.
One limitation of our research was not quantifying the internal concentration of fentanyl
metabolites in zebrafish larvae and evaluating the metabolites’ effects on the observed phenotypes.
Further investigations would be required to understand any correlations between the
concentrations of these metabolites and toxicological effects. Differences in glucose metabolism
after fasting were reported in various adult zebrafish strains as well as behavioral variation in wild
type strains [209, 210]. Therefore, future zebrafish strain variation studies can be performed to
compare the phenotypes and metabolic differences upon fentanyl exposure to understand if one
strain provides more reproducible and robust results than another.
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3.5.0 Conclusions
We present an in vivo vertebrate model to evaluate toxicity and metabolism of fentanyl. Fentanyl
disrupted in a dose-dependent manner five out of seven morphological parameters observed—
survival, yolk extension, tail, pericardium malformation, and swim bladder inflation, but no effect
on coagulation and hatching. A targeted metabolomics approach showed that three metabolites of
fentanyl were detected at each observation time and concentration. In addition to opioid zebrafish
behavioral studies [211], a combination of developmental defects and metabolite analysis can
provide greater insight into the effects of drugs.
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Chapter 4: The metabolism of valerylfentanyl using human liver microsomes
and zebrafish larvae
Reproduced with additions and permission from Wiley and Travon Cooman, Brianna Hoover, Brianna Sauvé, Sadie
A. Bergeron, Natalia Quinete, Piero Gardinali, Luis Arroyo, Drug Testing and Analysis, DOI #: 10.1002/dta.3233

4.1.0 Introduction
Fentanyl and novel synthetic opioids (NSOs) are continuously impacting the workload of multiple
sectors including law enforcement, first responders and forensic toxicology personnel [212]. The
large number of overdose deaths associated with these types of compounds have reached epidemic
proportions in recent years. At the front end, the high potency of fentanyl analogs requires trained
personnel on the correct use of personal protection equipment, and to properly respond in
emergency situations. At the laboratory level, the isolation, identification and quantification of
NSOs in biological specimens can be challenging due to the time required for method
development, the need of high-end mass spectrometry instrumentation, and the availability of
standard reference materials for confirmation. NSOs are illicitly manufactured and sold as other
common drugs or laced into known drug entities to cause harm. In some instances, they are
consumed without knowledge of the contents and the dosage by the user, resulting in unexpected
effects or overdoses. From 2014 to 2016, the overdose deaths from fentanyl or its analogs increased
from 9% to 41% [213]. Between July and December of 2016, fentanyl analogs accounted for 20%
of overdose deaths [213]. Additionally, from July to December of 2018, 19.4% of opioid-involved
overdose death cases were reported to contain one or more fentanyl analogs, one of which was
valerylfentanyl, which appeared in 0.5% of those cases [214].
In the 1980s, researchers recognized the need for reference materials to confirm the identity of
fentanyl analogues and to evaluate their potency, therefore synthesizing many of which are reemerging today [215, 216]. Valerylfentanyl was included as one of these compounds and since
then it has been detected in wastewater effluents, postmortem samples, or in seized drugs in North
America, Australia, Europe and Asia [56, 217–221]. Figure 4.1 shows the structure of
valerylfentanyl, a homologue of fentanyl, differing by 28 Da. A study of valerylfentanyl in
monkeys showed that it was equipotent to morphine [216]. Another study in rats measured the
binding affinity at the opioid receptors and demonstrated the highest affinity—53.0 ± 5.13 nM at
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the µ opioid receptor compared to fentanyl—2.76 ± 0.38 nM [222]. In addition to the limited
investigations of the toxicity of valerylfentanyl, pharmacokinetics data are lacking. The zebrafish
model is emerging as a model for drug metabolism since they have similar enzymes as humans
including cytochrome P450s (CYP) [223]. Zebrafish (Danio rerio) have a fully sequenced genome
with 70% homology to humans, high fecundity, short generation time (about 3 months), rapid
embryonic development (48 hours), and external fertilization, which makes visualization of
developing internal organs easy [224, 225]. Additionally, they have opioid receptors similar to
humans and have been used as a human disease model [166, 196, 226]. Studies have been
performed to investigate metabolite markers for synthetic cannabinoids [227], human performance
enhancing drugs [50, 228], synthetic cathinones [163] and opioids [175, 193] using the zebrafish
model. More recently, we utilized the zebrafish model as a single assay for the toxicity and
metabolism of fentanyl, and detected norfentanyl, β-hydroxyfentanyl, and 4-anilino-Nphenethylpiperidine (4-ANPP) from 24 to 96 hours post fertilization[229], providing additional
support for their ability to metabolize opioids.

Figure 4. 1. Structural comparison between fentanyl, valerylfentanyl and the commercially
available metabolite of valerylfentanyl— valerylfentanyl carboxy metabolite.
Despite valerylfentanyl being a scheduled I drug, it is still consumed illegally. When a parent drug
is not detected in a biological specimen, a marker metabolite can be used to determine if the parent
was consumed. To our knowledge, no published studies have evaluated the metabolism of
valerylfentanyl, although valerylfentanyl carboxy metabolite (Figure 4.1) is sold commercially as
its marker metabolite. In this study, we compare the metabolism of valerylfentanyl in human liver
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microsomes and zebrafish. We also analyze an authentic liver specimen for valerylfentanyl and
metabolites.

4.2.0 Experimental
4.2.1 Chemicals and Reagents
Valerylfentanyl hydrochloride, valerylfentanyl carboxy metabolite, and 4-ANPP standards were
purchased from Cayman Chemical Company (Ann Arbor, MI, USA). NADPH regenerating
system solutions A (NADP+, Glucose-6-phosphate, and MgCl2) and B (Glucose-6-phosphate
dehydrogenase in sodium citrate), and 0.5 M potassium phosphate buffer, pH 7.4, were purchased
from Corning (Woburn, MA, USA). HPLC grade methanol, HPLC grade water, acetonitrile,
ammonium formate, sodium chloride (NaCl), formic acid, and potassium chloride (KCl) were
purchased from Fisher Chemical (Waltham, MA). Calcium chloride (CaCl2) was acquired from
LabChem (PA). Uridine 5’-diphosphoglucuronic acid (UDPGA), tris base, 4-(2-hydroxyethyl)- 1piperazineethanesulfonic acid (HEPES) buffer and magnesium sulfate (MgSO4•7H2O) were
purchased from Sigma Aldrich (St. Louis, MO, USA). Pooled human liver microsomes (20
mg/mL) were purchased from Thermo Fisher Scientific (Waltham, MA, USA).

4.2.2 Microsome Study
The microsome incubation was performed as previously described [230]. The human liver
microsome (HLM) suspension was thawed at 37°C. The reaction mixture contained 780 μL
distilled water, 100 μL 0.5 M potassium phosphate buffer, pH 7.4, 50 μL of solution A, and 10 μL
of 19.3 mM UDPGA. The suspension was pre-incubated using a Thermal Mixer (ThermoFisher
Scientific®; Waltham, MA, USA) at 37°C and 800 rpm for 3 minutes. 10 μL of solution B and 50
μL of HLM suspension were added to initiate the reaction. Aliquots of 300 μL were collected at
0, 150, and 300 minutes and were quenched with 300 μL ice-cold acetonitrile. The samples were
centrifuged at 10,000 rpm for 5 minutes. The supernatant was extracted from the samples and
placed into a 0.2 µm Nanosep water wettable hydrophilic polytetrafluoroethylene (ww PTFE)
centrifugal device (Pall Life Sciences, Port Washington, NY, USA) due to their low protein
binding ability. The samples were dried under nitrogen gas at 40°C and reconstituted with 200 μL
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methanol. The reconstituted samples were centrifuged again at 10,000 rpm for 1 minute, and the
supernatant transferred to LC vials. The experiment was performed in triplicate.

4.2.3 Zebrafish Study
All zebrafish experimental procedures were reviewed and approved by the West Virginia
University IACUC. Adult wild-type zebrafish breeders (TL strain) were crossed, fertilized eggs
collected and larvae were raised from 5-30 days post fertilization (dpf) on a flow-through housing
system on a 14h/10h light/dark cycle at 28.5°C. Daily and weekly checks were performed to
maintain the following conditions: pH—7.0 to 8.0, conductivity—600- 800 µS/cm, alkalinity—
50- 150 ppm, chlorine—0 ppm, ammonia—0 ppm, nitrate—<200 ppm [231], nitrite—0 ppm,
temperature—27- 30°C, and hardness—80- 300 ppm. Ten 30 dpf juvenile zebrafish were dosed
with 3 mL of 50 µM valerylfentanyl dissolved in E3 media (5-μM NaCl, 0.17-μM KCl, 0.33-μM
CaCl2, 0.33-μM MgSO4•7H2O, 1 M HEPES, at pH 7.4). At about 30 dpf, larvae begin to
metamorphosize into juvenile zebrafish—having most adult characteristics, and have fully formed
organs crucial for drug metabolism [232]. The experiment was performed in triplicate (n = 30) and
dosing occurred in a six-well plate. A negative control also contained 10x 30 dpf zebrafish in
media containing no drug. Incubation occurred for 24 hours, after which the fish were euthanized
by rapid chilling in ice-cold water per the American Veterinary Medical Association guidelines
[233]. The collected media was extracted by adding 1 mL to an Oasis PRiME MCX 3cc solid
phase extraction cartridge (Waters Corporation, Milford, MA) using a positive pressure manifold
system (United Chemical Technologies, Inc., Bristol, PA). After the sample was loaded, 1 mL of
methanol: ammonium hydroxide (95:5) was used for elution. The eluent was dried under nitrogen
at 40°C, reconstituted with 100 µL methanol. The collected fish tissue was extracted using the
same technique described for the microsome study above.

4.2.4 Instrumental Analysis
All samples were analyzed using a high-resolution mass spectrometer (HRMS)—Q-Exactive Orbitrap mass spectrometer coupled with a PAL HTC Accela autosampler and Accela1250 pump
(ThermoFisher Scientific; Waltham, MA, USA). A Hypersil GOLD™ C18 (30 mm x 2.1 mm x 3
μm) column with a guard column holder and 5 μm drop-in guard cartridge (ThermoFisher
Scientific, Waltham, MA) were used. Mobile phase B consisted of methanol whereas mobile phase
D consisted of water in 0.1% formic acid. The gradient system was as follows: 5% mobile phase
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B ramped to 10% at 0.1 min and held until 0.6 min, ramped to 95% until 10.5 min, ramped down
to 10% at 11 min and back to 5% at 13 min. The flow rate was kept at 300 μL/min.
Data were acquired using full MS and data dependent (dd𝑀𝑆 2 ) using the optimized parameters
listed in Table 4.1. The normalized collision energy was 30 V. Compound Discoverer version
3.2.0.421 (ThermoFisher Scientific; Waltham, MA, USA) and XCalibur™ version 2.2
(ThermoFisher Scientific®; Waltham, MA, USA) were used for metabolite profiling. The phase I
transformations used in Compound Discoverer workflow included dehydration, desaturation,
hydration, nitro reduction, oxidation, and reduction and phase II transformations included
glucuronide conjugation and sulfation. The mass error for metabolite analysis was set to a
maximum threshold of 10 ppm. A standard containing valerylfentanyl, 4-ANPP, and
valerylfentanyl carboxy metabolite was injected at the beginning of the run and after every 20
injections to verify the mass error was within the set threshold.
Table 4. 1. Q-Exactive -Orbitrap mass spectrometer full MS/ddMS2 parameters used for
metabolite identification.
General
Runtime

0-13 min

Polarity

Positive

Full MS
Resolution

70,000

AGC target

1,000,000

Maximum IT

200 ms

Scan Range

70-700 m/z

dd𝑴𝑺𝟐
Resolution

35,000

AGC target

100,000

Maximum IT

50 ms

Loop count

5

Isolation window

2 m/z

Collision energy

30 V
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The samples were also analyzed using an Agilent 6470A triple quadrupole mass spectrometer
coupled to a 1290 Infinity II Liquid Chromatography System (Agilent Technologies, Santa Clara,
CA). Mobile phase A consisted of water in 0.1% formic acid and 5-mM ammonium formate,
whereas mobile phase B consisted of methanol in 0.1% formic acid. The gradient program was as
follows: 5% B until 3.5 mins, 40% B until 9.0 mins, ramped back to 5% B at 9.5 mins and held
until 11 mins. The flow rate was 0.3 mL/min and 1 µL sample was injected for analysis.
Valerylfentanyl, 4-ANPP, valerylfentanyl carboxy metabolite, and selected newly proposed
metabolites of valerylfentanyl were detected in multiple reaction monitoring mode. The transitions
and instrumental conditions can be found in Table 4.2.
Table 4. 2. Compounds and monitored transitions by LC-MS/MS. Cell accelerator voltage was set
to 4 V, and the dwell time was 20 ms. The source parameters included: gas temperature- 325°C,
gas flow- 9 L/min, nebulizer pressure- 9 psi, sheath gas temperature- 349°C, sheath gas flow- 8
L/min, capillary- 3500 V, nozzle- 500 V.

Compound

Valeryl

Precursor
(m/z)
365.3

Ions (m/z)

Fragmentor
voltage (V)

Collision
energy
(V)

77.0

127

100

105.0

127

48

188.0

127

24

77.0

141

100

fentanyl

105.0

141

56

carboxy

188.1

141

28

77.0

107

80

105.0

107

36

188.0

107

16

fentanyl

Valeryl

395.2

RT

6.702

4.921

metabolite
(M19)
4ANPP (M6)

281.2

4.938
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Compound

Valeryl

Precursor
(m/z)

voltage (V)

Collision
energy

RT

(V)

84.0

98

20

norfentanyl

177.1

98

16

(M10)

178.0

98

16

91.0

107

56

4.932

105.0

107

52

5.336

188.1

107

28

5.597

91.0

107

56

6.091

105.0

107

52

6.420

204.1

107

24

105.0

107

52

7.248

204.1

107

24

7.538

M7/M8/M9

M12/14

M16/M18

261.2

Ions (m/z)

Fragmentor

381.3

381.3

381.3

5.717

4.2.5 Authentic Specimen Analysis
A previously analyzed postmortem liver sample positive for valerylfentanyl [221] was reanalyzed
using the Q-Exactive orbitrap and the triple quadrupole for metabolites of valerylfentanyl. The
liver specimen acquired from the Office of the Chief Medical Examiner in West Virginia was a
drug related overdose death case. Refer to Cox et al. for further details about the validation
procedure used in extracting the authentic specimen [221].

4.3.0 Results and Discussion
The metabolism of valerylfentanyl was elucidated using both human liver microsomes and
juvenile zebrafish. Nineteen metabolites were detected in the HLM model (Table 4.3), with two
confirmed using reference standards—M6 (4-ANPP) and M19 (valerylfentanyl carboxy
metabolite). The major metabolites in the HLM model were valeryl norfentanyl (M10) and
hydroxy valerylfentanyl (M7, M14) whereas in zebrafish the three major metabolites were M10,
M12 and M7.
The most prevalent biotransformation was mono hydroxylation, although dihydroxylation,
reduction and N-dealkylation were observed (Figure 4.2). In the zebrafish model, only M10, M7,
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M12, M14, M16, and M18 were detected using HRMS possibly due to the lower dose (50 µM)
and instrument sensitivity in comparison to the microsome model (dosed at 100 µM), but targeted
analysis of higher abundance metabolites observed in the HLMs using QqQ resulted in M6,
M7/8/9/12, M10, M14/16, M18, and M19 (Figure 4.2). The microsome model is commonly used
as a cost-effective alternative to elucidate the metabolism of novel drugs of abuse, but the findings
are not always reflective of in vivo results [162]. Microsomes are subcellular fragments, highly
purified to contain cytochrome P450 (CYP) drug metabolizing enzymes providing quick metabolic
data but do not contain drug transporters which affects therapeutic efficacy, absorption,
distribution, and elimination [234]. Zebrafish provide a whole organism model that can help
elucidate these mechanisms with stronger biological systems relevance.
In the fish samples, the peak intensity of valeryl norfentanyl (M10) was 2.6% of valerylfentanyl,
and valerylfentanyl carboxy metabolite (M19)—a minor metabolite commercially available as
valerylfentanyl metabolite, was 0.9% of valeryl norfentanyl (M10). The ratios in the microsome
sample varied because the incubation times were different. A longer incubation time resulted in a
lower parent drug to metabolite ratio. M19 was detected only after analysis on the QqQ and was
0.4% of the M10 metabolite peak. The ratio of M7/M10 was 60% and 63% for the HLM samples
and zebrafish, respectively, whereas the M8/M10 ratio was 11% and 20% for the microsome and
zebrafish assays, respectively. However, quantifying these metabolites and evaluating the
statistical significance would be required to demonstrate any meaningful model differences such
as enzyme effects on metabolism. No metabolites were detected in the negative controls.
Table 4. 3. Summary of detected metabolites. The [M+H]+ and selected diagnostic ions
correspond to the experimental accurate mass. The metabolites are listed as M1 to M18 according
to the retention times, but also ranked from major to minor metabolite based on the average peak
area. The mass error of M19 is based on the reference standard.

Compound

Valerylfent

Formula

C24H32N2O

Mass
[M+H]+
365.2607

Mass
Error
(ppm)
5.5

RT
(mins)
7.26

Peak Area

1.81 x 1010

anyl

Selected Diagnostic
ions (m/z)
188.1445, 105.0704,

Rank

---

244.1708,
281.2028

M1

C13H19NO

206.1552

6.3

3.21

1.36 x

108

188.1446, 105.0705,

11

146.0607, 134.0972

119

Compound

M2

Formula

C16H24N2O2

Mass
[M+H]+
277.1927

Mass
Error
(ppm)
5.8

RT
(mins)

Peak Area

3.80

5.20 x 107

4.28

1.41 x

107

4.84 x

107
108

Selected Diagnostic
ions (m/z)
84.0813, 177.1397,

Rank

14

194.1188, 259.1820
M3

C19H24N2O

297.1978

5.7

204.1395, 134.0972,

17

186.1289, 279.1873
M4

C19H24N2O

297.1978

5.7

4.74

204.1395, 134.0972,

16

186.1289, 279.1872
M5

C24H32N2O3

397.2511

6.3

5.07

1.02 x

†

C19H24N2

281.2029

6.0

5.43

7.50 x 108

5.71

9

204.1397, 186.1291,

12

279.1874, 297.1978
M6

188.1445, 105.0705,

5

134.0973, 146.0974
†

M7

C24H32N2O2

381.2558

5.5

2.53 x 10

188.1445, 105.0705,

2

260.1660, 363.2450
†

M8

C24H32N2O2

381.2557

5.2

5.98

7.17 x

108
108

188.1445, 105.0705,

6

260.1658, 363.2451
†

M9

C24H32N2O2

381.2558

5.5

6.17

3.41 x

M10

C16H24N2O

261.1977

6.1

6.32

4.59 x 1010

188.1445, 105.0705,

8

281.2028, 194.1185
†

84.0813, 177.1397,

1

178.1239, 244.1709
M11

C24H30N2O3

379.2404

6.3

6.45

5.08 x

106

3.83 x

108

1.92 x

108

1.71 x

109

188.1447, 105.0706,

18

258.1504, 281.2029
†

M12

C24H32N2O2

381.2560

6.0

6.71

204.1396, 121.0655,

7

261.1977, 297.1979
M13

C24H30N2O

363.2454

6.3

6.87

188.1446, 105.0705,

9

242.1554, 281.2030
†

M14

C24H32N2O2

381.2560

6.0

7.03

204.1396, 186.1289,

3

279.1872, 363.2453
M15

C24H32N2O3

397.251

6.0

7.10

8.57 x 107

7.52

1.64 x

108

5.00 x

107

9.17 x

108

121.0655, 277.1927,

13

193.1348, 202.1239
†

M16

C24H32N2O2

381.2559

5.8

189.1386, 105.0705,

10

204.1395, 297.1978
M17

C24H32N2O3

397.2513

6.8

7.77

202.1240, 244.1711,

15

220.1347, 379.2405
†

M18

C24H32N2O2

381.2559

5.8

7.93

186.1289, 105.0705,

4

273.1977, 204.1396
*†

M19

C24H30N2O3

395.2356

6.8

---

---

188.1429, 105.0702,

---

274.1433, 349.2274
*

M19 was not detected by HRMS analysis, therefore no retention time or peak area is reported.
†These metabolites were detected in both zebrafish and microsome models.
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Figure 4. 2. Proposed metabolic pathway of valerylfentanyl. M19 was detected only by QqQ
analysis.
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The primary purpose of metabolism is for elimination of substances which may result in toxic
effects to the body. This is achieved by enzymatically modifying the drug, thereby increasing its
polarity relative to the drug. Figure 4.3 shows the order of elution of the major metabolites of
valerylfentanyl detected in the microsome samples analyzed via HRMS. The extracted ion
chromatogram of the metabolites observed in the zebrafish assay via QqQ analysis is shown in
Figure 4.4. The hydroxylated metabolite M7/8/9 eluted before the dealkylated metabolite M10,
whereas M14 eluted after M10. Interestingly, two other proposed hydroxylated metabolitesM16/18 eluted after the parent drug but were minor metabolites. Previous studies have also
demonstrated metabolites can elute later than the parent compound [235–238].

Figure 4. 3. Extracted ion chromatogram for the major metabolites of valerylfentanyl detected in
the human liver microsome assay.
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Figure 4. 4. Valerylfentanyl metabolites detected in the zebrafish assay using MRM transitions on
the QqQ.
Figure 4.5 shows the spectra of valerylfentanyl and valerylfentanyl carboxy metabolite (M19)
standards. The product ion at m/z 188, observed in both spectra is common to many fentanyl related
compounds and the pathways through the intermediate at m/z 281 and m/z 216 have been described
[239, 240]. Similar to the 216 ion proposed as forming through charge stabilization on the tertiary
carbocation, it is likely m/z at 244 is formed through the same mechanism [241]. However, the
product ion at m/z 244 was proposed as an intermediate for the formation of m/z 188 in fentanyl
through a propionyl transfer to the piperidine moiety [239]. Although valerylfentanyl contains a
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pentanoyl moiety and is 28 Da more than fentanyl, if a similar rearrangement were to occur, a
product ion at m/z 272 (C18H26NO+) may have been observed even though the product ion at m/z
218.1553—C14H20NO+ (6.4 ppm mass error) suggests that it is the result of this rearrangement.
This does not imply m/z 272 is a precursor to m/z 218 but if this is the preferred pathway, its
abundance was negligible. The product ions at m/z 105, m/z 134, m/z 146, m/z 188, and m/z 281
similar for M19 and valerylfentanyl, are common to fentanyl analogues. Additional ions for M19
(Table 4.3) were observed at m/z 377—C24H29N2O2+, a loss of H2O—18 Da; m/z 349—
C23H29N2O+, a loss of CH2O2—46 Da, and m/z 274—C16H20NO3+, a loss C8H11N—121 Da.
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Figure 4. 5. Mass spectra of valerylfentanyl and valerylfentanyl carboxy metabolite (M19)
standards (Collision energy (CE) = 30 V).
The spectra of the most abundant metabolites M10 and M7 are shown in Figure 4.6. The base
peak for M10 is the piperidinylium ion at m/z 84. The product ion at m/z 244—C16H22NO+, formed
by a loss of NH3—17 Da from the precursor ion at m/z 261 also observed for valerylfentanyl. A
loss of C5H9N—83 Da from the precursor ion resulted in a product ion at m/z 178, but a loss of
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pent-1-en-1-one—C5H8O, 84 Da resulted in the ion at m/z 177. The proposed precursor ion for M7
is a result of mono hydroxylation on the pentanoyl group. The base peak is observed at m/z 188.
A loss of H2O—18 Da from the precursor ion resulted in m/z 363—C16H22N2O+. Subsequently,
the loss of 1-phenethyl-1,2,3,6-tetrahydropyridine (C13H17N)—187 Da resulted in the formation
of the observed ion at m/z 176. Although this is not a favorable pathway, it supports hydroxylation
on the pentanoyl group. Similarly, the product ion at m/z 260—a loss of 2-phenylethan-1-amine
(C8H11N), 121 Da, provides evidence for this metabolite.
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Figure 4. 6. Mass spectra of M10 (valeryl norfentanyl) and M7 (CE = 30 V).
The metabolites M14 and M18 as shown in Figure 4.7 are isomers. Whereas the base peak for
M14 is the product ion at m/z 204, the base peak for M18 is observed at m/z 186. Despite the low
abundance of the ion at m/z 188, the product ions at m/z 105, m/z 134, m/z 146, m/z 160 are common
to both metabolites. However, the difference between these metabolites is the position of the
hydroxyl group (Figure 4.2). The proposed structure of M14 is a result of hydroxylation on the
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alkyl group of the phenethylpiperidine moiety whereas M18 is hydroxylated on the piperidine ring.
Both M14 and M18 show a loss of H2O—18 Da for a product ion at m/z 363 but is more prominent
in M14. Subsequently, the loss of C5H10O—86 Da resulted in the product ion at m/z 279 which
may be isomeric in both spectra due to the position where dehydration occurs. Furthermore, the
loss of aniline—C6H7N, 93 Da resulted in the isomeric product ion at m/z 186, following the
pathway m/z 381→ 363 → 279 → 186. The product ion at m/z 204 was also observed for both
metabolites and follows the pathway m/z 381→ 297— loss of C5H10O, 86 Da → 204—loss of
aniline. The product ion at m/z 105 was the third most intense ion for M18 whereas it was one of
the least abundant for M14. This may have been due to the difficulty to form m/z 105 when a
hydroxyl group is present on the alkyl group of the phenethylpiperidine moiety (M14) compared
to its presence on the piperidine ring (M18). The product ion at m/z 273— C17H25N2O+ in Figure
4.7, M18 was also observed in the valerylfentanyl standard spectrum but at 0.013% of the m/z 188
base peak. In order for the 1-methylene-4-(N-phenylpentanamido)piperidin-1-ium ion to form
from M18, a loss of C7H8O —108 Da is expected, whereas a loss of C7H8—92 Da is expected for
valerylfentanyl.
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Figure 4. 7. Mass spectra of metabolites M14 and M18 (CE = 30 V).
The spectra of M6 (4-ANPP) and M8 are shown in Figure 4.8. M6 is a precursor to many fentanyl
analogues where modification occurs on the amide group of fentanyl [242]. Therefore, it can be
found as an impurity in street drugs containing fentanyl related compounds and is also an amide
hydrolyzed metabolite of fentanyl analogues modified on the amide group [243]. Although it is
not ideal as a marker metabolite, when detected in toxicological specimen, it can indicate the
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presence of fentanyl analogues. The product ions observed in the mass spectrum of M6 were also
observed for valerylfentanyl (Figure 4.5) and the characterization of the ions have been described
[239].
Other mono hydroxylated valerylfentanyl isomeric metabolites included M8 (Figure 4.8), M9,
M12 (Figure 4.9) and M16 (Figure 4.10). The mass spectra of M8 and M9 are similar due to
hydroxylation occurring on the pentanoyl group and the explanation for the product ions are
similar to M7 discussed above (Figure 4.6). The spectrum of M12 and M14 have m/z 204 as the
base peak but the distribution of the product ions is different. Whereas M14 has a product ion at
m/z 363, indicating a loss of H2O, no m/z 363 was observed in M12. This indicates M12 is
hydroxylated on either aromatic ring of valerylfentanyl. The presence of the product ion at m/z
261(Figure 4.9, M12)— a loss of C8H8O, 120 Da indicates the hydroxyl group is on the aromatic
ring of the phenethylpiperidine moiety which is further supported by the product ion at m/z 121
(C8H9O+) which corresponds to the hydroxy-phenethanylium ion—a loss of C5H9N, 83 Da if
produced via the product ion at m/z 204.
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Figure 4. 8. Mass spectra of M6 (4-ANPP) and M8 (CE = 30 V).
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Figure 4. 9. Mass spectra of M12 and M9 (CE = 30 V).
Figure 4.10 shows the mass spectra of the desaturated metabolite, M13 and another mono
hydroxylated valerylfentanyl metabolite, M16. Although similar product ions as the other mono
hydroxylated metabolites were observed for M16, such as m/z 363, m/z 297, m/z 279, m/z 204, m/z
188, m/z 186, the protonated precursor ion at m/z 381 was the base peak, followed by m/z 189
(C12H17N2+). A loss of pent-1-en-1-one— C5H8O, 84 Da from the product ion at m/z 273 resulted
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in m/z 189. The base peak for M13 and most product ions were similar to valerylfentanyl.
However, the product ion at m/z 242 and m/z 176 indicate the desaturation occurred on the
pentanoyl group. The position of the double bond in the proposed structures is only for illustration
purposes.

Figure 4. 10. Mass spectra of M13 and M16 (CE = 30 V).
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The spectra of the minor metabolites hydroxy-phenethylpiperidine (M1) and di-hydroxy
valerylfentanyl (M5) are shown in Figure 4.11. M1 was the earliest eluting metabolite detected
(3.21 mins). However, similar to 4-ANPP (M6), it would not be a marker metabolite for
valerylfentanyl as it is common to other fentanyl analogues where substitution occurs on the amide
group. The mass spectrum is also similar to 4-ANPP, but the base peak is the protonated precursor
ion—m/z 206. A loss of H2O, 18 Da from M5 protonated precursor ion—m/z 397 resulted in the
product ion at m/z 379. A subsequent loss of C5H6O, 82 Da resulted in m/z 297, and dehydration—
loss of 18 Da, resulted in m/z 279. The base peak at m/z 204 indicates at least one hydroxyl group
is present on the piperidine moiety and the hydroxypentylidyne-oxonium ion (C5H9O2+) at m/z 101
indicates another hydroxyl group on the pentanoyl group. Furthermore, the observed m/z 121
(C8H9O+), supports the other hydroxyl group on the alkyl chain of the phenethylpiperidine moiety.
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Figure 4. 11. Mass spectra of M1 and M5 (CE = 30 V).

Two isomers of the di-hydroxylated metabolite M5, eluted at 7.10 min (M15) and 7.77 mins (M17)
and were both less abundant than M5. The mass spectrum of M15 is shown in Figure 4.15. The
base peak is observed at m/z 121, C8H9O+ and corresponds to a loss of C5H9N—83 Da from the
product ion at m/z 204. The product ion at m/z 202 was more intense than m/z 204 and corresponds
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to C13H16NO+—a loss of 18 Da from m/z 220 (C13H18NO2+). The second most intense product ion
was observed at m/z 277—C16H25N2O2+, and resulted from the loss of C8H8O, 120 Da from the
protonated precursor ion at m/z 397. A subsequent loss of NH3—17 Da resulted in m/z 260
(C16H22NO2+). A loss of C5H8O, 84 Da from m/z 277 resulted in third most abundant product ion
at m/z 193—C11H17N2O+ providing support for hydroxylation on the piperidine ring. Furthermore,
m/z 295 (C19H23N2O+) was observed, indicating dehydration on the piperidine ring.
M17 shows the precursor ion m/z 397 as the base peak and m/z 202 as the second most prominent
in Figure 4.13. The product ion at m/z 220— C13H18NO2+, indicates the presence of
dihydroxylation occurring on the phenethylpiperidine moiety. A loss of water from this product
ion results in the favorable formation of m/z 202—C13H16NO+, and subsequent loss of a second
water molecule resulted in the product ion at m/z 184.
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Figure 4. 12. Mass spectra of M15 and M2 (CE = 30 V).
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Figure 4. 13. Mass spectra of M17 and M4 (CE = 30 V).

Hydroxylation of the major metabolite M10, and minor metabolite M6 produced highly polar
metabolites M2, M3 and M4 (Figure 4.2). The mass spectrum of M2, shown in Figure 4.12
consisted of product ions similar to M10 (Figure 4.6). For example, the base peak in both spectra
was m/z 84. However, the product ion at m/z 259 indicates a loss of H2O, 18 Da and a further loss
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of pentadienone, C5H6O—82 Da resulted in the observed product ion at m/z 177. A loss of
hydroxypentenone, C5H8O2—100 Da from the protonated precursor ion can also produce m/z 177.
The observed product ions at m/z 101—C5H9O2+, m/z 194—C11H16NO2+, and m/z 94—C6H8N+
also indicate hydroxylation of M10 occurred on the pentanoyl group. The mass spectra of M4
(Figure 4.13) and M3 (Figure 4.14) consist of similar product ions and abundance as they are
isomers with hydroxylation occurring on the ethylbenzene group. The base peak was observed for
both metabolites at m/z 204 and was discussed above for metabolites hydroxylated at a similar
position such as M12, M14, M16, and M18. The product ion at m/z 121 observed in the spectra
also supports the hydroxylation of M6.
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Figure 4. 14. Mass spectra of M3 and M11 (CE = 30 V).

Hydroxylation of M13 resulted in M11. The mass spectrum of M11 is shown in Figure 4.14. The
product ions at m/z 188, 281, 146, 134, and 105, also observed for valerylfentanyl (Figure 4.5)
were present for M11 indicating modification occurred on the amide group of valerylfentanyl.
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However, the product ion at m/z 258—C16H20NO2+ indicated hydroxylation occurred on the amide
group.
Analysis of the authentic sample by HRMS resulted in fentanyl and valerylfentanyl being detected.
However, 4-ANPP (M6), β-hydroxyfentanyl, norfentanyl, morphine, and methamphetamine were
detected using a triple quadrupole mass spectrometer operating in multiple reaction monitoring
mode (MRM) mode. A compound sharing the same transitions—381.3→105 and 381.3→188.1,
in a similar ratio as M7 and occurring at the same retention time was detected in the authentic
sample (Figure 4.15). This was not detected via HRMS, possibly due to the lower sensitivity of
the Orbitrap. The availability of reference standards would be vital in confirming this metabolite.
Butyrfentanyl, structurally similar to valerylfentanyl was found to undergo extensive metabolism
with the hydroxylated and carboxylated metabolites detected when a postmortem sample was
analyzed, but the anticipated major metabolite—nor butyrfentanyl was only detected as a minor
metabolite [235]. The authentic liver specimen analyzed in this study corresponded potentially to
M7—the hydroxylated metabolite of valerylfentanyl, but the expected valeryl norfentanyl
metabolite was not observed. However, further analysis of postmortem and antemortem specimen
would be required to understand if there are differences in the detected metabolites of
valerylfentanyl compared to our results.
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Figure 4. 15. Chromatograms showing the monitored transitions: 381.3 → 105.0 and 381.3 →
188.1 similar to M7 for (A)—Human liver microsome study, (B)—Zebrafish study, and (C)—
Authentic liver sample. The retention times (4.93 min) are the same in each sample. A higher
abundance is present in the microsome sample compared to the zebrafish and authentic sample.
Studies of other fentanyl analogues using in vitro methods such as HLM and hepatocytes have
demonstrated N-dealkylation and hydroxylation as prevalent metabolic pathways [235, 236, 244].
Furthermore, fentanyl studies demonstrated that human liver derived CYP3A4 had a high
contribution to N-dealkylation [53, 245]. Butyrfentanyl—which contains a butanoyl group
compared to valerylfentanyl which contains a pentanoyl group, also demonstrated N-dealkylation
as the major pathway with enzymatic contributions mainly from CYP3A4, and minor contributions
from CYP1A2, 2C8 and 2C19 [235]. Although the extent of the human CYP enzymes responsible
for the metabolism of valerylfentanyl have not been evaluated, it is possible the contributions are
similar to butyrfentanyl. Kirla et al. reported zebrafish larvae metabolized butyrfentanyl similar to
human but the metabolites were not fully described [193]. The authors also suggest CYP3A4 was
responsible for butyrfentanyl metabolism in zebrafish. However, cyp3a65 in zebrafish was
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identified as the human CYP3A4 orthologue [47] and the role of both enzymes in valerylfentanyl
or butyrfentanyl metabolism is yet to be evaluated for a comprehensive understanding of the
metabolism differences between the two species.

4.4.0 Conclusion
As fentanyl analogues continue to emerge, elucidation of marker metabolites, and selection of an
appropriate model that reflect human metabolism are critical. In this study we used a common in
vitro model, human liver microsomes, and compared the major metabolites of valerylfentanyl to
an in vivo zebrafish model. N-dealkylation, and hydroxylation observed with fentanyl analogues
were the primary biotransformations. Although 19 metabolites were detected using the human
liver microsome model, we propose the two major metabolites M10—valeryl norfentanyl and
M7—hydroxy valerylfentanyl as marker metabolites for valerylfentanyl as they can be
discriminated from other fentanyl analogs. The commercially available metabolite M19—
valerylfentanyl carboxy metabolite, was detected as a minor metabolite only after analysis by
tandem mass spectrometry. Whereas this metabolite provides evidence for the consumption of
valerylfentanyl, its low presence makes it a poor marker metabolite. The major metabolites in the
microsome model were highly corroborated by the zebrafish model, providing support for
zebrafish as a model for metabolism of fentanyl related compounds.
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General Conclusions
Measures to mitigate and understand the adverse effects of novel psychoactive substances and
other common drugs of abuse to users, first responders, or forensic science personnel are
constantly being studied. In the first phase of this project the detection of these substances was
evaluated using a portable, rapid, non-destructive, safe technique commercially available. A novel
approach which utilized both Raman and DART-MS was implemented for seized drug analysis.
After demonstrating that portable Raman resulted in poor accuracy for mixtures, machine learning
was implemented to classify compounds by drug name and drug class. In the second phase, a single
zebrafish assay was developed to investigate the toxicity and metabolism of opioids, providing
critical information for drug metabolite markers and a foundation to extend the toxic effects
observed in zebrafish to the relationships in human. The findings in this dissertation demonstrate
the need to improve the accuracy of rapid onsite techniques and greater understanding of the effects
of NPS on human.
Portable Raman analysis is advantageous over many onsite drug testing strategies because of its
ability to analyze unknown substances through certain packaging types, thereby reducing the risk
of exposure, and can assist in decreasing drug backlogs. However, issues such as fluorescence,
and analysis of multicomponent mixtures may affect the instrument’s overall accuracy. The
benefits of orthogonal methods as DART-MS to improve Raman results were demonstrated in
chapter 1. Analysis of solid drug/diluent standards using a combination of the two techniques
resulted in 96% drug accuracy, 100% diluent accuracy, and 96% two-part mixtures accuracy.
Authentic case samples which contained multiple drugs were assessed using both methods.
Diluents which contain poor sensitivity using DART-MS such as sugars were easier to detect using
Raman. Drugs, which were typically present in lower concentrations were detected easier using
DART-MS. The accuracy of the portable Raman was 44%, DART-MS—74%, and the
combination of both techniques—83%. Future work can extend Raman and DART-MS analysis
to other drugs of abuse and NPS. Moreover, evaluation of other techniques in detecting
multicomponent mixtures such as SERS and the use of Raman instruments containing a 1064 nm
laser to combat fluorescence can be studied in future work.
Analysis of in-house binary mixtures using the portable Raman instrument only, resulted in 30%
correct identification for drugs, 89% for diluents, and 19% for both drugs and diluents. For this
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reason, machine learning was implemented in chapter 2 as a method of improving the instrument’s
accuracy. Machine learning and deep learning methods have been increasingly utilized as
classification methods in instances where the human judgment in detecting spectral differences
may suffer. Out of the six machine and deep learning methods—kNN, NB, RF, SVM, NN, and
CNN, higher accuracies were observed with CNN models—69% for drug, 95% for diluent, 64%
for both drug and diluent classification compared to the portable Raman instrument’s built-in
algorithm—30% for drug, 89% for diluent, 19% for both drug and diluent classification. Although
binary, ternary and quaternary mixtures were evaluated, future studies can include more complex
mixtures. This work can also be extended to SERS which is advantageous over conventional
Raman by having higher sensitivity to low drug concentrations in complex mixtures. Initial
identification of unknown compounds can be challenging. Therefore, the substances evaluated in
chapter 2 were not only classified by the drug name for pure substances, or drug mixtures, but also
by compound class for pure substances and class mixtures for multiple component substances.
When compounds in binary mixtures were classified by drug class (for example, fentanyl’s drug
class is opioid) using CNN models, the correct classification was 78%, 93% and 72% for drug
class, diluent class, and both compound classes, respectively. The presumptive results can help
drug analysts better understand the substance they have encountered and provide guidance for
further investigations. Future work will include a graphical user interface to incorporate the
algorithms developed in this study. Providing pre-trained models to users of the TaticID instrument
will give them the capability to add compounds and re-train the model as their database increases.
The algorithms presented in this work were multiclass which allows a spectrum prediction to
belong to only one class. Even though probabilities can be used to report the top three hits for an
unknown, it may result in lower accuracy for reporting all components in mixtures. Therefore,
multilabel classification algorithms—which can result in a spectrum prediction to belong to
multiple classes, can be explored to compare the accuracy when analyzing mixtures.
Chapters 3 and 4 investigates an in vivo model for opioid metabolism and toxicity. Zebrafish have
emerged as whole organism model to study human disease and functions. Their genetic similarities
to human and cost-effective approaches to maintain them increase their tendency as research
animals over rodents in many labs. Although in vitro models such as human liver microsomes can
provide pharmacologic data, they do not always reflect in vivo effects crucial for understanding
human function. Fentanyl, one drug responsible for many drug overdose cases in the United States
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of America was evaluated in chapter 3. A single assay was presented to evaluate fentanyl’s toxicity
and metabolism in zebrafish larvae (0 - 96 hpf). Major phenotypic effects included heart, yolk
extension and spinal malformation in a dose dependent manner. These findings warrant further
investigations into the mechanism of action, methods of reducing these effects or even reversing
them. This can provide vital information to first responders and medical personnel when treating
overdosed patients. Additionally, analysis of the zebrafish media detected fentanyl metabolites—
4ANPP, norfentanyl, and β-hydroxyfentanyl, all of which have also been observed in human and
microsomal studies.
After demonstrating zebrafish larvae were capable of metabolizing fentanyl, an uncharacterized
fentanyl analogue—valerylfentanyl was evaluated using 30 dpf zebrafish in chapter 4. The
zebrafish data was compared to human liver microsomes and analyzed using high resolution mass
spectrometry. N-dealkylation, and hydroxylation were the primary biotransformations. Nineteen
metabolites were detected using the human liver microsome model and many of these metabolites
were observed in the zebrafish assay. The two major metabolites M10—valeryl norfentanyl and
M7—hydroxy valeryl fentanyl were proposed as marker metabolites for valerylfentanyl. Future
work will include evaluating the toxic effects of valerylfentanyl on zebrafish larvae and comparing
the data to fentanyl. Furthermore, the toxicity of fentanyl metabolites such as 4ANPP, norfentanyl,
β-hydroxyfentanyl, and metabolites of valerylfentanyl will be assessed. Extending the zebrafish
assay to newer emerging synthetic opioids would also be crucial in providing support for this
alternative model for human toxicity and metabolism.
This work has therefore demonstrated that reliance on similarity metrics built into portable
Raman instruments do not always result in high accuracy when drug mixtures are analyzed, but
the implementation of machine learning algorithms improve identification of multicomponent
mixtures. More accurate preliminary drug screening techniques can help reduce backlogs in
forensic chemistry laboratories because when field tests are performed, only suspected controlled
substances would be sent for confirmation to the laboratory. The second major contribution of
this work was the development of a single zebrafish model as an alternative to investigate drug
toxicity and metabolism, laying the foundation for future mechanism of action studies that can be
translated to human. The genetic similarities between zebrafish and humans, the observed
phenotypic effects such as respiratory depression due to fentanyl overdose in both species, and
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the detection of similar fentanyl metabolites in both species provide strong evidence for
zebrafish as a toxicity and metabolism model. Extension of this work to novel drugs will alert
users of a drug’s potency and elucidate marker metabolites that can be incorporated in screening
of human specimens at forensic toxicology laboratories.
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